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Abstract 
Worcester County, a region in Central Massachusetts, has established a series of 
initiatives to develop a life science cluster.  To foster growth of the life science industry in 
Worcester County, Massachusetts Biomedical Initiatives (MBI), a biotechnology incubator, 
requested a study to document the current state of the life science economy, and highlight the 
strengths of the area.  The primary objective was to determine the competitive advantage of 
Worcester County.  This was accomplished by identifying the strengths of the life science 
cluster specific to Worcester County, and determining the weaknesses of that region.  The 
analysis shows that a critical mass of institutions and infrastructure, and attraction of funds is 
required to maintain a vibrant life science cluster.  Through comparison with relevant state 
data, the strengths of the life science industry in Worcester County became evident.  These 
include the location of region, unique opportunities at local institutions, lower costs of living 
and renting lab space, and incubators.  Finally, suggestions for remediation were offered to MBI 
to rectify or alleviate the weaknesses discovered.  
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Executive Summary 
Worcester County is emerging as a prime location for startup and growing companies.  
As a biotechnology incubator, Massachusetts Biomedical Initiatives (MBI) plays a large role in 
attracting and fostering the growth of such companies.  To attract new and existing companies 
to the area, MBI requested a study to document the current state of the life science economy 
and highlight the strengths and weaknesses of Worcester County.  With this information, the 
implications of the strengths, and suggestions to remedy or improve the weaknesses were 
offered to MBI. 
There are several terms that had to be defined in order to gain an understanding of the 
parameters of the project.  The most essential terms were life sciences, competitive advantage, 
cluster, and indicators.  Life science is mainly comprised of biological studies and has expanded 
into a more technological and interdisciplinary field.  Competitive advantage is the ability of a 
region to outperform its competitors using skills and resources other regions do not possess.  
Clusters “are geographic concentrations of interconnected companies, specialized suppliers, 
service providers, firms in related industries, and associated in a particular field that compete 
but also cooperate” (Porter, 2000).  An indicator is a term referring to economic benchmark 
that measures the overall productivity of a region.   
First, factors that affect growth in life science industries were determined.  The Index of 
the Massachusetts Innovation Economy, published by the Massachusetts Technology 
Collaborative, and the 2012 Biopharma Industry Snapshot, published by the Massachusetts 
Biotech Council are reports that were used as a guideline to determine such factors.  These 
documents evaluated and compared the Massachusetts state economy to other states and 
countries using various measures, or indicators.  Of these indicators, sixteen were chosen that 
would best illustrate growth in a life science economy.  The indicators selected were 
occupations and wages, employment growth, research and development, patents, approvals of 
pharmaceuticals, technology licensing, small business innovation research grants and small 
business technology transfer research grants, business formation, mergers and initial public 
offerings, biomanufacturing, federal funding, private funding, capital and human resources, lab 
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inventory, workforce education level, and science, technology, engineering and math (STEM) 
degrees.  
Background research was conducted to gain an understanding of the significance of 
each chosen indicator and to gather raw indicator data specific to the United States and 
Massachusetts.  From this preliminary research, Massachusetts compared favorably to other 
states in many of the indicators.  More than half of Massachusetts’ key industry sectors, such as 
health care delivery and postsecondary education, reported growth in employment from 2011 
to 2012 and wages from 2007 to 2012 (Kispert et al., 2012).  In 2011, Massachusetts rose from 
seventh to fourth in rank in the world in patents issued relative to Gross Domestic Product 
(GDP).  GDP is the total market value of all officially recognized final goods and services 
produced within a country in a given period of time (Gutierrez, 2007). For National Institute of 
Health Research and Development Funding per 1,000 dollar GDP, Massachusetts ranked first in 
the country in 2011.  In 2011, Massachusetts had a higher median household income than any 
other state.  
The second goal of this project was to offer ways to improve and grow the life science 
industry in Worcester County.  In order to achieve this goal, data on the sixteen indicators were 
gathered specific to Worcester County. Through expert interviews, resources that provided 
information regarding Worcester County were identified. These resources included the National 
Institute of Health (NIH), National Science Foundation (NSF), United States Bureau of Labor 
Statistics, Small Business Association (SBA), United States Census, and United States Patent and 
Trademark Office. These resources provided data such as number of employees, total wages, 
STEM degrees awarded, total funding, and patents issued in Worcester County. These data 
were analyzed and compared to Massachusetts to identify Worcester County’s competitive 
advantage.  
The strengths identified were state of the art facilities, prestigious institutions to 
produce a qualified workforce, competitive employment and salaries, overall federal funding, 
proximity to Boston and Cambridge, lower cost of renting and living, and low vacancy rate for 
lab space.  The following are a few examples to elaborate on some of these strengths. There are 
three sophisticated biotech parks in the county. There has been an overall increase in STEM 
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degrees awarded from 2006 to 2010.  From 2009 to 2010, the number of patents issued has 
increased by 20.34%.  More than 35% of these patents were in the life sciences.  Compared to 
Massachusetts, Worcester County has seen an increase in total number of employees from 
2009 to 2011.  Proximity to Boston is essential for business and gives Worcester County the 
ability to complement the success of the eastern part of the state by providing opportunities for 
companies to start or expand and remain connected to the epicenter of the biotechnology 
world.  Unique opportunities are also offered through institutions such as the University of 
Massachusetts (UMass) Medical School and the Tufts Cummings Veterinary School.   
However, Worcester County still has weaknesses to overcome in order to further the 
growth of the industry.  These weaknesses include attracting funds in the forms of Angel 
funding and Venture capital, acquiring federal grants such as SBIR/STTRs, slow business 
formation, and developing pharmaceuticals and medical devices for approval.  Companies in 
the area find it difficult to receive Angel funding because there is only one Angel Funding group, 
The Boynton Angels, in Central Massachusetts and it is not fully developed due to their inability 
to attract a sufficient number of investors. Also, Venture capital is hard to acquire because 
there are no Venture capital companies located in Worcester County. The process for applying 
for federal grants is tedious and requires a level of expertise in grant writing that only a few 
companies in the county have consistently found success in.   
After identifying the weaknesses of the county, recommendations were offered to 
potentially remediate the issues facing the region.  Funding, both private and federal, is crucial 
for sustaining academic, non-profit and health-related research and the growth of private 
companies.  Institutions and companies in Worcester County should work to develop a 
community initiative that will educate companies on how to successfully write grant 
applications to attract federal funds.  It would be beneficial to the growth of the industry if the 
Boynton Angel group was further developed by attracting more investors in the county.  
Networking and developing relationships with Angel and Venture groups in the Boston area is 
crucial in securing funding.  Also, in recent years, large drug companies have experienced a 
major challenge due to the drug pipelines beginning to dry up, resulting in cheaper, generic 
brands taking over. A new business model is emerging that involves the relationship between 
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academia, health care providers, drug makers, and biotechnology makers (Rothwell, 2013).  
Worcester County must adapt this model by utilizing one of its strengths; the Albert Sherman 
Center.  This facility will provide the unique opportunity to develop new treatments for disease, 
the new focus of large pharmaceutical companies.
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1.0 Introduction 
               Worcester County is one of fourteen counties in Massachusetts, located in the central 
part of the state.  It is comprised of sixty cities and towns, and the city of Worcester is the 
second largest city in New England. In the mid-1900s Worcester County was primarily a 
manufacturing economy until outsourcing and innovation crippled the industry (Pearson, 2004).  
In an effort to revitalize the economy, a series of initiatives were put in place.  The life science 
industry has been extremely successful in Massachusetts especially in the Boston area and 
these initiatives sought to complement the successes of the eastern part of the state.  Over the 
past few decades the industry has shown tremendous growth from a few million dollars to 
hundreds of millions.  However, there are still obstacles that Worcester County must overcome 
in order to remain successful in the future and continue on a path of growth, one of which 
includes attracting attention and investment west of Boston.  In order to attract attention of 
startup and established companies to Worcester County, MBI developed an Interactive 
Qualifying Project (IQP) to determine the competitive advantage of Worcester County Life 
Science Economy. 
 MBI is a private, non-profit organization in Worcester, MA, that specializes promoting 
the growth of startup biomedical companies. MBI “lowers barriers to success for emerging 
companies by providing cost-effective, high quality laboratory space and support services” 
(MBI, 2012).  
MBI hopes to identify the foundation of competitive advantage in the Worcester County 
life science industry.  The best way to achieve this would be to analyze the past and current 
state of Worcester County compared to other regions that are leading areas in the life science 
industry.  The data will be used to create a blueprint which will further the momentum for 
future economic growth in the life science industry.  
First, sixteen quantitative indicators that are benchmarks for economic growth in the life 
science industry were identified. An analysis of Massachusetts and United States in terms of 
those specific indicators was conducted, and these results were compared to Worcester 
County.   This is important because strong indicators suggest strong clusters. A cluster is a group 
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of interconnected companies, specialized suppliers, service providers, firms in related 
industries, and associated institutions in a particular field that compete but also cooperate 
(Porter, 1998). Clusters are advantageous to any region as they helps develop connections 
between institutions, which can be useful when trying to fill specific job positions, streamline 
research and development processes or share techniques (Porter, 1998). The second step was 
to determine the strengths and weaknesses of the Worcester County cluster. This will aid in 
preparing a plan to improve the weaknesses and highlight the strengths in Worcester County.  
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2.0 Background 
The term competitive advantage “is the ability gained through attributes and resources 
to perform at a higher level than others in the same industry or market” (Porter, 1980). In order 
for Worcester County to attract more life science companies, its competitive advantage must 
be evident. In this chapter, the significance of life science, technological innovation in 
biomedical research and biotechnology, business incubators, startup companies and the 
challenges faced by them will be examined. Additionally, the importance of competitive 
advantage and clusters associated with it will be explained.  
2.1 Life science 
Life science is a general term encompassing biological sciences, biotechnology, 
biomedical sciences, biochemistry, medicine, and certain environmental sciences. Although it is 
mainly centered on biological studies, recent advances have expanded the concept of life 
science to become a more technological and interdisciplinary field of study.  For example, 
biomedical engineering and biotechnology are now leading areas in terms of technological 
innovation, adding new dimensions to the life sciences field and incorporating the engineering 
sciences (Kahn et al., 2005).  In addition to conducting basic research, scientists and engineers 
are being encouraged to invent and innovate as well.  Life science is no longer simply an area of 
research; it has become an area of invention and business development as well. Although 
startup companies are growing in Massachusetts, they face many challenges in a highly 
competitive business environment. 
2.2 Technological innovation in biomedical research and biotechnology 
 Technology and innovation are the driving forces behind today’s global competition.  
The focus of global economics has shifted from manufacturing to information and technology, 
leading to new developments and innovation in many markets (Bartholomew, 1997).  One such 
industry that has seen advances is life sciences because of the emergence and achievements 
biomedical research and of biotechnology.  Biomedical research is a general term that 
comprises of the life and physical sciences, aiming at preventing and treating diseases (What is 
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Biomedical Research?, 2012). Biotechnology is defined as the manipulation of living organisms 
for the production of goods and services (Bartholomew, 1997). Humans have been participating 
in this manipulation all throughout history to manufacture food and nourishment through 
selective breeding and cross fertilization (Bartholomew, 1997). However, in the 1970’s and 
1980s, biotechnology had made significant advances that in turn attracted substantial interest 
and investment in the global market (Kenney, 1986).  Martin Kenney of Yale University Press 
describes this advancement of knowledge as:     
“A ‘biotechnology revolution’ [that] began when developments in molecular biology made it 
possible to precisely alter the genetic structure of living organisms. Critical new technologies 
such as genetic engineering (recombinant DNA) and cell fusion (hybridoma technology) have 
laid the foundation for ‘the new biotechnology’ (hereafter referred to simply as biotechnology) 
and a new era of industrial advance” (Kenney, 1986). 
 With this revolution comes a workforce that must develop and grow the industry.  It 
would be simple to say that large firms would generate this growth, but this is not the case in 
the biotechnology and biomedical field. 
Surprisingly enough, universities and startup companies have been the driving forces 
behind biotechnology rather than large firms.  Biotechnology relies heavily on basic research 
conducted in research institutions by graduate students and university professors leading small 
startups (Bartholomew, 1997).  Heavy research on topics such as genetics, tissue engineering, 
pharmaceuticals, etc. is critical for innovation to occur and an end product to be fashioned.  
Large firms have a large reliance on the research done by these smaller organizations to 
manufacture a successful product.  However, startup companies and research institutions face 
many challenges in these early phases because of the high level of uncertainty with the 
research and possible social controversy that can result from their findings. 
2.3 Startup Companies 
Large biotech firms rely heavily on the success of startups because very little preliminary 
work is done within larger companies (Audretsch, 2000).  Startup companies are those that are 
still in the research phase and have not yet created a product (Audretsch, 2000).  They consist 
5 
 
of graduates, professors, and scientists conducting research to ultimately develop a product for 
larger companies to sell commercially (Audretsch, 2000).  The work of these startups fuels the 
pipelines of the large firms because their initial research and findings allow the large firms to 
create a product.  Large companies rely on smaller startups because liability and risk are 
avoided by conducting the research outside the firm.  Biotechnology can be very unpredictable 
and, “The product development process contains unpredictable biological and technical risks. 
These risks arise from a core technology based upon promising yet unproven science. 
Entrepreneurs must be prepared for an extraordinarily long product development timeframe”` 
(Shimasaki, C.D., 2009).  This potential risk has formed a strategic alliance between the two 
entities and promoted biotechnology in a great way.  
The economy of biotechnology consists of regional clusters located around established 
institutions with access to private and federal funding, small startup companies, and larger 
firms.  The relationship between large and small companies is significant in understanding why 
startups are so important to the economy of a biotechnological cluster.  Tasking startups with 
the research phase rather than leading it internally is advantageous because it enables the 
startups to focus on, “moving from basic research to commercialization through technological 
innovation” (Audretsch, 2000).  In addition to a centralized focus on research, startup 
companies have less liability than large firms because they have limited assets and failure is 
somewhat common among startups (Audretsch, 2000).  Research can take up to fifteen years 
or more for a startup company and they must overcome many obstacles on the way to create a 
product.  The cooperation between firms, scientists, institutions, and universities is important 
in overcoming these obstacles and establishing a product. 
2. 3.1 Challenges Facing Startups 
 Startup companies typically face many challenges in their first few years of operation, so 
identifying and overcoming these challenges is key in their successes.  There many ways in 
which a company can fail, including poor management, deficient marketing plan, lack of 
funding, failure to adapt to changing business climates, societal issues, and a poor or otherwise 
unsuccessful end product (Durai et al., 2006).  However, along with these internal factors there 
are external, more routine factors such as acquiring space, securing licenses and permits, and 
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daily household tasks including accounting, infrastructure, and physical plant.  Neglect or 
mismanagement of these factors can lead to the quick failure of a company quickly which lacks 
the appropriate funding and/or resilience to see itself through a crisis.   
 Startup companies in the life sciences face such challenges in particular because time 
consuming and capital-intensive research must be conducted in order to make progressive 
steps for them to become successful and independent companies. If funding is not available to 
support this research, then an end product will not be developed.  They are susceptible to all of 
these factors mentioned above; therefore it is important to find effective ways of reducing risk.  
Life sciences research can typically take many years, so budgeting and constant funding is 
required to maintain progress in the research (Durai et al., 2006).  However, there are paths 
that can be taken to relieve smaller companies that may not have the personnel and financial 
means to handle these tasks by referring them to a third party.  This third party known as a 
business incubator offers startups valuable resources, giving the company a greater potential 
for success.  For example, in the life sciences field, business incubators provide startups with lab 
space, equipment and provide services such as taking care of licenses and permits, and covering 
the expenses for office and R&D space (Kahn et al, 2005, pg.3).  Business incubators play an 
important role in the development of startup companies leading to economic growth in 
general. 
2.4 Business Incubators 
It requires a vast amount of time and investment for an entrepreneurial company to 
succeed and continue growing.  Startup costs are substantial and can often lead to the failure of 
the company.  However, as noted above, an effective way for companies to reduce expensive 
startup costs is through partnership with a business incubator.   Business incubators are 
organizations or programs that provide startup companies with the resources and support 
needed to ensure success.  These resources may include leasable lab space, providing 
equipment, and fostering collaborative opportunities with other startups.  Business incubators 
take on the mundane tasks of paying bills, acquiring licenses and permits, and janitorial 
services, which allows the small company to focus on their research and the end product.  
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Reports have shown that this method works for small companies.  According to Business 
Incubation Works, “National Business Incubation Association (NBIA) member incubators have 
reported that 87 percent of all firms that have graduated from their incubators are still in 
business” (Business Incubation Works, 2012).  This is significant considering the generally high 
failure rate of startup. MBI has been prominent in the Worcester area for a number of years 
and has had many successes, focusing its attention on the life sciences sector in Central 
Massachusetts. 
2. 4.1 Massachusetts Biomedical Initiatives Overview 
MBI is a non-profit, “private, independent economic development organization 
dedicated to job creation and innovative healthcare throughout Massachusetts by promoting 
the growth of startup biomedical companies” (MBI, 2013).  Since its inception, MBI developed 
its long term strategic business plan.  This is a dynamic plan that allows MBI to make 
adjustments every three to five years, adapting to the needs of the current economy and 
predicted growth of industries.   
The first objective of MBI, as stated in their Strategic Plan, is to “identify and attract 
entrepreneurial scientists and emerging companies, keeping existing criteria for incubation” by 
targeting “academic/science/ commercial institutions to identify scientists doing research” (MBI 
Strategic Plan Update, 2011).  MBI meets this objective by setting up locations for startups in 
Worcester, an area densely populated by academic institutions and commercial entities and 
with personnel trained in the biomedical sciences and biomedical engineering.  In addition to 
locating their facilities in close proximity to prestigious institutions, MBI seeks to recruit 
biomedical companies from other parts of the country and world, in hopes of attracting them 
to the area, as well as marketing MBI’s information through the web.  This strategic approach 
to marketing and recruiting has led to MBI’s long term success.   
MBI’s success correlates directly with the success of its tenants; to whom lab space is 
leased.  Given this correlation, another significant objective of MBI is to provide mentor 
services to the tenants.  The mentoring advice includes:  
1. “Emphasizing opportunities for developing new resources.” 
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2. “Offering advice to entrepreneurs as to how to develop sound business & scientific 
plans.” 
3. “Offering assistance in identification and recruitment of technical staff” (MBI 
Strategic Plan Update, 2011).   
These strategies lead not only to the operation of a successful incubator organization, but to 
the creation of strong new companies stemming from the MBI startup program. 
 
2.5 What is a Cluster? 
 Simply stating a cluster is “bio-tech” or “manufacturing” is far too broad of a definition.  
This removes the idea that the term clusters create “crucial interconnections with other 
industries and institutions that strongly affect competitiveness” (Porter, 2000).  Clusters, as 
defined by Porter, “are geographic concentrations of interconnected companies, specialized 
suppliers, service providers, firms in related industries, and associated institutions (e.g. 
universities, standards agencies, trade associations) in a particular field that compete but also 
cooperate” (Porter, 2000). Porter defines the geographic scope of a cluster as relating “to the 
distance over which informational, transactional, incentive, and other efficiencies occur” 
(Porter, 2000).  Clusters branch off downstream to channels and customers in addition to 
lateral shifting to incorporate manufacturers of complementary products and to companies in 
industries related by skills and technologies (Porter, 1999).  Clusters combine “linked” 
industries in order to fuel competition, and can include suppliers of specialized inputs such as 
components, machinery, and services as well as providers of specialized infrastructure (Porter, 
2000).  Such “specialized infrastructure” encompasses universities, research labs and many 
other facilities.  Yasuyuki Motoyama of University of California at Irvine further synthesizes part 
of Porter’s definition of what a cluster is into four points (Motoyama, 2008): 
 1. Firms of a similar industry, its strategy and rivalry 
2. Supply conditions (such as suppliers and extending to legal, technological, and 
consulting services) 
3. Demand conditions (such as core customers) 
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4. Related and supporting industries. 
Secondly, Motoyama cites how Porter believes that the “interconnectedness through 
collaboration and competition among these cluster elements is the source for growth, 
innovation, and competitiveness (Motoyama, 2008). An example of this “interconnectedness” 
can be found when Motoyama references the work of Chinitz from the early 60s and his 
explanation of the “growth of the New York region by uncovering the role of immediate goods 
and services, such as legal, accounting, and duplicating services as well as the competition 
between small enterprises, which promoted entrepreneurship.”  The interconnectedness 
amongst the small enterprises, drove competition between the intermediate goods and service 
companies. These companies and small industries complement each other; compete against 
each other, while also sharing resources such as a specialized labor force, equipment, or 
technology.  
2.5.1 Advantages and Disadvantages of Clusters 
 Clusters can generate “increasing returns that can take the form of lower unit operating 
costs due to the concentration of specialized suppliers or the existence of pipeline economies” 
(Hill et al., 2000).  These specialized suppliers refer to the specialized pools of labor that are 
present in cluster economies.  The specialized pools of labor that come from universities, 
training programs and a skilled work force is essential for cluster development and growth.  The 
term “pipeline economies” refer to “lower costs generated by the large flow of specialized 
shipments of inputs into the region or products out of the region” (Hill et al., 2000).  The fact 
that such a high volume of shipments flow in and out of a cluster region, leads to reduced costs; 
similar to the concept of buying in bulk.   
2.5.2 Cluster Innovation 
  Alternatively, returns can be generated by higher unit earnings due to product 
innovations or innovations in production processes that are generated by the intense local 
competition or the density of suppliers and customers.  This intense local competition provides 
for “arguably the most important source of cluster economies, generated by the forces of 
competition in product innovation; quality enhancement; the adoption of process innovations; 
10 
 
and the encouragement of entrepreneurship to take advantage of perceived market, supply, or 
distribution gaps within the cluster” (Hill et al., 2000).  This entrepreneurship stems from 
people working for major firms, who may recognize a need for a certain product in the industry, 
or recognize some “unfilled market niche” and break off and begin their own company 
addressing these issues.  Reasons for doing so may include a more established company may 
not to directly associate with a new, unproven idea, and would prefer to fund a smaller startup 
to do the work (Hill et al., 2000).  It is easier for these startups, who spin off from larger firms in 
the same cluster, to find “financing than it is for competitors located elsewhere because local 
investors and lenders will have a better understanding of the risks and opportunities to which 
entrepreneurs are responding” (Hill et al., 2000). 
2.5.3 Worcester County Cluster 
 Middlesex and Suffolk County, Massachusetts are recognized as a leading innovative 
cluster in the life sciences industry, specifically in biotechnology and biomedical research.  The 
success of this cluster is due largely to the outstanding reputation and achievements of 
institutions in the region such as Harvard and MIT as well as the surplus of hospitals and 
medical facilities in the area.  However, as these Counties become more and more occupied, 
opportunities are beginning and have begun to arise in the Central and Western part of the 
state.  In 2001, construction on two new biotech facilities began in Springfield and at the 
University of Massachusetts at Amherst (Peacock, 2001).  Central and Western Massachusetts 
also have very established institutions of learning which makes them an attractive market 
(Peacock, 2001).   
With the opening of these new facilities, established schools like WPI and UMass 
Memorial Medical Center, and an increased interest in expanding west, Worcester County can 
become a very successful cluster.  Biotechnology and life sciences has great potential in 
Worcester County because it is very geographically concentrated around the best scientific 
talent which is located in Boston, California, Worcester, New Jersey, etc. (Audretsch, 2000).  
Also, Worcester County is an attractive market because a manufacturing cluster was once 
prevalent in the area and new businesses are more easily formed in existing clusters rather 
than isolated locations (Porter, 2000).  Location relative to Boston is very important as well 
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since Worcester County is located relatively close.  These factors have made it possible to start 
this cluster in Central Massachusetts, but to further enhance the cluster, drivers of productivity 
must be identified.   
2.6 Competitive Advantage 
According to Edward W. Hill and John F. Brennan of Cleveland State University, 
“competitive advantage is revealed through the lens of a region’s complement of industries and 
the competitive position of those industries in the national marketplace” (Hill et al., 2000). This 
competitiveness is the “productivity with which a state utilizes its human, capital and natural 
endowments to create value” (Porter, 2012).  To further validate this claim that productivity is 
crucial for a competitive advantage Hill and Brennan present that “the most telling indicator of 
competitive advantage is the productivity of each worker in an industry…a direct measure 
would be value added per hour worked.”  Other factors that Hill and Brennan used to examine 
competitiveness include the regional industry’s change in national employment share, relative 
earnings, local average earnings to national average earnings, and change in relative earnings. 
Three other variables that can be used in determining competitive advantage are exports, 
centrality, and employment specialization.  Centrality refers to buying and purchasing 
relationships, and change in local employment share (Hill et al., 2000).  
Porter (2012) argues that strong clusters drive regional performance.  The specialization 
in strong clusters, the breadth of industries within each cluster, strength in related clusters, and 
presence of a region’s clusters in neighboring regions collectively  lead to job growth, higher 
wages, higher patenting rates, and greater new business formation, growth, and survival.  
2.7 Evaluating a State’s economy 
 The first step in improving key drivers of a state’s economy is to evaluate its current 
position with a state performance scorecard (Porter, 2012). This will help explain the state’s 
performance, strengths, and weaknesses in certain areas and indicators. Also, since this 
scorecard can be conducted for every state, it is much easier to compare states in a particular 
area or on an indicator. Figure 1 below shows the performance scorecard for Massachusetts. It 
shows that Massachusetts leading clusters are Education and Knowledge Creation, Financial 
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Services, Analytical Instruments, Information Technology, and Medical Devices. On the other 
hand, one of Massachusetts’ weakest cluster or indicator is New Business Formation.  
Figure 1: Massachusetts Performance Scorecard 
 
(Porter, 2012) 
 
To understand the State Performance Scorecard fully, a little background on the indicators is 
necessary.  
2.8 Indicators 
 In the words of the Index of the Massachusetts Innovation Economy (MIE), indicators 
are, “quantitative measures that allow performance comparisons with other leading regional 
innovation economies” (Massachusetts Technology Collaborative, 2011). These indicators help 
examine the long-term changes and trends in regional economic fundamentals, such as 
manufacturing productivity, as well as variables that are subject to short-term fluctuations, 
such as venture capital funding. Both of those categories are critical to analyze. In this project, 
the team will be focusing on certain indicators that are essential to cluster building and 
strengthening.  
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 The Index of the Massachusetts Innovation Economy (MIE), which was first released 15 
years ago, examines and provides benchmarks of the state of Massachusetts’ innovation 
ecosystem.  It also signals the importance of innovation in our economy and therefore triggers 
attention, conversations, and media references. At the core of the Index are quantitative 
assessments in the form of 25 indicators. The index can document the commanding position of 
the Massachusetts Innovation Economy nationally and worldwide. It also presents a 
comprehensive view of the performance of the Commonwealth’s innovation ecosystem and its 
impact on the state’s economic prosperity through these 25 quantitative indicators. However, 
the focus of this paper will be on a few quantitative indicators.  Those indicators are listed in 
Table 1 below.  
These specific indicators were chosen precisely to better understand the importance of 
innovation in our economy and it also serves a purpose in informing evidence-based decision-
making in industry, academia and government. Each of the previously mentioned indicators 
plays a key role in determining the strength of a particular cluster and, in the sense of the 
bigger picture, analyzing the growth of the life science industry in Massachusetts. To better 
understand and organize these indicators, they are placed in six categories, Economic Impact, 
Research, Technology Development, Business Development, Capital, and Talent. Table 1 shows 
which indicator corresponds with which category.  
Table 1: Indicator Categories 
 
Economic Impact consists of two indicators: lab inventory & employment growth and 
occupations & wages. Employment growth and increased lab inventory can indicate 
competitive advantages for the MIE and potential for future economic growth. Also, 
employment concentrations that is higher than the national average indicates skill strengths 
Economic Impact Research
Technology 
Development
Business 
Development Capital Talent
Occupations and Wages
Research and 
Development
Approvals of 
pharmaceuticals and 
medical devices
Business Formation
Federal Funding
Workforce Education 
Level
Employment Growth Patenting Technology Licensing
Mergers and Initial 
Public Offerings Private Funding
Science Degrees 
Awarded
Small Business 
Innovation Research & 
Small Business 
Technology Transfer Biomanufacturing
Capital and Human 
Resources
Lab Inventory
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that are unique to Massachusetts. Occupations & wages is an important indicator because 
shifts in this indicator could suggest shifts in job content and skill utilization. (Massachusetts 
Technology Collaborative, 2011) 
Research also consists of two indicators: research & development (R&D) performed and 
patenting. “R&D performed in Massachusetts is an indicator of the size of the science and 
technology enterprise,” (Massachusetts Technology Collaborative, 2011). It also provides a 
sense of the region’s capacity for knowledge creation. Patenting is also a crucial indicator 
because, “high levels of patenting activity indicate an active R&D enterprise combined with the 
capacity to codify and translate research into unique technology with commercial potential” 
(Massachusetts Technology Collaborative, 2011). 
Three indicators fall under the category of technology development: approvals of 
pharmaceuticals and medical devices, Small Business Innovation Research (SBIR) grants, and 
technology licensing. Approval of pharmaceuticals and medical devices is a very important 
indicator in Massachusetts, and in fact in the whole country, because America is one of the 
leading countries in manufacturing medical devices (Shah et al., 2008). These approvals indicate 
important relationships with research hospitals where many of such devices have to go through 
clinical investigations and trial. SBIR grants enables small companies to conduct proof-of-
concept research on technical merit and idea feasibility and prototype development building on 
previous findings. Technology licensing promotes and reinforces incentives at universities, 
hospitals, and non-profit research institutes. This is because technology licenses “provide a 
vehicle for the transfer of codified knowledge in the form of intellectual property (IP),” 
(Massachusetts Technology Collaborative, 2011). 
Business Development has two indicators: business formation and mergers/initial public 
offerings (IPO’s). Business formation is a useful indicator for the overall volume of job creation 
and cluster growth.  Mergers/IPO’s indicates which important business strategies can help 
startup companies access capital, expand operations, and support business growth. 
(Massachusetts Technology Collaborative, 2011) 
There are two indicators in the Capital category: federal funding for academic, non-
profit, commercial and health R&D, and venture capital. Federal funding is essential for 
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sustaining academic, non-profit, and health-related research and this research is critical for 
Massachusetts to advance in basic science and creating technologies so it is no surprise that 
this indicator is very important (National Science Board, 2012). Venture capital is, “an important 
source of funds for the creation and development of innovative new companies,” 
(Massachusetts Technology Collaborative, 2011) 
Talent consists of two indicators: workforce education levels and science degrees 
awarded. Massachusetts' capacity to generate and support innovation-driven economic growth 
is dependent on a well-educated workforce (Porter, 1995). Science degrees awarded are very 
important because the demand for professionals in the science field is particularly high in 
Massachusetts (National Science Board, 2012). 
2.9 Summary 
By understanding key terms related to the life science and also business field, we gain the 
ability to evaluate Worcester County Life Science Economy. Life Science encompasses the fields 
of biological sciences, biotechnology, biomedical sciences, biochemistry, medicine, and certain 
environmental sciences. Biomedical research is an already emerging industry which continues 
to grow and has been a key portion of the Worcester County economy. Many companies began 
as small startups, which grow within business incubators and some progress into self-sustaining 
companies.  These companies form interconnections with other industries and institutions 
which form clusters that affect competitiveness of a region. There are many approaches to 
evaluate a region’s competitiveness. Quantitative economic indicators are benchmarks to 
measure growth in the life science industry.   
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3.0 Methodology 
In order to determine the competitive advantage of the Worcester County life science 
economy, four objectives were addressed: determining factors that drive growth in a life 
science industry, documenting the recent state of the life science industry in the United States 
and Massachusetts, and documenting the growth of the life science industry in Worcester 
County and making recommendations to remediate the weaknesses. Various methods that 
include data collection, expert interviews and secondary data analysis were conducted to 
achieve the objectives. 
3.1 Determining factors that drive the growth in a life science industry 
Two documents were used as guidelines in order to assess what factors best illustrate 
the growth of a life science industry. Those documents are:   
1. 2011 and 2012 Index of the Massachusetts Innovation Economy, published by 
Massachusetts Technology Collaborative  
2. 2012 Biopharma Industry Snapshot, published by Massachusetts Biotechnology Council 
These documents provided the indicators (see Table 1) that corresponded with the factors that 
drive growth in life science industry. This IQP followed the organizational format of the Index of 
the Massachusetts Innovation Economy due to its clarity and effectiveness.  
Background research was conducted on the determined indicators to understand their 
significance in the life science industry. 
The indicators provided a platform through which Massachusetts economy can be 
compared to other states and countries, including the United States.  
3.2 Documenting the state of the life sciences industry in the United States and 
Massachusetts 
 The team used expert interviews as the primary method of obtaining resources that 
provided raw data on the previously stated indicators. Interview protocols that catered to each 
interviewee’s expertise were designed to facilitate the dialogue. Kevin O’Sullivan, the CEO of 
MBI, was the team’s main adviser in selecting these experts and contacting them to arrange 
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interviews.  Candidates for interviews included the developers of the 2012 Index of the 
Massachusetts Innovation Economy, officials from the Massachusetts Biotechnology Council, 
local Worcester County life science business experts, and WPI business professors.  A final list of 
the interviewees was determined with Mr. O’Sullivan’s assistance.  In the interviews, the 
candidates were provided the list of the quantitative indicators and were asked to provide 
insight into which of these indicators they felt were strong and weak in Massachusetts and 
United States.  The interviewees were also asked to utilize their years of research experience to 
provide reliable resources specific to the indicators. Some of these resources included National 
Institute of Health (NIH), United States Patent and Trademark Office, National Science 
Foundation (NSF), United States Bureau of Labor Statistics, Small Business Association (SBA) 
and United States Census. 
3.3 Documenting the growth of the life science industry in Worcester County 
The resources that the interviewees provided, mentioned above, were also utilized to 
gather raw data on Worcester County. The interviewees were also asked to discuss what they 
felt were Worcester County’s strengths and weaknesses in terms of the quantitative indicators.  
3.4 Making recommendations to remediate the weaknesses  
 After the weaknesses were identified, recommendations for remediation were offered 
to MBI. With these recommendations, MBI can advise companies to take steps necessary to be 
competitive and further their growth. Recommendations were formulated through the 
thorough analysis of the basic background research and the raw data collected. Feedback from 
experts also helped determine the recommendations. 
3.5 Summary 
The team relied on information provided through the interviews to guide secondary 
data collection and analysis. These analyses generated conclusions about the Central 
Massachusetts life sciences cluster, and subsequent recommendations.   
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4.0 Results 
This section organizes each indicator into the aforementioned categories, Economic 
Impact, Research, Technology Development, Business Development, Capital, and Talent. Each 
indicator section starts off with a basic background. A thorough analysis was conducted on each 
indicator’s significance and the raw data that was collected for Massachusetts and Worcester 
County was organized and examined to determine if the indicator in question is a strength or 
weakness. One major setback was, for some indicators, the data on Worcester County was not 
readily available. 
4.1 Economic Impact 
4.1.1 Occupations and Wages 
The Massachusetts economy contributes to a higher standard of living throughout the 
Commonwealth because it supports middle and high wage jobs (Abair, 2012). Employment 
concentrations that are higher than the national average indicate skill strengths particular to 
Massachusetts, its competitive advantage (Abair, 2012). Changes in occupational employment 
and wages suggest shifts in job content and skill utilization, as well as in the overall skill mix of 
the workforce across all industries, including Life Science (Abair, 2012). 
The estimated average salary in the biopharma industry is 90% higher than the 
estimated state average salary of $59, 676 (see Figure 2). More specifically in the Life Science 
industry, Massachusetts has seen a 42% growth in employment from 2002 to 2011 (Abair, 
2012).  
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Figure 2: Comparison between estimated State Average Salary and Biopharma 
Industry Average Salary 
 
 
Just as with employment growth, NAICS codes were used in the Bureau of Labor 
Statistics’ Quarterly Census of Employment and Wages Location Quotient Calculator to 
calculate total wages in life sciences in both Worcester County and Massachusetts (Refer to 
Table #2 for full list of NAICS codes and the percentage of those codes that could be used in 
estimating overall life science employment).  
Figure 3 below shows the graphical representation of the raw data (which can be found 
in the Appendix C) of total wages in life sciences in Worcester County from 2005 to 2010. 
Surprisingly, the total wages in life sciences increased during the recession of 2007 and 
continued to rise until 2008. It decreased slightly from 2008 to 2009, but is back on the rise and 
can be predicted to stay on the positive trend for the next five years.  
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Figure 3: Total Wages in Life Sciences in Worcester County (2005-2010) 
 
 
Shown below in Figure 4 is the graphical representation of the raw data (which can be 
found in the Appendix C) of total wages in Massachusetts between 2005 and 2010. When 
compared side by side, it is clear to see that Massachusetts follows the same trend line as 
Worcester County, rising from 2006-2008 with a slight depression from 2008-2009 and then a 
slight rise. However, as the linear trend line below shows, Massachusetts, just as Worcester 
County, has experienced a steady positive trend. It can be projected that the total wages will 
rise and continue rising for the next five years. 
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Figure 4: Total Wages in Life Sciences in Massachusetts (2005-2010) 
 
4.1.2 Employment Growth  
Contrary to belief, annual net job gain is not positive at existing companies even though 
they constantly create – and destroy – jobs. A relatively new dataset from the U.S. government 
called, Business Dynamics Statistics (BDS) confirms that the net job growth occurs in the U.S. 
economy only through startup companies. In terms of numbers, the dataset reveals that, both 
on average and for all but seven years between 1977 and 2005, existing firms are net job 
destroyers, losing one million jobs net combined per year. On the other hand, new firms add an 
average of 3 million jobs in their first year. A study done by the Kauffman Foundation analyzed 
these numbers from the BDS. This study called, Importance of Startups in Job Creation and Job 
Destruction also revealed that job growth patterns at both startups and existing firms are pro-
cyclical, although existing firms have much more cyclical variance. Pro-cyclical is any economic 
quantity that is positively correlated with the overall state of the economy. On the other hand, 
cyclical variance AKA counter cyclical is any economic quantity that is negatively correlated with 
the overall state of the economy (Kane, 2010). 
With that in mind, data on the number of employees in both Worcester County and in 
Massachusetts was collected and analyzed using the Bureau of Labor Statistics’ Quarterly 
Census of Employment and Wages Location Quotient Calculator. The search was limited to 
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several specific North American Industry Classification System (NAICS) codes which are 
considered to fall into the category of “Life Sciences” as outlined by Peter Abair, Director of 
Economic Development and Global Affairs for MassBio. However, only in certain cases can the 
industry claim 100% of any one NAICS code. Therefore, MassBio has determined that a 
percentage of some industry classifications could be used in estimating overall industry 
employment. Those NAICS codes and the percentage of those codes that could be used in 
estimating overall life science employment are shown below in Table 2. 
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Table #2: NAICS Codes with Life Science Employment Percentages 
NAICS Code NAICS Name Percentage 
334510 Electro-medical Apparatus 100% 
334517 Irradiation Apparatus 100% 
339112 Surgical and Medical Instruments 100% 
339113 Surgical Appliances and Supplies 100% 
339114 Dental Equipment and Supplies 100% 
3254 Pharmaceutical MFG, including biologics 100% 
541711 Research and Development in 
Biotechnology 
100% 
541712 R&D in Physical, Engineering, and Life 
Sciences 
22% 
334516 Analytical Laboratory Instrument MFG 30% 
54138 Testing Laboratories 30% 
622 Hospitals 4.5% 
61131 Universities 1.9% 
 
Each of those codes was looked at for Worcester County and Massachusetts between 
the years 2005-2010 (Refer to Appendix D). The numbers for each code were added to create 
one general, “Life Sciences” category for each year. Shown below in Figure 5 is the graphical 
representation of the total number of employees in Worcester County between 2005 and 2010. 
The steady increase that had started at 2006 abruptly ceased due to the recession and slowly 
decreased until 2009. From then on, Worcester County Employment numbers has seen a steady 
growth. As the linear trend line below shows, Worcester County has experienced a steady 
positive trend. It can be projected that this positive trend will continue for the next five years. 
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Figure 5: Total # of Employees in Worcester County (2005-2010) 
 
 
Shown below in Figure 6 is the graphical representation of the total number of 
employees in Massachusetts between 2005 and 2010. When compared side by side, it is clear 
to see that Massachusetts follows the same trend line as Worcester County; a steady increase 
that started at 2006 and slowed down due to the recession of 2007. The difference from 
Worcester County is that Massachusetts continued at a slow increase till 2008 and from then 
on its employment numbers has seen a steady decrease. However, as the linear trend line 
below shows, Massachusetts, just as Worcester County, has experienced a steady positive 
trend. It can be projected that the employment growth will rise and continue rising for the next 
five years. 
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Figure 6: Total # of Employees in Massachusetts (2005-2010)
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4.2 Research  
4.2.1 Research and Development 
 Research and development is the process of taking an idea from its preliminary phases 
and developing products or applications that will hopefully benefit the human population 
(Definitions of Research and Development: An Annotated Compilation of Official Sources, 
2012).  Understanding where research and development is being performed and the 
investment in this area is important in understanding the strength of a life science cluster.  If 
research and development is not being performed in a life science cluster, then it will have very 
little success.  Research and development leads to receiving patents, technology licensing, and 
eventually revenues and is an indicator for the size of the science and technology sector of the 
region.    
According to the 2012 Biopharma Industry Snapshot, a study done by Massachusetts 
Biotechnology Council, Massachusetts is a leader in research and development with the highest 
biotechnology research and development employment between 2007 and 2011 (Abair, 2012).  
Table 3 shows the biotechnology research and development employment growth from 2007 
until 2011.  Massachusetts clearly shows an advantage in this area leading all states in 
employment even the state of California which is a much larger state than Massachusetts in 
terms of population, size and economy overall. 
Table 3: Biotechnology Research and Development Employment 
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Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW) 
 
 Table 4, shown below, gives a breakdown of research and development performance in 
the U.S. by ranking states in 2008.  Massachusetts is ranked fourth in the U.S. in this category 
which is mainly attributed to renowned universities and high technology industries in the state 
(Research and Development: National Trends and International Comparisons, 2012). 
Massachusetts also ranks fourth in research and development intensity which is calculated as a 
ratio of research and development to Gross Domestic Product (GDP).  This is an important 
statistic to measure because it represents a state’s investment in research and development.  
For example, California ranks first in Research and Development expenditures, but ranks ninth 
in research and development intensity.  Likewise, New Mexico does not rank in the top ten for 
research and development, but is first in terms of intensity.  From these two sets of data below, 
it is apparent that Massachusetts invests a substantial amount of money into research and 
development.  
 
Table 4: Breakdown of research and development performance in the U.S. by ranking states 
in 2008 
 
(Research and Development: National Trends and International Comparisons, 2012) 
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 It was important to understand the contribution Worcester County had to 
research and development in Massachusetts.  Figure 7 presents the top sixteen counties in the 
country in biotechnology research and development employment.  Worcester County was 
number sixteen in employment with 1,248 bitoechnology research and development 
employees.  Middlesex, MA, which includes Cambridge, led all counties with 17, 090 
employees.  Another interesting statistic to note was that four Massachusetts counties ranked 
in the top sixteen in the country for research and development employment.  Although 
Worcester county has a minor contribution to this statistic compared to other Massachusetts 
counties, there has still been success in the region in comparison to other counties in the 
country.  Worcester County continues to develop its life science industry and this statistic 
showed that it has begun to compete with other life science clusters already.    
Figure 7: Top sixteen counties in the U.S. in biotechnology R&D employment 
 
Source: U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages (QCEW) 
Exact employment numbers can be found in Appendix D. 
Unfortunately, county data on research and development expenditrues are not readily 
available or documented for Massachusetts .  Only the National Institute of Health provided 
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data on research and development contracts and was able to be broken down by company or 
university.  Although useful, this data was only responsible for a small portion of the available 
research and development in Massachusetts or in Worcester County.  There was also funding 
from the National Science Foundation and Department of Defense that was not available.  
Although not all of the data are available, it can still be useful to follow the trends of the 
funding that were found and where it is being allocated to.   Figure 8 shows the trends of NIH 
funding in Worcester County for research and development. 
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Figure 8: NIH funding in Worcester County for R&D 
 
From 2004 until 2011, an upward trend is clear despite a substantial drop in funding in 
2007.  However, closer inspection at the data showed that most if not all of the research and 
development funding was distributed to the UMass Medical School and Seracare Life Sciences 
Inc.  Also, Biomedical Research Models Inc. was also able to receive funding in 2006 and 2008 
which is important to note because they have been successful in acquiring SBIR/STTR funds as 
well.  Exact amounts for each company found on the NIH database can be found in Appendix D.  
Since the data presented only accounts for a portion of available research and development 
funds, it would be inaccurate to draw conclusions from this data.  However, it was beneficial to 
discover to what companies and institutions these funds were being allocated to because the 
methods that they are using to successfully acquire funding can be studied and implemented in 
other parts of the county.  Comparing this data to Massachusetts was not necessary because of 
the lack of information available at the county level. 
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4.2.2 Patents 
The United States Government grants inventors their intellectual property right through 
patents “to exclude others from making, using, offering for sale, or selling the invention 
throughout the United States or importing the invention into the United States” (Patents, 
2012). The patent is approved for a limited time in exchange that the invention is released 
publicly.  
There is certain usefulness of patents. Through patents, an inventor can compare 
his/her own inventions to existing inventions, conduct competitive market analysis, track 
innovations and understand product design features and specifications (The New Inventors, 
2011).  
Three types of patents which are granted are utility patents, design patents and plant 
patents: 
“Utility patents may be granted to anyone who invents or discovers any new and useful 
process, machine, article of manufacture, or composition of matter, or any new and 
useful improvement thereof. Design patents may be granted to anyone who invents a 
new, original, and ornamental design for an article of manufacture. Plant patents may 
be granted to anyone who invents or discovers and asexually reproduces any distinct 
and new variety of plant”  
(The United States Patent and Trademark Office, 2012).  
Life science patents not only gives the public knowledge about a new product, but also 
addresses questions about the impact of the patents on several ethical and technical issues 
such as access to medicines and transfer of environmentally friendly technology. 
The characteristics that are significant to life science policymakers, “who are concerned 
not only with the substance of emerging technologies, but also with who holds exclusive rights 
over technologies, where and for how long” are revealed through the patent system (Taubman, 
2008): 
 “Legal information, including published details of what material is patented, with what 
legal scope, in what countries, in whose name, and when it passes into the public 
domain 
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 Technological information, such as a patent’s so-called ‘teaching’ or technical disclosure, 
which is required to give a skilled reader all the information needed to put the new 
technology into practical effect” (Taubman, 2008) 
Table 4 below shows the total number of patents issued in United States, Massachusetts and 
Worcester County from the year 2006 to 2010. 
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Table 4: Total Number of Patents Issued in the United States, Massachusetts and Worcester 
County 
FIPS 
Code 
Mail 
Code 
State Or 
Territory 
Regional 
Area 
Component 
2006 2007 2008 2009 2010 Total 
All All All U.S. 
States/Region
s 
All Area 
Components 
89814 79522 77500 82379 107787 437002 
  Massachusett
s 
All County In 
Massachuset
ts 
4012 3508 3519 3697 4924 19656 
25027 MA Massachusett
s 
Worcester 
County 
394 362 372 413 497 2037 
(U.S. Patent and Trademark Office, 2011) 
 
The percentage of total number of patents granted in the U.S. decreased by 11.46% 
from the year 2006 to 2007. From 2007 to 2008, the decrease in the number of patents granted 
in the U.S. was 2.54%. However, from 2008 to 2010 the total number of patents granted 
increased: 6.3% between the year 2008 and 2009 and 30.84% between the year 2009 and 2010. 
The reason for the rise is that from 2008 the economy of the U.S. was slowly recovering from 
the recession it experienced the year before. From 2008 to 2009, the recovery was slow, but 
the recovery was much faster from 2009 to 2010. During the recovery, companies and 
institutions had been getting more funds and employees to work on patents and thus a higher 
percentage of patent applications were successful during those years.  Figure 9 below shows 
the total number of patents issued in the United States. 
  
34 
 
Figure 9: Total Number of Patents Issued in U.S. (2006-2010) 
 
(U.S. Patent and Trademark Office, 2011) 
 
During the recession (from the year 2006 to 2007), the number of patents granted in 
Massachusetts decreased by 12.56%, whereas patents granted in Worcester County decreased 
by 8.12% during the year. After the recession of 2007, patents approved in Massachusetts 
increased only by 0.31% (the increase was by 11 patents), whereas patents granted in 
Worcester County increased by 2.76% (the increase was by 10 patents). Between 2008 and 
2009 the patents granted in Massachusetts went up by 41, which is a 1.17% increase and the 
patents granted in Worcester County increased by 41 also, which is a steep increase of 11.02%. 
Patents issued in Massachusetts increased by 84 (increase of only 2.27%) from the year 2009 to 
2010, and the increase in Worcester County was also by 84 patents, which is a steep rise of 
20.34%. From 2007 to 2010, the percentage increase in Massachusetts patents was solely due 
to the increase in Worcester County patents. Figure 10 and 11 below shows the total patents 
established in the State of Massachusetts and in Worcester County from the year 2007 to 2012 
respectively. 
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Figure 10: Total Number of Patents Issued in Massachusetts (2006-2010) 
 
(U.S. Patent and Trademark Office, 2011) 
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Figure 11: Total Number of Patents Issued in Worcester County (2006-2010) 
 
(U.S. Patent and Trademark Office, 2011) 
 
Table 5 below shows the percentage of Massachusetts Patents issued to Worcester County 
(U.S. Patent and Trademark Office, 2011) 
  
Table 5: Percentage of Massachusetts Patents Issued to Worcester County (2006-2010) 
2006 2007 2008 2009 2010 Total 
9.82% 10.32% 10.57% 11.17% 10.09% 10.36% 
 
Figure 12 below shows the percentage of Massachusetts patents comprising of patents granted 
in Worcester County. 
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Figure 12: Total Number of Patents Issued in Worcester County (2006-2010) 
 
(U.S. Patent and Trademark Office, 2011) 
 
Table 6 below shows the life science related patents issued to Worcester from the year 2006 to 
2010. 
 
Table 6: Life Science Related Patents Issued to Worcester County (2006-2010) 
2006 2007 2008 2009 2010 Total 
88 96 90 104 174 552 
 
The percentage of Worcester County patents related to life-science from the year 2006 to 2010 
is shown in Table 7 below.  
 
Table 7: Percentage of Worcester County Patents Related to Life Sciences (2006-2010)  
2006 2007 2008 2009 2010 Total 
22.34% 26.52% 24.19% 25.18% 35.01% 27.10% 
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Figure #13: Life Science Patents Issued in Worcester County (2006-2010) 
 
(U.S. Patent and Trademark Office, 2011) 
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4.3 Technology Development 
4.3.1 Approvals of Pharmaceuticals and Medical Devices 
Premarket Approvals (PMAs), Premarket Notifications (PMNs), and New Drug 
Applications (NDAs) are an important benchmark for regions because they measure the 
productivity of companies, institutions, and organizations in the region.  PMAs are the most 
tedious type of marketing application required by the Food and Drug Administration (FDA).  
They are used to evaluate Class III medical devices, “devices used to support or sustain human 
health, are of substantial importance in preventing impairment of human health, or which 
present a potential, unreasonable risk of illness or injury” (Premarket Approval, 2012).   
Approving a PMA, grants the involved party the permission to market the device 
because it has been deemed safe and effective for use.  Massachusetts has been steady 
averaging around 2 or 3 PMAs per year since 2005, but none have come from the Worcester 
County area (Kispert, 2012).  The Middlesex County area has been the leader in PMAs which is 
not very surprising considering the level of success the region has experienced for quite some 
time in the life sciences industry.  A less sophisticated, but still significant benchmark of success 
in terms of commercialization is PMNs.  These are improvements to existing products already 
on the market and Worcester County has found some success in this area.  Table 8 shows the 
amount of PMNs in the Worcester County compared to the total PMNs approved in 
Massachusetts from 2005 to 2011.  Data from 2012 is not included because it is incomplete. 
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Table 8: Premarket Notifications 
Year 
Worcester 
County Massachusetts 
2005 11 238 
2006 7 261 
2007 3 250 
2008 12 215 
2009 7 225 
2010 11 209 
2011 9 208 
(Massachusetts Technology Collaborative) 
  
It is evident that Worcester County does not contribute significantly to the overall 
number of PMNs in Massachusetts.  However, other than the year 2007, Worcester County has 
averaged around ten PMNs per year despite the declines of Massachusetts.  Therefore, it can 
be concluded that the trend of PMNs in Worcester County does not follow Massachusetts 
trends and this data is a result of type of the companies and research being done in the county.   
 New Drug Applications is a lengthy, time consuming, and financially risky process.  
According to the Tufts Center for the Study of Drug Development it can take anywhere from ten 
to fifteen years for a new drug to reach the market from clinical stages (New Drug Approvals in 
2011, 2012).  It can take on average $1.2 billion for a drug to get to patients from the laboratory 
including costs of failure (New Drug Approvals in 2011, 2012).  Creating a billion dollar drug is 
rare and is something that Worcester County has not produced yet other than the drug Humira 
developed by Abbvie Inc. located in Worcester County, but credit is given to the Abbot Inc. 
headquarters located in Illinois.  Middlesex County, specifically Cambridge, Massachusetts has 
been the leader in NDAs producing two in 2011.  Figure 14 displays the difficulty associated 
with moving a drug through clinical phases to market development. 
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Figure 14: Drug Discovery and Development 
 
(New Drug Approvals in 2011, 2012) 
Only Big Pharma companies have the resources available to push a drug to market with 
all these obstacles present.  Worcester County is made up of primarily smaller startup 
companies so it is fair to assume that this is the reason for the absence of NDAs in the 
Worcester County area.  Until larger companies begin to move westward in Massachusetts, the 
concentration of these NDAs will remain in the Boston area.     
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4.3.2 Technology Licensing 
“Codified” information in the form of intellectual property, from universities, hospitals, 
and non-profit research organizations, can be transferred to “companies and entrepreneurs 
looking for to commercialize the technology” through technology licenses (Kispert et al., 2007) 
The companies and entrepreneurs who want to get into contracts with the original owner(s) to 
receive the intellectual property have to give compensation for the license. The compensation 
can be: 
 lump sum royalty 
 royalty based on volume of production, which is known as running royalty) 
 right to use licensee's technology, which is also known as cross licensing) 
License royalties are typically established by comparing the “revenue generated from 
the sales of the products and services using the licensed intellectual property or from the 
achievement of milestones on the path of commercialization.” In order to authenticate the 
original research and invention and to reinvest in new or follow-on R&D, rise in royalty returns 
is essential. 
Through licensing of patented or trademarked technology, small firms can earn substantial 
revenue from markets that they could not enter on their own and large firms can have foreign 
connections without high commercial and legal risks.  
 
Biotech patent owners grant licenses for many reasons: 
•       “to trade long-term risk and the possibility of substantial income for the certainty of a, 
perhaps    more modest, short-term payoff 
•       to obtain development and marketing assistance beyond the owner’s abilities 
•       to obtain clinical development for applications of academic discoveries 
•       to obtain funding for further research 
•       to exploit areas that would not be developed in-house by the patent owner 
•       to enhance reputation in a field by collaborating with a well-known company” 
The owner is open to many risks while allowing licenses: 
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•       “adding a competitor if the product is in an area the licensor already exploits 
•       having to depend on the choice of the licensee to realize the value of the discovery (if the     
licensee fails, the opportunity may be lost) 
•       having to share profit in the long run if the invention succeeds 
•       losing control over information that could be kept secret if development were done in-
house” (Freeman, 2007, pg 998) 
The licensee accepts a license for different reasons: 
•       “to ensure freedom to use a product line 
•       to obtain exclusivity for a product line 
•       to become current quickly without the cost of internal research” (Freeman, 2007, pg 999) 
Massachusetts has risen to achieving the highest number of technology licenses in the 
nation between 2001 and 2011. There was a 36% increase in the total number of licenses in 
Massachusetts while there was a drop by percent in California. This was due to increase 
production innovation and rise in business establishments in Massachusetts (Kispert et al., 
2012).  Figure 15 below shows the total number of technology licenses and options executed in 
the United States in 2001 and 2011. 
 
Figure 15: Technology Licenses and Options Executed in U.S. 
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The academic sector implemented the majority of technology licenses between the year 
1996 and 2007. However, from 2008, research institutions and hospitals implemented the most 
number of licenses. There has been a 143% rise in licenses executed from research institutions 
and hospitals while there was 11% decrease in the number of licenses executed from 
universities (shown in Figure 17).  
After the recession of 2007, revenues from technology licenses in Massachusetts 
dropped sharply in 2008. However, there has been slow growth from 2009 to 2011 in the total 
revenues earned from the commercializing intellectual property from universities, hospitals and 
research institutions (shown in Figure 16).  
Figure 16: Revenues from Technology Licenses and Options Executed 
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Figure 17: Technology Licenses and Options Executed in Massachusetts 
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4.3.3 Small Business Innovation Research Grants/STTR 
Small Business Innovation Research Grants (SBIR) and Small Business Technology 
Transfer Grants (STTR) are very competitive sources of funding that provide small businesses 
the opportunity to further conduct research.  It can take many years and millions of dollars to 
move an idea to commercialization (New Drug Approvals in 2011, 2012).  Therefore, being 
successful in acquiring these types of funds is important for small businesses in the life sciences 
industries because they keep the company alive.  SBIR funds make it feasible for companies to 
perform Phase I and Phase II research and development.  Phase I typically consists of research 
and Phase II enables companies to conduct development work on Phase I findings (SBIR, 2012).  
Appropriate funding is necessary in these phases in order to bring an idea to commercialization.  
STTR funds are geared towards the relationship between small business and research 
institutions.  They are utilized with the intention of supporting the involved parties in 
commercializing innovative technologies (SBIR, 2012).  It is apparent that securing these sorts of 
funds is vital to the success of a company especially in an area where small businesses play an 
important role in the economy.  This is the case in Worcester County where many small 
businesses have been able to settle and thrive due to these funding programs.  Figure 18 
displays the National Institute of Health (NIH) and National Science Foundation (NSF) SBIR/STTR 
funds acquired in Worcester County.  It is important to understand the trends of this data as 
compared to funding in Massachusetts as a whole which is displayed in Figure 19 as well as the 
portion of Massachusetts funds that Worcester County is responsible for presented in Figure 
20. 
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Figure 18: NIH/NSF Worcester County SBIR/STTR Funds 
 
(Small Business Association, 2013) 
 
Figure 19: NIH/NSF Massachusetts SBIR/STTR Funds 
 
(Small Business Association, 2013) 
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Figure 20: Massachusetts Funds Allocated to Worcester County 
 
(Small Business Association, 2013) 
 
From examining the trends of both Worcester County and Massachusetts, it is apparent 
that the funds allocated to Worcester County are based on the availability of funds in 
Massachusetts.  However, in recent years, Worcester County has deviated from this pattern 
showing a decrease while fund allocation increased as a whole in Massachusetts.  Excluding the 
year 2006, Worcester County funding has remained around $8 million.  The project group 
discovered that a large percentage of funding in Worcester County has been allocated to the 
same companies every year.  Two of these companies are MicroBiotix and Biomedical Research 
Models, Inc.   
After discussion with the project sponsor, Kevin O’Sullivan, it was revealed that these 
companies employ full time grant writers that are experts in preparing grants which has led to 
the success of these companies in acquiring them.  The largest challenge in acquiring SBIR/STTR 
grants is the application process because of the length and difficulty associated with it.  If an 
inexperienced grant writer were to attempt this application process, their chance of success is 
much lower than that of an experienced writer that understands the process.  In an interview 
with Dennis Guberski, CEO of Biomedical Research Models, described the difficulty associated 
with the grant application process.  He stated that for an inexperienced writer it can take up to 
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a month just to learn how to write a grant application and then another month to complete it.  
Then it can take up to three months to review the application and if accepted, another ninety 
days for funds to be dispersed to the company.  Along with this, applicants must compete with 
other companies in a very competitive process.  Therefore, it is advantageous to have 
experience in the application process to increase the chances of successfully acquiring these 
grants.  Evaluating the data more closely has shown that this holds true for Worcester County.  
Figure 21 displays Worcester County SBIR/SSTR funds allocated by NIH/NSF to MicroBiotix and 
Biomedical Research Models, Inc., two companies with experienced grant writers. 
Figure 21: Worcester County Funds Allocated to MicroBiotix and Biomedical Research 
Models, Inc. 
 
 
Since 2004, these companies have received approximately 40% of NIH funds allocated to 
Worcester County for SBIR/STTR grants.  In 2010, there was a dip to 14% but that was opposed 
the next year with a large increase to 72%.  Other companies that have had success every year 
in Worcester County are GLSynthesis, Inc. and Grove Instruments LLC.  However, many 
companies in Worcester County have only been able to receive funding for one or two years 
and lack consistent funding.  This is attributed largely to the inability to write grant applications 
efficiently.  Many companies that are not large enough to employ a full time writer are usually 
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not consistent in acquiring SBIR/STTR funding.  The project team hopes to suggest 
recommendations to address this issue.   
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4.4 Business Development 
4.4.1 Business Formation 
 The number of business establishments is recorded annually by the United States 
Department of Labor, Bureau of Labor Statistics (BLS) for all types of business industry.  Each 
business is issued a North American Industry Classification System (NAICS), which categorizes 
them into a specific industry.  In the BLS database, establishments can be sorted by region, 
state, and county.  The field of life sciences was defined earlier in the employment growth 
section, and consists of twelve NAICS codes.  Not all twelve codes can be considered completely 
part of the life science field, so a weight was assigned to each category, which was determined 
by Massachusetts Biotechnology Council. 
 From 2007 to 2011, the total number of life science establishments increased by 12%.  
This was an addition of 145 establishments.  The greatest increase in business formation can be 
seen from 2007 to 2008, which accounted for 44% of business formation increases in the 5 year 
time period.  The next largest business formation increase occurred from 2009 to 2010, with 
22% jump.  Business formation was relatively slow from 2008 to 2009 and 2010 to 2011 with 
15% and 18% increases respectively.  Overall, business formation has slowed since 2008 (shown 
in Figure 22). 
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Figure 22: Number of Life Science Establishments in Massachusetts 
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In comparison, in the same time frame, Worcester County life science establishments 
increased only 6.5%.  Over this time frame, only 6 new businesses were formed.  Contrary to 
the State trend, the greatest increase of business formation in Worcester County was observed 
from 2008 to 2009, which accounted for 50% of business formation.  Over the next two years, 
only 2 more businesses were formed (shown in Figure 23). 
 
Figure 23: Number of Life Science Establishments (Worcester County) 
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Over this 5 year period, Worcester County has accounted from 7.7% to 8.3% of the 
State’s life science business establishments (shown in Figure 24).  Worcester County has seen 
slight decline over this period compared to the State.  Business formation data indicating slow 
to no growth can result from a variety of reasons.  One being firms are expanding size, rather 
than breaking off to form new companies, or new companies forming on their own.   
 
Figure 24: Percentage of Worcester County Establishments out of Massachusetts Total 
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4.4.2 Mergers/IPOs 
Usually issued by smaller, younger companies, Initial Public Offering (IPOs) where shares of 
stock are sold to the public for the first time. This transforms the once private company into a 
public one. In an IPO, an underwriting firm, usually an investment bank helps the issuer 
determine what type of security to issue, the best offering price and the time to bring it to 
market (Ellis et al., 1999). There are four main reasons why a company would want to go public: 
 
 Raises capital 
- For expansion efforts or to pay back debt. 
 Provides an exit  
- For existing investors – whether the company is private equity (PE) owned, venture 
capital (VC) backed, or owned by a small group of individuals or a single person. 
 Gets an acquisition currency  
- To make it easier to acquire other companies using stock once they’re public since 
most private companies’ stock is not highly valued. And raising debt to do deals can be 
easier once you’re public as well. 
 Rewards employees  
- Making employees work crazy hours for 5-10 years is tough to pull off, but the lure of an 
IPO that will make them all wealthy is a great incentive for them to stick around. 
 Markets themselves  
- Especially for lesser-known companies in “boring” industries, an IPO is a great way to 
increase prestige and attract new investors, partners, and customers. (Lee, 2012) 
 
A merger, in the strictest terms, is when two firms agree to combine and go forward as a 
single new company rather than remain separately owned and operated. Usually a “merger of 
equals” does not happen very often in reality. Typically one company, the larger, more 
successful of the two, will buy the other and simply allow the acquired firm to proclaim that the 
action is a merger of equals, when in reality it is an acquisition. There are several types of 
mergers, horizontal mergers, vertical mergers, market-extension merger, product-merger, and 
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conglomeration. There are many strong reasons of why companies would decide to merge. 
Strong companies will merge with smaller companies to create a more competitive, cost-
efficient company. On the other hand, smaller companies in danger of falling apart will merge 
in order to gain a greater market share or to achieve greater efficiency. Mergers enhance 
research outcomes by bringing together technological expertise and enhancing efficiency 
(Wagner et al., 2009).  
Mergers & acquisitions and initial public offerings represent important business 
strategies with which startup companies can access capital, expand operations and support 
business growth. Mergers and IPOs also provide opportunities for early-stage investors to 
liquidate their investments. “Mergers and acquisitions can alter incentives to innovate within a 
business by reducing competition or by allocating innovation to outsourcing via acquisitions of 
startup companies with proven or promising technologies” (Kispert, 2012).  
Although the focus of this project is the Worcester County, there is no data on mergers 
and IPOs that could be found that was any more specific that state wide. Because of this, 
mergers and IPOs were looked at in terms of Massachusetts. 
The venture-backed initial public offering in Massachusetts from 2004 to 2011 is 
graphically shown in Figure 25 below. After the record breaking number of venture backed IPOs 
(18) in 2007, the number of IPOs dropped to zero in 2008. Since then, Massachusetts has 
remained well below pre-recession levels.  It started increasing after 2009 and continues to rise 
(Kispert, 2012).  
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Figure 25: Venture-Backed Initial Public Offerings in Massachusetts (2004-2011) 
 
  
The number of 2010 venture-backed companies that went public in the U.S. was only 
12.7% below the number of venture-backed IPOs in 2007. IPOs grew from five to eight between 
2011 and 2012 in Massachusetts, which ranks second to California, as seen below Figure 26 
(Kispert, 2012). Figure 26 also shows the number of Initial Public Offerings for the years 2005, 
2011, and 2012 for New York, Pennsylvania, and Maryland. 
Figure 26: Number of Initial Public Offerings 
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However, when the number of IPOs is compared with the population of each state, the 
graph looks completely different in terms of which state comes in first. As can be seen from 
Figure 27 below, Massachusetts comes in first when IPOs are calculated per capita.  Figure 
27 also shows the number of Initial Public Offerings per capita for the years 2005, 2011, and 
2012 for New York, Pennsylvania, and Maryland. 
 
Figure 27: Number of Initial Public Offerings Per Capita 
 
 
In case of Mergers and Acquistions, Massachusetts is third behind California and New 
York. The number of deals in 2008, 2011, and 2012 (through the third quarter) for California, 
New York, Massachusetts, Pennsylvania, and New Jersey is shown below in Figure 28. Although 
in 2008, New York and Massachusetts had the same number of deals, New York’s numbers 
leaped up to around 230 deals, while Massachusetts went up to only around 130 deals, which is 
why New York is second place behind California.  
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Figure 28: Mergers and Acquisitions 
 
 
As in the case of IPOs, mergers and acquisitions were also looked at per capita. As Figure 29 
below shows, Massachusetts is once again ranked 1st in the number of deals per capita for 
mergers and acquisitions. Figure 29 also shows the number of mergers and acquisitions per 
capita for the years 2008, 2011, and 2012 for California, New York, New Jersey, and 
Pennsylvania.  
 
Figure 29: Mergers & Acquisitions Per Capita 
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In conclusion, Massachusetts is easily one of the top states in terms of Initial Public Offerings 
and Mergers & Acquisitions, especially when considered per capita. 
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4.4.3 Biomanufacturing 
Biomanufacturing represents “the production, isolation and purification of medicines 
made by pharmaceutical companies” (Biomanufacturing Home, 2013).  Growth of 
biomanufacturing companies and competition among them is important to ensure sustaining 
production of new drugs and to validate drug development.  
Massachusetts has “more than 500 biotech and pharma companies” (Massachusetts 
Biotechnology Council, 2011). There are about 314 companies which work on medicine 
development (Evaluate Pharma, 2012). Massachusetts Biotechnology Council reported in 
August 2012, that there were about 955 drugs in development in Massachusetts, which ranged 
from research project to pending approval stage.  Figure 30 below shows under separate 
categories, the number of drugs being developed in Massachusetts.  
Figure 30: Number of Drugs Developed in Massachusetts 
 
(Massachusetts Biotechnology Council, 2011) 
Worcester County has about 159 biomedical companies, which comprises of about 
23.2% out of all Massachusetts pharmaceutical companies. Massachusetts has about 1553 
medical equipment and devices companies, 684 pharmaceutical companies and 790 
manufacturing companies (Manta, 2013).  
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4.5 Capital 
4.5.1 Federal funding for academic, non-profit, commercial and health  
The U.S. government supports research and development (R&D) through various 
policies. The most prominent is federal performance and funding (Research and Development: 
National Trends and International Comparisons, 2012). The government finances R&D through 
spending and tax benefits that give business an incentive to increase their R&D spending 
(Federal Support for Research and Development, 2007). It was reported by the Congress of the 
United States Congressional Budget Office that in the fiscal year 2007 appropriations for R&D 
activities were a total of $137 billion (Federal Support for Research and Development, 2007). 
The federal funds are appropriately allocated, in general, depending on the areas of inquiry and 
projects that will potentially provide the highest returns on the investment (Federal Support for 
Research and Development, 2007). In order to understand the importance of multifaceted 
distribution of federal funds and to evaluate the effectiveness of the government’s R&D 
spending and the benefits it may provide, it is important to distinguish between research and 
development.  
Research has large prospective for spillovers and benefits in the economy (Federal 
Support for Research and Development, 2007). That is why research is favorable and may be 
conducted without a specific commercial purpose in mind. The knowledge produced by 
research is valuable to both researchers in other areas and to businesses that are looking to 
develop “new products and production processes” (Federal Support for Research and 
Development, 2007). Development applies scientific knowledge to the manufacture of specific 
marketable goods. Benefits of development reaches directly to “innovating firms and their 
customers” since it occurs closer to a product’s introduction (Federal Support for Research and 
Development, 2007). Federal funding deployed to development has certain criteria, such as 
focusing mainly on accomplishing public missions such as in the area of national defense 
(Federal Support for Research and Development, 2007). Although such funding in the 
development sector has spawned some commercially workable bonus technologies in the past, 
but the chances of that happening is unpredictable. About 50 percent of all research conducted 
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in the United States receive and rely on federal funding and development receives only 17% of 
federal funds (Federal Support for Research and Development, 2007).  Figure 31 below shows 
the total amount of federal grant spent on applied and basic research and development.  
 
Figure 31: Total U.S. Federal grants spent on applied research, basic research and 
development during the year 1953 to 2004 
 
 
There are two types of research that get funded, which are defense-based and non- 
defense based research (Federal Support for Research and Development, 2007). The two broad 
categories that determine the allocation of the federal funds to each of the types of research 
are mission-oriented activities and scientific and technical knowledge that will be beneficial to 
the economy (Federal Support for Research and Development, 2007). Most life science 
research falls under non-defense type.  Health-related R&D has been experiencing the greatest 
rise over the last two “which accounts for just over half of nondefense R&D spending” (Federal 
Support for Research and Development, 2007). Figure 32 shows the total United States federal 
spending on defense and non-defense related research and development. 
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Figure 32: Total U.S. Federal spending on defense and non-defense related research and 
development 
 
Over the last decade, the portion of federal funding assigned to life sciences has 
increased significantly since life sciences offer high rates of returns. The other reason that 
federal funding is critical to the growth of life sciences is it gives incentives to the researchers to 
identify new ideas and tools that generate substantial economic returns (Research and 
Development: National Trends and International Comparisons, 2012) . Figure 33 below shows 
the total funds allocated to different fields due to federal obligations.  
Figure 33: Total federal obligations for different research fields 
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There have been changes noticed in the funding trend for industrial, intramural and 
academic R&D over the same time period. In 2004, about 10 percent of government funds were 
allocated to industrial R&D while in the late 1950s and early 1960s; more than 50 percent were 
allocated for industrial R&D (Federal Support for Research and Development, 2007). Federal 
funding is being allocated more towards intramural and university R&D. the government 
funded about 10 percent (Federal Support for Research and Development, 2007). In fact, the 
percentage rate of federal funding for University-performed research increased more rapidly 
than federal funds allocated to any other sectors performing R&D. Federal funds for University 
R&D increased at real annual rate of 6.8 percent, and that fund is responsible for 60 percent of 
university R&D (Federal Support for Research and Development, 2007). 
The National Institute of Health (NIH) is one of the major sources of funding to the 
biomedical or the life science industry.  The allocations of funds are established upon three 
different qualifications, according to National Institute of Health, which are: 
a. “Grant proposals of high scientific caliber that are relevant to public health needs that are 
within the NIH Institute and Center’s priorities” (National Institute of Health, 2013) 
b. The project should “encourages investigator-related research across the spectrum of its 
mission” (National Institute of Health, 2013) 
c. The projects the individual or institution is conducting must be unique in the sense that they 
have never been done before. 
NIH funds create job opportunities in the U.S. and serve “as a foundation for the medical 
innovation sector, which employs 1 million U.S. citizens” (National Institute of Health, 2013). 
The main source of federal funding for health-related R&D is the Department of Health 
and Human Services (HHS). An estimate of 35.7 billion dollar was obligated for R&D and R&D 
plant, which is 26% of the total federal obligations, in the fiscal year 2009 returns of which 
about 34.6 billion dollars represented R&D activities of NIH (Research and Development: 
National Trends and International Comparisons, 2012).  During the fiscal year 2009, the federal 
government was obligated to provide 4.9 billion dollars to HHS due to the American Recovery 
and Reinvestment Act, making this the largest appropriation of all the federal agencies returns 
(Research and Development: National Trends and International Comparisons, 2012). Intramural 
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activities and FFRDCs received 21% of the total budget and Extramural performers, among 
which universities and colleges and other non-profit organizations are the main performers, 
received 79% of the total budget returns (Research and Development: National Trends and 
International Comparisons, 2012). The major portion of HHS R&D funding is allocated for 
research. In the fiscal year 2009, basic research received 53% and applied research received 
47% of the total research grant returns (Research and Development: National Trends and 
International Comparisons, 2012). Figure 34 below shows federal spending for research and 
development in the United States. 
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Figure 34: U.S. Spending for Research and Development 
 
(Federal Support for Research and Development, 2007) 
 
In the fiscal year 2009, about 6.9 billion dollars were allocated to R&D and R&D plants 
by the National Science Foundation (NSF), which is about 5% of the total federal budget returns 
(Research and Development: National Trends and International Comparisons, 2012). Mainly 
universities and colleges, which are part of the Extramural performers, represented 96% of the 
total funds allocated by NSF. In that period, American Recovery and Reinvestment Act were 
obligated to provide $2.2 billion to NSF for R&D and R&D plant, which accounted for the second 
largest funding among the agencies returns (Research and Development: National Trends and 
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International Comparisons, 2012). About 92% of the R&D funds went to basic research. “NSF is 
the federal government’s primary source of funding for academic basic science and engineering 
research and the second-largest federal source (after HHS) of R&D funds for universities and 
colleges” returns (Research and Development: National Trends and International Comparisons, 
2012). However, even if NSF is not the major source for life science funding, it is still a 
significant source.  
Therefore, in fiscal year 2009, about total of 133.3 billion dollars accounted for federal 
obligations to R&D and an additional 3.6 billion dollars accounted for R&D plant. “The American 
Recovery and Reinvestment Act of 2009 granted “$8.7 billion for R&D and $1.4 billion for R&D 
plant for the same fiscal year” returns (Research and Development: National Trends and 
International Comparisons, 2012). Figure 35 shows federal research and development, by 
Agency.  
 
Figure 35: Federal R&D Outlays, by Agency 
 
(Federal Support for Research and Development, 2007) 
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Universities and other non-profit research institutions are important to both the 
Massachusetts and Worcester County’s life science economy. Basic science field and 
technologies are growing with the help of these institutions and the products made by them 
are becoming commercially available through private sectors easily. To sustain academic, non-
profit and health-related research, federal funding is essential. “Awards from the National 
Institutes of Health (NIH) help fund the Commonwealth’s biotechnology, medical device, and 
health services industries which together comprise the Life Sciences cluster” returns (Research 
and Development: National Trends and International Comparisons, 2012).   
For National Institute of Health (NIH) R&D Funding per $1,000 GDP, Massachusetts 
came in first in 2011 but in terms of total funding to the state in came in second, behind 
California (Kispert et al., 2007). After the recession of 2007, NIH funding for Massachusetts 
increased only by 0.43%, whereas funds allocated to Worcester County increased by 3.8%. 
Between 2009 and 2008 the funding for R&D for Massachusetts went up by $119,137,380, 
which is a 5.09% increase and the funds for Worcester County increased by $12,814,804.00, 
which is a 9.41% increase. The NIH funding for Massachusetts increased by only 3.47% from the 
year 2009 to 2010, but funding for Worcester County showed a rise of 12.48%. However, from 
2010 to 2011 and from 2011 to 2012, the federal funding for Massachusetts went down by 
1.38% and 1.51% respectively (National Institute of Health, 2013).  
A fall was also noticed in the funds allocated to Worcester County. From the year 2010 
to 2011, the funds in Worcester County dropped by 1.59%. From 2011 to 2012, there was a 
sharp drop in the County funds by 10.35%. This is due to resolution passed by the Congress 
which includes a 10% across-the-board budget cut.  The cut includes most of the critical medical 
research in the U.S. Forbes reported that “80-85% of projects submitted to NIH, many of them 
excellent, don’t make the cut because NIH just doesn’t have enough funding for them” 
(Salzberg, 2013). Table 9 below shows the total NIH funding received by the State of 
Massachusetts and Worcester County and the percentage of funds allocated to Worcester 
County from the year 2007 to 2012. 
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Table 9: NIH Funding 
 
2007 2008 2009 2010 2011 2012 
Mass. 
$2,32
8,733,
874 
$2,338,640
,674 
$2,457,778
,054 
$2,543,013,
395 
$2,507,870,
229 
$2,470,036
,857 
Worcester 
County 
$131,1
22,438 
$136,110,64
2 
$148,925,44
6 $167,512,845 $164,854,428 
$147,798,15
9 
Percentage 
of Funds 
allocated 
to 
Worcester 5.63% 5.82% 6.06% 6.59% 6.57% 5.98% 
 
The total NIH funds and the trends (rise from 2007 to 2010 and decrease from 2010 to 2011) 
for the State of Massachusetts and Worcester County are shown below in Figure 36 and 37 
respectively from the year 2007-2012. 
 
Figure 36: NIH Funding for Massachusetts 
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Figure 37: NIH Funding for Worcester County 
 
The bar graph, Figures 38 and 39, below shows the total funds allocated to 
Massachusetts and Worcester County respectively for the year 2007 to 2012. 
 
Figure 38: NIH Funding MA 
 
 
  
72 
 
Figure 39: NIH Funding Worcester County  
 
 
Figure 40 below shows the percentage and trend of Massachusetts NIH funds allocated 
to Worcester County from the year 2007 to 2012. In the year 2007, the proportion of 
Massachusetts funds allocated to Worcester County was 5.63%. In the year 2008, the amount 
of Massachusetts NIH funds allocated to Worcester County was 5.82%. 6.06%, 6.59%, 6.57%, 
5.98% of Massachusetts NIH funds were allocated to Worcester County during the year 2009-
2012. 
Figure 40: Percentage of Massachusetts funds allocated to Worcester County 
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Even though Worcester County receives a fair proportionate of Massachusetts NIH 
funds, not many institution, organization and businesses are performing well in the federal 
funding grant applications. Most of the Worcester County NIH funds go to University of 
Massachusetts followed by Microbiotix Inc. and the GLSynthesis Inc. Table 1 below shows the 
proportion of Worcester County NIH funds received by different institutions and businesses 
during the year 2007 to 2012. 
 
Table 10 below shows the percentage of Worcester County NIH funds allocated to the top 
institution and companies in Worcester County.  
 
Table 10: Percentage of Worcester County NIH funds 
Rank Institution/ Companies 2007 2008 2009 2010 2011 2012 
 
1 
UNIV OF MASSACHUSETTS 
MED SCH  
WORCESTER 90.65% 90.22% 90.94% 91.56% 93.13% 90.78% 
2 MICROBIOTIX, INC 3.66% 4.45% 4.36% 3.27% 2.46% 5.47% 
3 GLSYNTHESIS, INC. 2.38% 1.72% 1.46% 1.01% 0.57% 1.16% 
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4.5.2 Private Funding 
In order to turn ideas and technologies into products, companies, and jobs, sufficient 
funding must be available (Kispert, 2013).  Funding can come from a variety of sources.  
Generally at a company’s early stages, funding comes from family, friends, or fools.  As they 
grow, opportunities for Angel funding are available, and after further growth is reached, 
Venture Capital becomes an option.  These organizations invest in a variety of fields ranging 
from biotech, gaming companies, to security systems companies.  Angel groups generally offer 
investments in the range of $250,000 to $500,000, in high growth and high tech industries.   
Many Angel groups determine how much money to invest by first predicting what the exit value 
of the company will be.  Overall in Massachusetts, Angel funding is playing a large role by 
financing startup companies, as Venture Capital investment has dropped 28% since 2007 before 
the recession.  More specifically at the startup level, Venture Capital investment has dropped 
45% between the years 2009 to 2011 (Kipert, 2012).   
According to the Angel Capital Association, there are 25 Angel groups in New England 15 
located in Massachusetts; only one, the Boynton Angels, is located in Central Massachusetts 
(Angel Capital Association, 2013).  Angel groups prefer to invest in companies that are relatively 
close to them, and with Worcester County only having one Angel group; it puts the region at a 
disadvantage compared to an area like Boston and Cambridge.  The Boynton Angels are unable 
to make many investments, due to the fact that they lack a sufficient number of investors 
(Schaufeld, 2013).   
Below is a graph on Venture Capital and Angel Investment in startup companies in 
Massachusetts from 2007 to 2011 from the 2012 Innovation Economy Index.  (No data on Angel 
funding specific to Worcester County could be obtained).  Since the Great Recession in 2008, 
the amount of Venture funding for startup companies deceased dramatically and continued to 
decline even until 2011.  Over this five year span, both low and high estimates for Angel funding 
decreased for four years, but noticeable growth occurred in 2011.  
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Figure 41: Startup and Seed Investment in Massachusetts 
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4.5.3 Capital and Human Resources  
Innovative ideas and products require state of the art facilities in which work can take 
place.  A location that has specialized facilities can be considered to have a competitive 
advantage over other regions that lack said facilities.  Worcester County features many of the 
state’s specialized life science facilities and “today, 49 of the state’s largest 100 life sciences 
companies are located west of Route 128” (Hurd, 2007). This indicates biotech has been 
expanding west of Boston, and new construction of facilities in Worcester County confirms 
this.  Companies may be expanding west into areas in Worcester County that have been 
identified as “Economic Target Areas” which offers state tax incentives, 5% investment tax 
credit for equipment, municipal tax incentives 
            Gateway Park located in Worcester, MA, was built by WPI and features “Five life 
sciences buildings totaling 550,000 square feet of flexible, adaptable lab space designed to 
meet the needs of research organizations” (Facts and Figures, 2013).  The Park is home to WPI’s 
Biomanufacturing Education and Training Center, “which provides innovative workforce 
development solutions customized to the specific needs of your company…Serving life sciences 
companies from across the region and the globe, the center represents an innovative 
partnership of academia and industry” (Life Science and Bioengineering Center, 2013). 
Massachusetts Biotechnology Research Park is a so called “Master-Planned 
Biotechnology Development” (Massachusetts Biotechnology Research Park and CenTech Park, 
2013).  Since its creation in 1985, the park has grown to be one of the country’s leading centers 
for biotechnology research and production, with almost one million square feet of building 
space across 105 acres of land (Massachusetts Biotechnology Research Park and CenTech Park, 
2013).  The Park has five main buildings which are home to 2,000 employees (Hurd, 
2007).  According to BioSpace, Massachusetts Biotechnology Research Park anchors the 
western end of Massachusetts’ 40-mile long “Genetown” corridor, which further supports the 
claim that more biotech companies are expanding out towards Worcester from Boston.  The 
Park is home to companies such as Abbott Bioresearch Center, Athena Diagnostics, Advanced 
Cell Technology, and BioVest International, as well as housing offices and labs for UMass 
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Worcester Medical School (Worcester Business Development Corporation, 2010).  More 
specifically the Park features UMass Worcester Medical School “labs of the departments of 
Biochemistry & Molecular Pharmacology, Physiology, and the Program in Molecular Medicine 
and of the Diabetes Endocrinology Research Center...the Meyers Primary Care Institute and the 
departments of Biochemistry & Molecular Pharmacology, Cell Biology, and Molecular Genetics 
& Microbiology and Physiology (Directions to Biotech Park, 2013).  In addition to established 
companies occupying space, the Park “offers a range of facility options, from fully built-out wet 
lab space for lease in units as small as 1,000 square feet to build-to-suit opportunities on land 
parcels up to 35 acres” (Massachusetts Biotechnology Research Park and CenTech Park, 2013, 
2013). 
            CenTech Park is a development similar to the Massachusetts Biotechnology Research 
Park, and the 121 acre site has been developed over the past ten years by the Worcester 
Business Development Corporation alongside the towns of Shrewsbury and Grafton, with help 
from Tufts University’s Cummings School of Veterinary Medicine.  The development received 
several million dollars in federal and state funds to update the infrastructure (Worcester 
Business Development Corporation, 2010). CenTech tenants include State Street Bank, IDEXX, 
Primary Colors, Verrillon, TriTech Software Systems, and UMass.   
            In two years, from 2007 to 2009, Bristol-Myers Squibb’s built a $750 million BioPharma 
manufacturing facility, in Devens, MA, which at the peak of construction employed over 1,000 
contractors.  The facility consists of four main buildings, a central utility building, an 
administrative/quality control building and a warehouse/storage structure, a waste water 
pretreatment plant, and accommodations for future expansion (Devens, Massachusetts, 
2013).    
In addition to private sector facilities, Worcester County colleges and universities 
feature state of the art science facilities.  According to the National Science Foundation, at the 
end of FY 2011 completed construction of science research and lab facilities at University of 
Massachusetts (UMass) Worcester Medical School totaled to over 535,000 square feet.  In this 
number, includes just over 300,000 square feet of biological and biomedical science space, 
more than 150,000 square feet of health and clinical science space, and nearly 40,000 square 
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feet for other science and engineering related fields (National Science Foundation, 2013).  The 
costs of all new construction and renovation from FY 2003 to FY 2011 totaled to over $550 
million (National Science Foundation, 2013).  With state of the art workspace, UMass 
Worcester Medical School can conduct innovative work in stem-cell research and also the 
science of RNAi (the discovery of which (RNAi) earned Dr. Craig C. Mello the Nobel Prize)” 
(Hurd, 2007).  With new construction, UMass Worcester Medical School has expanded its ability 
“to conduct clinical trials of investigative new medicines” (Hurd, 2007).   
            Tufts University’s Cummings School of Veterinary Medicine is the only American 
Veterinary Medical Association accredited institution in New England (Massachusetts 
Veterinary Medical Association, 2013).  Their campus is located just 20 minutes east of 
Worcester in Grafton, MA.  The school has built the 41,000 square feet New England Regional 
Biosafety Laboratory (NE-RBL) and has spent nearly $26 million on this lab (New England 
Regional Biosafety Laboratory, 2011).  This lab is “dedicated to the study of existing and 
emerging infectious, diseases, toxin-mediated diseases and medical countermeasures 
important to biodefense.  Tufts also “has a major research program studying the development, 
detection and potential treatments for infectious diseases that are food- or water-borne, or 
that originate in animals and spread to people” (New England Regional Biosafety Laboratory, 
2011). Scientists within the NE-RBL are conducting research to develop therapeutics, vaccines 
and diagnostic tools in a safe, secure, regulatory-compliant environment” (New England 
Regional Biosafety Laboratory, 2011).  This school offers research and collaborative 
opportunities to “investigators in academia, not-for-profit organizations, industry, and 
government” (New England Regional Biosafety Laboratory, 2011).  
There are several other well-known universities in Worcester County with large, state of 
the art facilities of their own, which help bolster the areas educational edge.  Worcester 
Polytechnic Institute reported through the National Science Foundation survey of Universities 
Science and Engineering Facilities, that as of FY 2011 they had over 100,000 square feet of 
science, technology, engineering, and mathematic (STEM) space.  The majority of space is 
devoted to various engineering fields which account for over 65,000 and 20,000 square feet is 
dedicated to biological and biomedical studies.  As of FY 2011, College of Holy Cross reported 
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over 130,000 square feet of STEM facility space, with 100,000 square feet dedicated to Physical 
Sciences such as astronomy, astrophysics, chemistry, and physics.  Also in FY 2011, Clark 
University reported 43,000 square feet of STEM facilities, and almost 50% being used for 
biological and biomedical sciences.  In addition to the above mentioned state of the art 
facilities, other institutions, such as Massachusetts College of Pharmacy & Allied Health Science, 
Worcester State, Assumption, and Fitchburg State possess facilities.   
Worcester County’s Life Science Parks, biomanufacturing facilities, and university 
research labs create the necessary critical mass of infrastructure for it to be considered an 
enticing location for biotech operations.  It is imperative for Worcester County not only to 
maintain this infrastructure, but improve and add to it in order to maintain this strength.   
Unique features to the facilities in Worcester can be easily found at Tufts University’s 
Cummings School of Veterinary Medicine.  Not only is it the only veterinary school in New 
England, but the programs and opportunities it offers make for a unique resource to the 
county.  The opportunities to collaborate give a distinctive advantage to companies located in 
the vicinity.  At UMass Medical, researchers are given the opportunity to work with the 
discoveries of Nobel Prize winner Dr. Craig C. Mello, a very unique advantage to conducting 
research here in Worcester County. 
The construction of these facilities has implications not only for life science companies 
who occupy the building, but also for the cities and towns in which they are located by creating 
more tax bases and employment opportunities.  All of the facilities located in the county are 
located within an Economic Target Area and a “job-creating project on this site (Tufts Cumming 
School of Veterinary Medicine) can obtain negotiated municipal property tax rates and a 5% 
Investment Tax Credit against state income taxes with unlimited carry-forward provisions” 
(Worcester Business Development Corporation, 2010).  The economic designations in place 
yield a tremendous advantage for Worcester County. 
The location of Worcester County is one of its greatest competitive advantages.  It is an 
hour drive from Boston and Providence, cities which contain valuable resources such as an 
International airport, funding, and life science businesses.  Within the county’s limits sits one of 
the top engineering schools in the country, WPI.  An hour to the east is MIT, the top 
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engineering school in the country, and two hours to the west is RPI.  This central location allows 
Worcester County businesses to draw from a specialized pool of talent (Guberski, 2013).  The 
location of Worcester city businesses are a short distance to Union Station commuter rail.  The 
Tufts University’s Cummings School of Veterinary Medicine site is also ideal because of its 
proximity to MBTA commuter rail transportation (Worcester Business Development 
Corporation, 2010).   
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4.5.4 Lab Inventory  
There are two main types of laboratories, wet and dry; each with its own unique 
advantages. Wet Laboratories are defined as laboratories where chemicals, drugs, or other 
biological matter are handled in liquid solutions or volatile phases, requiring water, direct 
ventilation, and/or specialized piped utilities. One of wet labs’ most unique advantages is that it 
must accommodate simultaneous and separate ventilation and utility connections at individual 
lab modules to ensure both the reliability and accuracy of results as well as occupant safety 
throughout the space. Some fundamental wet laboratory features include: 
 Separate Laboratory Modules: a wet lab space is typically divided into separate 
laboratory modules that contain individually controlled connections to HVAC, utilities 
and safety devices.  
 Constant and Reliable HVAC: As some equipment and experiments are temperature- 
and humidity-sensitive, constant conditions are required in Wet Laboratory spaces to 
ensure that equipment can perform properly and that experiments produce accurate 
results.  
 Gas/Utility Services: Utility connections in Wet Laboratory space types can include 
vacuum, pneumatic supply, natural gas, O2 and CO2, and distilled water. 
 Fume Hoods: wet laboratories accommodate one 6'-0" chemical fume hood for each 
laboratory module, and provide direct 100% exhaust.  
 Laboratory Occupancy: Occupancy Group Classification for Wet Laboratory is B2, 
Sprinkler protected construction, as per IBC, with a GSA Acoustical Class C1 for enclosed 
spaces and Class C2 for open spaces (WBDG, 2010). 
On the other hand, dry laboratories refer to spaces where work is done with dry stored 
materials, electronics, and large instruments with few piped services. Work such as for 
example, computational or applied mathematical analyses that can be done on a computer to 
generate a model to simulate a phenomenon in the physical realm. Similar to the wet 
laboratories, these analytical dry laboratories also have a few fundamental features, including: 
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 Constant and Reliable Temperature and Humidity: as some equipment and 
experiments are temperature- and humidity-sensitive, constant conditions are required 
to ensure that equipment can perform properly and that experiments produce accurate 
results. 
 Laboratory Occupancy: Occupancy Group Classification for Dry Laboratory is B2, 
Sprinkler protected construction, as per IBC, with a GSA Acoustical Class C1 for enclosed 
spaces and Class C2 for open spaces (WBDG, 2010). 
 
 In a study done by Colliers International, most of Worcester County is termed as 
“Suburban” and is compared with Boston, MA and Cambridge, MA (Kelly, 2012). The following 
is what the report had to say on the velocity of the Suburban Market: 
 
“Wavering tenant demand resulted in a sizable amount of negative absorption during the third 
quarter. After falling to 19.1% last quarter, the suburban vacancy rate inched back up to 19.4% 
at the end of September. Even still, year-to-date the suburbs clocked in more than 1.1 million 
square feet of positive absorption, already surpassing net absorption in 2010 and 2011 
combined. Given that the fourth quarter is expected to be positive, 2012 is likely to be the 
strongest year since 2007,” (Kelly, 2012). 
 
 A crucial competitive advantage Worcester County has in terms of lab inventory is that 
its vacancy rate is much slower than that of Boston and Cambridge (Kelly, 2012). Local 
companies are becoming more and more confident in economic conditions which are bringing 
back tenant growth and expansion. This has encouraged several firms to proceed with 
relocations and expansions throughout the suburban market, which includes Worcester County 
(Kelly, 2012). Another reason for local companies to relocate to the Worcester County lab 
market is for its reasonably priced rental lab space so close to mainstream cities such as Boston 
and Cambridge.  
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 The trend for new and premier Class A, amenity-rich buildings in the suburban area 
should continue to rise in 2013 (Kelly, 2012). In addition to the economics of rent per square 
foot, tenants seek value through efficiency, amenities and sustainability (Kelly, 2012). 
 
 Unfortunately, there was no county wide data available for lab space/inventory. 
However, that information was available specifically for Worcester, MA, shown below in Figure 
#4 (Kelly, 2012). 
Table 11: Lab Space in Worcester, Massachusetts 
Town Address Built Floors Biotech SF Available for lease SF 
Worcester 
100 Barber Avenue 1920 1 10,000 0 
1 Innovation Drive 1991 4 80,000 16,610 
100 Institute Road 2005 2 16,589 0 
377 Plantation Street 1994 3 93,000 91,531 
381 Plantation Street 2000 3 94,000 35,930 
60 Prescott 1900 4 125,000 0 
85 Prescott 1900 4 12,000 0 
100 Research Drive 1994 4 166,000 0 
Total 596,589 144,071 
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4.6 Talent 
4.6.1 Workforce Education Level 
A well educated work force is important because it is essential for the economic growth 
of a region and its ability to innovate and improve itself.  Without a well skilled labor force, the 
abilities of the region are limited.  Workforce education levels is a measure of the percentage of 
the labor force with a bachelor’s degree or higher (Kispert et al., 2012).  Using the U.S. Census 
Bureau from 2000 and 2008-2010 that was available in a report done by Robert Clifford of the 
New England Public Policy Center, workforce education level data were compiled for 
Massachusetts and Central Massachusetts.  There were no data available for Worcester County 
but Central Massachusetts included all of Worcester County and some cities in Middlesex 
County (Clifford, 2012).  From 2000 to 2008-2010, Massachusetts has showed overall 
improvement in the number of employees with a Bachelor’s degree or higher in seven 
occupations that encompass science, technology, engineering, and math.  Table 12 compiles 
this information along with a net change for each occupation.   
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Table 12: Workforce Education Levels in Massachusetts 
 
2000 2008-2010  Net Change  
Workforce 
Education Levels in 
Massachusetts 
Less than 
Bachelor's 
Degree 
Bachelor's 
Degree or 
more 
Less than 
Bachelor's 
Degree 
Bachelor's 
Degree or 
more 
Less than 
Bachelor's 
degree 
Bachelor's 
Degree or 
more 
Architecture & 
Engineering 30,322 54,257 21,079 52,369 -9243 -1888 
Life, Physical, & 
Social Sciences 6,078 42,915 6,781 53,672 703 10757 
Computer & 
Mathematical 36,647 85,647 27,178 89,953 -9469 4306 
Healthcare 
Practitioners & 
Technical Services 66,202 104,040 74,849 131,721 8647 27681 
Healthcare Support 57,445 8,129 71,759 11,042 14314 2913 
Personal Care & 
Service 64,168 13,654 87,164 21,966 22996 8312 
Production 193,745 16,369 133,970 16,748 -59775 379 
Total Degrees in 
Workforce 454,607 325,011 422,780 377,471 -31827 52460 
(Sources: U.S. Census Bureau 2000, 2008-2010 Census and Clifford 2012) 
Analyzing the data showed that employment for education levels less than a bachelor’s 
degree had fallen while employment for the labor force with a bachelor’s degree or higher had 
risen.  This signifies a demand for more skilled and educated labor that implies an overall 
increase in innovation.  Taking a look at Central Massachusetts workforce education levels gave 
insight into the contribution this region had on the state as a whole.  The data for Central 
Massachusetts employment is tabulated below.   
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Table 13: Workforce Education Levels in Central Massachusetts 
 
2000 2008-2010 Net Change 
Workforce 
Education Levels in 
Central 
Massachusetts 
Less than 
Bachelor's 
Degree 
Bachelor's 
Degree or 
more 
Less than 
Bachelor's 
Degree 
Bachelor's 
Degree or 
more 
Less than 
Bachelor's 
Degree 
Bachelor's 
Degree or 
more 
Architecture & 
Engineering 2,741 3,593 2,009 3,866 -732 273 
Life, Physical, & 
Social Sciences 601 2,353 422 3,438 -179 1,085 
Computer & 
Mathematical 1,905 3,930 1,947 5,325 42 1,395 
Healthcare 
Practitioners & 
Technical Services 7,223 9,576 7,881 12,433 658 2,857 
Healthcare Support 6,461 713 9,311 1,215 2850 502 
Personal Care & 
Service 6,288 1,070 8,669 1,960 2381 890 
Production 26,026 1,485 18,958 1,448 -7068 -37 
Total Degrees in 
Workforce 51,245 22,720 49,197 29,685 -2048 6,965 
(Sources: U.S. Census Bureau 2000, 2008-2010 Census and Clifford 2012) 
Central Massachusetts followed a similar trend as the state increased the education 
level of the workforce over the past decade.  Employment decreased by roughly two thousand 
for education levels less than a bachelor’s degree and increased by almost seven thousand for 
employees with a bachelor’s degree or more.  This increase in education levels is important for 
the growth of the cluster in Central Massachusetts and Worcester County because it signifies a 
higher level of innovation and a greater demand for specialized skills.  The impact that a greater 
demand for educated labor has on the region is higher wages, the development of more 
sophisticated products, and business formation.  Creating a talent pool in Worcester County is 
essential for attracting companies large and small to locate to the area to access this resource.   
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4.6.2 STEM Degrees Awarded 
Science, Technology, Engineering, and Mathematic (STEM) Degrees Granted 
The National Science Foundation organizes college degrees into 54 general categories, 
and then more specifically into level of degree.  According to Massachusetts Technology 
Collaborative, there are 5 categories which reflect Science, Technology, Engineering, and 
Mathematic (STEM) degrees.  Science degrees include the categories of Biological & Biomedical 
Sciences, Physical Sciences; technology degrees include Computer & Information Science and 
Support Services; engineering degrees includes Engineering; and mathematics degrees include 
Mathematics & Statistics.  For this study, doctorate, masters, and bachelor degree data were 
collected and analyzed.   
Below is a graph (Figure 42) documenting the number of doctorate, masters, and 
bachelor STEM degrees awarded to all Massachusetts colleges from 2006 to 2010.  The greatest 
spike in degrees awarded is observed from 2007 to 2008 and a similar spike is observed from 
2009 to 2010.  There was a noticeably lower amount of increase in degrees awarded in 2009.  
The small increase from 2008 to 2009 led to a very large increase in 2009 to 2010.  This 
observation can be made from the 2006 data.  A small increase is seen from 2006 to 2007, 
which then is followed by a very large jump from 2007 to 2008.  Possible reasons for small 
increases in degrees awarded could result from students choosing to stay in school longer due 
to poor economic situations or students needing advanced degrees to land better jobs.  From 
this small sample size of only five years, a pattern of degree spikes is seen every two years.  A 
larger pool of data is needed to confirm this pattern. 
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Figure 42: Massachusetts STEM Degrees Granted 
 
 
Below is a graph (Figure 43) documenting the number of doctorate, masters, and 
bachelor STEM degrees awarded to all Worcester County colleges from 2006 to 2010.  The 
colleges included in this data are colleges who offer a doctorate, masters, or bachelor degree in 
the STEM field from 2006 to 2010 and reported to the National Science Foundation.  They 
include Assumption College, Atlantic Union College, Becker College, Clark University, College of 
the Holy Cross, Fitchburg State College, Massachusetts College of Pharmacy & Allied Health 
Science, Nichols College, University of Massachusetts at Worcester, Worcester Polytechnic 
Institute, and Worcester State College.  The Worcester County data follows similar patterns to 
the overall state data.  Similar to the state trend, the greatest spike in degrees awarded is 
observed from 2007 to 2008 followed by the spike from 2009 to 2010.  Small increases in 
degrees granted are observed from 2006 to 2007 and 2008 to 2009.  The trend of large spikes 
in degrees granted every two years holds true for Worcester County colleges.    
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Figure 43: Worcester County STEM Degrees Granted 
 
 
Figure 44: Worcester County % of Mass. STEM Degrees Granted
 
 From 2006 to 2010, Worcester County accounted for about 11% of the total STEM 
degrees granted in Massachusetts.  There is an overall increase over this time period which 
indicates Worcester County colleges are contributing a larger part to Massachusetts higher 
education.   
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Figure 45: STEM Doctorate Degrees Awarded in Worcester County and Massachusetts
  
  
From 2008 to 2010 a steady, large increase is observed in the amount of doctorate 
degrees awarded to Worcester County colleges.  In contrast to the Worcester County data, the 
overall State data has either declined or remained the same.  For the state data, a large spike 
occurred from 2006 to 2007, and in that time, Worcester County remained almost unchanged, 
concluding that Worcester County did not grow in that time period.  94% of Worcester County’s 
growth from 2006 to 2010 occurred in the last three years.  UMass Worcester Medical School 
accounted for 54% of doctorate degrees. 
 The data shows Worcester County is competing well in producing qualified people for 
the workforce.  For local companies to compete, they must be able to hire qualified people, and 
this pool of candidates educated in Worcester County provides just that.   
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4.7 Conclusions 
Analysis of the data compiled lead to an understanding of the strengths and weaknesses 
of the Worcester County life sciences economy.  Strengths of the region included its proximity 
to Boston and Cambridge, infrastructure, laboratory rental costs, prestigious institutions, skilled 
workforce, knowledge creation, and ability to attract federal funding.  Weaknesses identified 
included overall distribution of federal funds, ability to attract private investments, overall new 
business formation, and development of new drugs and sophisticated medical devices. 
Locating in a region that is less than 45 miles from the “epicenter” of the biotechnology 
world, is an advantage not many life sciences regions possess.  Worcester County anchors the 
west end of the Massachusetts life sciences corridor and has the ability to complement from 
the success of the east.  Being a part of this particular regional cluster, Worcester County has 
the unique opportunity to attract ‘spinoff’ companies from Boston and Cambridge.  State of the 
Art and specialized infrastructure currently in place in Worcester County, coupled with the low 
cost of renting lab space compared to Boston and Cambridge, will draw ‘spinoff’ companies to 
the area.  Prestigious institutions of learning produce a qualified workforce that is needed to fill 
professional employment opportunities presented by this innovative industry.  Worcester 
County has a skilled workforce and this is indicated by increased number of degrees awarded by 
area universities in advanced fields of science, technology, engineering, and mathematics, 
increased net change of workers who possess a bachelor degree or higher in the region, and an 
overall increased trend in employment and wages in skilled labor fields.  Worcester County 
shows strength in overall knowledge creation, and is indicated by increases patenting activity, a 
vital source of innovation.  Also, Worcester County demonstrated an ability to either sustain or 
increase its level of attraction of federal funds as the total funds for the state declined.   
Weaknesses facing the region stem from insufficient funding and investments which has 
seemed to slow new business formation.  Federal funding has been determined as a strength of 
the region solely based on the total volume that has been allocated.  The overall distribution of 
funds is an issue that faces the region.  In 2012, 95% of the $150 million in NIH grants was 
allocated to only three organizations.  Angel and Venture capital has been observed to be at 
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low levels in the county as well.  The inability of the majority of companies in Worcester County 
to attract both public and private investments hinders both their productivity and ability to 
grow operations, as well as affects new business formation.  This is exemplified in the fact that 
there have been zero new drug approvals and pre market approvals for sophisticated medical 
devices.   
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5.0 Recommendation 
The life sciences industry in Worcester County will be more successful if companies 
improve their grant writing application process. Since many of the companies are smaller 
startups, they do not have the resources or expertise to hire a full time grant writer.  Therefore, 
institutions and companies in Worcester County should work to develop a community initiative 
that will educate companies on how to successfully write these applications.  This will ideally 
develop a special skillset in the region to give these smaller companies the tools they need to 
be competitive in acquiring federal funding on a consistent basis.  One such company that has 
developed this skillset within their workforce is Biomedical Research Models.  They have 
trained their employees to become successful grant writers and the benefits of doing this is 
reflected in the amount of funding they have attracted on a consistent basis over the last 
decade.  Using this model for the rest of Worcester County and coupling it with innovative ideas 
will be an important step to take the development of this cluster to new heights.  
 After a review of the investment portfolios of all Massachusetts based Angel groups, 
the amount of investment in Worcester County based life sciences companies was determined 
to be smaller than that of other life sciences clusters.  This lack of funding in startup, early, and 
expansion stage companies hinders their ability to expand to a size where they can successfully 
attract larger investments through Venture capital sources.  An extremely important 
determining factor for companies securing investments results simply from a personal 
recommendation in support of the company, by someone the investment group respects and 
trusts.  Marc E. Goldberg, Managing Director for BioVenture Investors, mentioned that this is 
one of the “secrets” of securing investments, and that the only investments he has ever made 
in his career, have come with a recommendation made by a trusted individual.  This tip was 
confirmed by David Verrill, Managing Director of Hub Angel Investment Group, LLC.   
Angel groups and Venture groups receive upwards of 1,000 applications for funding a 
year, and only extensively review approximately 100.  By networking and developing 
relationships with Boston based Angels and Ventures, Worcester County companies will be 
gaining an advantage with investors to increase their likelihood of securing investments.  The 
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Boynton Angels have a small number of investors which has minimized their ability to make 
numerous investments in the area.  It would be beneficial to the growth of Worcester County 
companies if the Boynton Angel group was further developed and more investors were added.   
 In recent years, large drug companies have experienced a major challenge due to the 
expiration of patents of major drugs already on the market known as the “patent cliff” 
(Rothwell, 2013, pg. A10) . The patent cliff is described as “the unprecedented number of 
patents expired on drugs worth billions of dollars in sales” (Rothwell, 2013, pg. A10).  This is 
allowing for generic brands to slowly replace these billion dollar drugs and slash the revenue of 
large companies significantly.  However, what has come to be known as the “patent cliff” is 
dissipating as big pharma companies are beginning to pursue a new business model (Rothwell, 
2013, pg. A10).  This new business model involves the relationship between academia, health 
care providers, drug makers, and biotechnology makers (Rothwell, 2013).  Worcester County 
should adapt this model by utilizing one of its strengths which perhaps holds the most potential 
for the region.  On January 30th, 2013, a $400 million facility, the Albert Sherman Center, was 
opened at the UMass Medical School (McCluskey, 2013).  The goal of this center is to 
encourage collaboration and bring together researchers who currently work in different 
locations (McCluskey, 2013, pg.A8).    
The research in this building will lead to developments in new treatments for disease, 
which has become the focus of large pharmaceuticals that are searching for new ways to 
increase their revenue.  Developing a partnership between these large companies and UMass 
Medical may prove beneficial to the life sciences economy in Worcester County because of the 
contributions each side can make.  With recent budget cuts set to take place for federal 
funding, research universities will need to find other sources of funding (McCluskey, 2013, 
pg.A8).   This partnership will provide the researchers with the funding that larger companies 
already possess, and in turn make up for the budget cuts that will affect the work conducted at 
universities like UMass Medical.  Larger companies will also benefit from this collaboration 
because they will team up with the talent available in the universities, and with a streamlined 
research process, effectively develop the next big name drug that will generate billions of 
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dollars in revenue.  This relationship between academia and private investors is already being 
taken advantage of in the Boston/Cambridge area with local hospitals, so it would be an avenue 
that Worcester County may find success in.  
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Appendix 
Appendix A: Interview Protocol 
1. Out of the fifteen indicators we have identified, which ones do you think are required to 
sustain the Worcester life science cluster? 
a. Why? 
b. Are there other required ones that we should identify? 
 
2. Which indicators are unique to this Worcester region? 
 
3. What groups/companies are involved in the Worcester County cluster? 
a. Specifically, what biotech companies? 
  
4. How do groups/companies operate with one another in the cluster setting? 
 
5. What other clusters can serve as a model for comparison to Worcester County? 
6. Can you give us data specific to Worcester County? or, can you tell us how to access 
those data? 
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Appendix B: Peter Abair Interview  
Interview Date and Time:  22 January, 2013; 11:30 AM 
Purpose of the Interview: 
The purpose of the interview was to gain a better understanding of the identified indicators and 
to determine which indicators are essential for the growth of life science industry in Worcester 
County, MA through an industry expert who has hands-on experience with such matters.  Prior 
to the interview, he had already sent useful resources that would help the MBI group advance 
their research. 
Interviewee: 
Peter Abair- Director, Economic Development & Global Affairs, Massachusetts Biotechnology 
Council 
Telephone: 617-674-5130 
Email: peter.abair@massbio.org 
 
The Massachusetts Biomedical Initiatives (MBI) group contacted Mr. Abair for a knowledgeable 
discussion on the sixteen indicators and their impact on the life science industry.  He was 
identified to be a resourceful contact in terms of getting access to and gathering data specific to 
Worcester County. The MBI group determined that his vast knowledge on many aspects of the 
indicators and life science industry would be able to assist us in our research.  
 
Interview Transcript: 
MBI Group: Good Morning Mr. Abair! We are the Massachusetts Biomedical Initiatives 
Interactive Qualifying Project Team. I am Ehab Hamdan, Junior minoring in Civil Engineering at 
WPI. This is John Antonopoulos, also a Civil Engineering major here. I am Poonam Barot, 
majoring in Biology. I am Monolina Binny, majoring in Biology and Biotechnology here and I am 
also a junior. First, we would like to thank you for taking the time out of your day to speak with 
us and also thank you for all the information that you have given us so far. The information has 
proven to be very helpful.  
 
Mr. Abair: Great! 
 
MBI Group: Before we proceed with the interview, Is it alright if we record this? 
 
Mr. Abair: Sure, no problem. 
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MBI Group: Thank you. Since you gave us a lot of information already, we will start off by asking 
out of the sixteen indicators we have given you, which ones will be beneficial to us and we 
should further look into? And, which one should we just throw out of the window and replace 
with other ones? 
 
Mr. Abair: Well, I have a general idea about the purpose of the study, but if you could spend a 
little time describing the purpose and who the audience is for your project that will be helpful 
for me. 
 
MBI Group: By March 1st, we want to have an Executive Summary to present to Kevin 
O’Sullivan, who is the CEO of MBI. We will be breaking down the Worcester County life 
science’s cluster and basically tell him how the life science cluster in Worcester County is doing 
right now. Also suggest any recommendations we might have and identify what Worcester 
County is doing well in and what the County needs to improve on in terms of progress in the 
industry. This is the purpose of our project. 
 
Mr. Abair: Ok, so certainly the employment growth and the trends in employment will be 
interesting to see overtime. At MassBio, we used to do a County-by-County basis report, but we 
have not done much on the County level for the last four to five years. I can dig up some of the 
older stuff that we did and send it your way. However, that data is of course not up-to-date 
with the past few years. We also used a different data source- we used the Census Bureau’s 
County Business Patterns. The information there is good and available on a County basis, but it 
is also slow- almost a year and a half behind. So, it is difficult to use on a timely basis. We found 
it easier to use the quarterly census of employment and wages from the Bureau of Labor and 
Statistics because it is more directly connected to the State sources, which is called the ES202- 
Employment Data. The Bureau of Labor Statistics data is build off of that. So, even our older 
stuff that we can throw at you was based on sort of older and different data sources. I think in 
terms of doing employment trends, the quarterly census of employment and wages works well 
and the website is easy to use- it shows that Worcester has a very strong standing and is 
comparative to other clusters around the country. There are certainly larger clusters and when 
you separate Worcester from the Massachusetts clusters, we found the numbers are 
interesting to look at in that context because Worcester does well on its own. Worcester did 
develop something in a fashion as a cluster onto itself and has been part of the larger 
Massachusetts cluster, which has its core in Cambridge, but it has very distinct identity and its 
reforms over the years sort of suggest that. So, looking at those trends, such as employment 
trends, and number of establishments in the sector over the years as well, I think would 
certainly be a good place to start. It may be even, though I don’t know this for a fact, the 
number of employees may have gone up and number of establishments may have gone down. I 
am not sure, but that is what I sometimes see when I look at different clusters because they 
have a greater concentration of employment at large or employers or not- well that’s an 
interesting thing to take note of as well. It’s good to have some big players in any cluster and it 
is also pretty critical to have a start-up creation happening in the early stage companies 
because that helps fuel innovation and growth in the future. Looking at number and size as 
much possible of the establishments is helpful. I think some of the workforce education levels is 
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important for contacts, in terms of how if there is certainly an issue that the education levels in 
the area are going down, and that can be supportive for the industry by tracking down the 
industry.  The FBIRR information is again useful. There is certain percentage of companies in the 
industry that take advantage of the FBIRR dollars and they are typically companies that are not 
venture-backed and they use FBIRR funds as long as they can before they have a different 
business strategy after that, but again these are all typically early stage companies that use the 
FBIRR. I didn’t see that you had venture capital in the list you provided me with? 
 
MBI Group: We had venture capital originally, but after speaking with Kevin O’Sullivan and our 
advisor, we found out that venture capital is not really available or offered that much in 
Worcester. So, that’s why we are supposed to be looking at funding, specifically angel funding. 
 
Mr. Abair: Ok, do you have a source for that at this point? It is not easy to gather so much 
specific data. 
 
MBI Group: Yes right. John is doing some research on different kind of funding and he is going 
to start looking more specifically into the Worcester County. We just wanted to find some 
sources that would tell us where private funding is going to, specifically to which companies if 
the information is available?  
 
Mr. Abair: There is a great national website that we use for aggregate information and you can 
get it on a State-basis but not below that and it’s PWC [Pricewaterhouse Coopers] Money 
TreeTM Report. It is a terrific database but it does not break down below the State-level. So, only 
a handful of these will be needing industry database and there are bunch of other information 
out there. It is probably an area I can help out with and provide some data to you because we 
subscribe to an industry database called EvaluatePharma® and from that you will be able to pull 
up, for example, the M&A, the Merger and Acquisition data that you might be looking for under 
indicator thirteen, and the number of IPOs. The information is out there in other third party 
reports that as been done before or you can get them in one of these industry databases. And 
that is something I can probably pull up together for you, along with the rough statistics, and 
you can go take it from there. I might be able to pull this up by State-wide basis but I might 
probably be able to include the city or town data that the different companies are in or the 
mergers that different companies have and you can take the information and write with that. I 
would be happy to help you that and also these database costs fifteen to twenty thousand 
dollars each year so you would not be able to subscribe to that. So, that is something I can 
knock-off. Angel funding is a little more difficult to track. These databases have some of it, but 
we have to see what we can come up with. So, going back down to the list- approvals of 
pharmaceuticals and medical devices are also difficult using the free databases out there. I 
don’t know if anybody has gone to the FDA? 
MBI Group. Yes, I [Ehab Hamdan] took a look at it and didn’t find a lot of information. It just 
said there was one approval last year in Massachusetts. 
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Mr. Abair: Yes it’s not easy to navigate and I never spent a lot of time to figure it out. Some of 
these government databases are jammed, like the Bureau of Labor and Statistics makes it easy 
but the FDA does not. So, that is another I can look at in the industry database. The problem is 
our database is very Biotech Pharma oriented and there is not much medical devices 
information, but I can certainly give you information on the approvals but not the medical 
devices information. 
MBI Group: Well, do you think this indicator would be helpful in understanding the Worcester 
County cluster or should we find another indicator to look at? 
Mr. Abair: I think if you are measuring the Worcester versus other regions, one way you can do 
that is if you look at clusters around the country and rate of approvals for Worcester-based 
companies versus the rate of approvals in these other areas and that might be interesting to 
see. On the drug side, there has been within about two hundred and fifty to about two hundred 
and sixty approvals for drugs developed by Massachusetts head-quarter companies. The 
problem in considerate in Worcester is Abbott [Laboratories] has probably developed products 
out of the facilities in Worcester, but Abbott headquarters is based in Illinois. So, Worcester and 
Massachusetts quite does not get credit for that drug development which ends up going to 
Illinois in the way they track the data. So the amount of activity, let’s say in the twenty years 
spread, is going to be limited out of Worcester. So, it is not going to be a striking number and it 
would be something you want to compare to other similar-sized clusters, but then also requires 
a lot more work. But maybe, it is something like getting all these data, then what you can do 
with it might be something rather limited. It might be something to know to expand in a 
particular direction. On the other hand, the federal research funding which again is easily 
available in an easy manner from the National Institute of Health website, that link is included 
in what I sent. That’s great data and we definitely have a couple institutions there that are 
beneficiaries of it and that’s good to track overtime to see what the trends are. I would expect 
that UMass at Worcester has grown its share of those dollars over the years, so that is easy to 
get. Though it is not broken down already, but you can cut it by institution. Knowing the 
institutions first who received those NIH funds in Worcester and then tracking the trends and 
analysis overtime.  So, that’s a great indicator. Patents, I think, should be helpful. I have not 
done any of it really and we kind of rely on third-party reports out there on that, so other than 
doing a web search, I don’t have a good guidance on that. Licensing, again, will be pretty 
difficult to get information on without the industry databases. You can get that information out 
of UMass, for example, has its license data over the years and they would be able to provide, as 
well as WPI, but that does not give you what has happened in the private sector in terms of 
their companies developing in intellectual property and then licensing it out to other 
companies. I don’t know where to get that information other than from one of these industry 
databases. That again is something which would suggest looking at trends overtime and levels 
of activity that speak to the vibrancy of the cluster that is based in Worcester and whether or 
not it is growing new technologies at a greater rate than earlier time. That is a good indicator 
and something I could probably assist you with, in terms of giving you some pretty rough data, 
which I can download and send it your way. I guess, in terms of looking at this information, 
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what is the timeline you would be looking at? Is it 1985 and forward or do you want to look at it 
for the last ten to five years? What exactly, do you think of the timeline? 
MBI Group: We think, the recent data from the last five years is the period we want to look at. 
We don’t want to go back all the way to 1985. 
Mr. Abair: Good. So, for indicator number 2 and 7 I should be able to gather information and 
send it your way. For biomanufacturing, I sent in the email, there is an organization out there 
called Biomanufacturing Roundtable- they pull together some information which is fairly 
current, like a couple years old maybe at this point. One of the nice things they discovered that 
New England, including Massachusetts, New Hampshire and Rhode Island have the greatest 
capacity of mammalian cell culture as measured by leaders of capacity that produce these 
products and that is sort of the cutting edge of the biomanufacturing industry and it’s 
something we did not really know. We didn’t realize that there is such concentration of that 
capacity here. So, along with microbial manufacturing capacity, those are the numbers 
Elizabeth Beckrenolds pulled together. I can ask her for that information or I can give you her 
contact information for that information. A conversation with her would enable you to get that 
information and you can cut it down to Worcester. Worcester County would certainly be avid as 
a manufacturer. Is Devens part of Worcester County or Middlesex?  
MBI Group: We are not sure. 
Mr. Abair: Devens, which is part of the Old Fort Devens, above route 2.  
MBI Group: It is part of Worcester County [web search]. 
Mr. Abair: Well that is the largest bulk biomanufacturing facility in the Western Hemisphere I 
think. At least it was when it was first build. That’s a lot of capacity there and then you have 
Abbott and some smaller contract manufacturing organizations that are probably in Worcester 
as well. It is a finite number though and you can get that information from Elizabeth in terms of 
capacity. To know what the capacity of the area is to serve the needs of commercialization and 
manufacturing side of the industry. We have the Snapshot to describe why that is important. 
The science degrees awarded is good information database is good to find that information, but 
I am not sure how the new layout of that database accommodates the data. I have gotten that 
information from that site before and used it. I have also asked UMass to provide that 
information and the stuff I have from them is pretty old, from 2008. So, going back to the 
database see if you can extract the information from there. I would start with IPEDs?? Tell me 
more about the Capital and Human resources, including construction, indicator. Is it 
expenditures? 
MBI Group: Our sponsor and advisor told us to focus on facilities located in Worcester, like how 
many life science building are in each college and also, what is their purpose and how are they 
focused in the industry? Like, for example, WPI recently built two building at Gateway Park. I 
think, they want us to look at all of Worcester County and who is building life science buildings 
and what these schools are focused on, for example buildings like UMass Medical.  
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Mr. Abair: So, that ties into indicator number 14 as I would expect. 
MBI Group:  And what types of equipment are in these facilities.  
Mr. Abair: In terms of lab inventory, information concerning what is available in the market is 
available to brokers. I could send you the contact of this one organization that does a great job 
for that. All these different brokers who specialize in the life sciences have good information on 
where the spaces are and what is in the spaces. I would recommend you get in contact with 
someone from CBRE, I can’t recall her name at the top of my head. CB Richard Ellis is a big 
commercial broker; they have a specialty in the life sciences and lab market. They do really 
good quarterly report. I can get you in contact with the individual who develops that report and 
publishes it every quarter. I am sure she would be happy to provide you with Worcester-specific 
information on lab inventory. Lab inventory is going to be the commercially available lab and so 
then it would be very interesting to know and it is something I don’t know in my own backyard 
here in Cambridge. What the research institutions hire at lab space and how much it accounts 
for, as in how much is it and what are the specialties and that sort of thing. But you have, again, 
finite number of those facilities in Worcester, so, I think it would be the same process like 
working with UMass, WPI and that sort of doing an accounting of what is there and having that 
sort of inventory, finding out what is there in the higher end of the non-profit side and on the 
commercial space side. It is a great thing to highlight, to understand and it is a good metric to 
go forward with, in terms of growth, in both of those sectors. We already sort of discussed 
funding, mergers, M&A activities, IPOs. Looking back five years, I can pull that information and 
send it your way. It will be like angel information and also the way this information will be 
called up is it will have Massachusetts head-quartered companies. So again, if it is a licensing 
deal between Abbott in Worcester and somebody out of the State that has value, we are not 
going to catch that because the Abbott numbers go to Illinois for no good reason. But I can pull 
that stuff together and send it your way. Number 12, business formation is, I think, would be 
great metric. Other than really looking at M&A activities, the IPOs and funding, it is really 
difficult to figure out who is new on the scene and what new companies are being created 
because some of these companies are below the radar and there are lots of virtual companies 
out there. Some of these companies can be formed and then gone out of business in the same 
year- the industry is for some early stage companies pretty fragile. I don’t know a good place to 
go and get that information. You folks might have discovered one, but I don’t know how to 
access that information easily. I like the idea though. 
MBI Group: We will try to figure it out.  
Mr. Abair: So for creating a business, you go to town hall, you get a certificate and you are in 
business, you are known locally. Then there is a process of corporation and that is through the 
Secondary State Office. It’s public information but it is not provided easily. You might want to 
take a look at the Secondary State Office; however, I think their stuff is not updated, maybe 
that has changed, but that would be a place to look at. Otherwise, I think it is pretty difficult. 
Occupations and wages- that is easy stuff to find. The Illustrator website has that information. 
They also do projection, but I am not sure if they do projections on a County basis, and it is 
based on what happened in the last ten years and they sort of just flip it forward for the ten 
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years and based on these projections they have new jobs in the job and occupation 
classifications - these are the number of replacement jobs that have to be part of that in 
addition to the new jobs to replace jobs that are leaving because of retirement. So that is a 
good website and fun to use. I think they might even break information down to Community 
level, but I haven’t been on there in a while. Again, good indicator! 
MBI Group: I [Poonam Barot] have one question on the lab inventory that we were talking 
about. In your Snapshot you have a slide on lab inventory growth, I was just wondering how 
you came up with those numbers, was there a specific site you looked at?  
Mr. Abair: We did that by looking at different information from the brokers. We have able to 
compile all that from the year 2007. There are commercial reports that these brokers put out 
what the lab market looks like, so we had that amount of history. Recently, when we tried to go 
back to the year 2000, we did not have the hardcopy fiscal reports, the contacts of the couple 
researchers who put that information and we did not have any information prior to the year 
2005. They were not tracking lab inventory before that. The information was mostly part of 
industrial space or office space. They did not break it out in terms of lab space. I will be happy 
to send contact information for; I can’t remember the name at the top of my head. Merith and 
Greu? They have done a good job on that sector. She is probably a good source to know what 
the commercial lab space is in Worcester and probably even the addresses of the physical 
spaces out there. It is pretty known, I think Kevin O’ Sullivan has a pretty good idea about 
where everything is. If you get out of Worcester, you definitely want to have a verifiable source 
for that because there is always something that could be beyond somebody’s knowledge. There 
is lab space in Shrewsbury, but most of it is going to be in Worcester. So Kevin has a lot of lab 
space in MBI, then you have Alexandria Real Estate Equities that have pretty substantial share 
of the market out there in terms of commercial space. If you combine those two and the WPI 
facilities in Gateway that is probably going to be I would guess 75 percent of the whole market. 
For the other 25 percent having a third person source would be helpful.  
MBI Group: Thank you. Also, I [John Antonopoulos] have a question. Another piece of our 
project is that after compiling all the data, Kevin wanted something where we can breakdown 
and advertise to companies saying this is what we have in Worcester. Do you think there are 
any other areas or indicators that would be enticing to them and they would want to relocate 
their companies to Worcester?  
Mr. Abair: That is a great question. I think one of the arguments about moving to Worcester is 
the cost structure and capturing that in terms of employment and occupations and wages 
would be good. You can do that by comparing between Worcester County and Middlesex 
County for example and there is going to be a difference there, or Worcester and New York or 
New Jersey for that matter. The competition is that we are in Massachusetts, where within an 
hour of Cambridge and international airport and we are at x percentage less cost in terms of 
real estate, in terms of wages than Cambridge or Waltham for that matter. We are less 
expensive than core industries of Cambridge. We have all these capacity over here and we have 
a lot of assets and that is a potential compelling case. To see what about clusters beyond 
Massachusetts, what is cost in Worcester versus New Haven, which is sort of the base industry 
109 
 
in Connecticut, New Jersey, Philadelphia are also competitive market places and Worcester will 
probably compare well in terms of cost to those different areas. That might be interesting 
information to have. So you can look at what State and government has information about 
wage for, let say you pick fifteen industry occupations and compare the wages in Worcester, 
Middlesex County, New Haven or sort of the Princeton area or New Jersey for example. I think 
that would be interesting if you can find anything else other than using those variables and 
same for lab costs.  Labs in Worcester are based on per square foot area, for example in 
Cambridge it is 55 to 60 dollars per square foot and in Waltham it is in the 30s. That is 
something to compare and contrast. If you could find a good geographic based cost of living 
index, because that is one area I have failed in the past to really find good sources. If you can 
find that then you can apply that Worcester has all these resources, it has proximity to 
Cambridge and see if it has the same cost of living as a different cluster such as North Carolina 
or Saint Louis area, that would be interesting. 
MBI Group: Well that is all that we want to get out of you. Thank you, we appreciate your time. 
Thank you for the information, it was really helpful. 
Mr. Abair: Well I would love to provide you information about the contacts of drug approvals, 
licensing, mergers and IPOs. I know providing you the information sooner would be better, but 
when will you like to have it? 
MBI Group: Soon as possible. We are doing this research on these indicators and by the end of 
the next week we should be done with the basic research on these indicators. If you are not 
able to give us the information until after next week, it is not a huge issue. 
Mr. Abair: I should have little time this week. It might be half an hour or might be three hours 
to pull up the information from these databases, but it depends on being able to start the 
search. Sometimes it is easy to extract something and sometimes it is surprising how difficult it 
is to extract such information. Anyway, I will look at the information this week and get you all 
the contacts and I will work on the other stuff this week. Well. Feel free to call back with any 
questions. Glad that you have a good team there.  
MBI Group: Thank you, you helped a lot. Take care. 
Mr. Abair: Take care.  
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Appendix C: Occupations and Wages 
Raw Data for Total Wages in Worcester County in Thousands (2005-2010) 
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Raw Data for Total Wages in Massachusetts (2005-2010) 
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Appendix D: Employment Growth 
Raw Data for Total Number of Employees in Worcester County (2005-2010) 
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Raw Data for Total Number of Employees in Massachusetts (2005-2010) 
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2010 218 389 641 1206 1248 140 169 797 108 43 4959.8 
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Appendix E: Research and Development 
Raw Data for Research and Development Contracts in Worcester County 
  
NIH R&D contracts 2004 2005 2006 2007 2008 2009 2010 2011 
UMASS Med School $5,263,468  $2,466,338  $1,104,273    $1,178,772  $185,389  $1,041,446  $3,302,969  
Biomedical Research Models Inc.     $2,000,000    $767,501        
Individual Award- Conuel, 
Thomas       $12,000          
Jeffrey D. Mancevice       $8,870          
Security Engineered Machinery 
Company       $46,800          
Seracare Life Sciences Inc.          $10,497,976  $7,587,578  $3,333,763  $6,695,460  
                  
Total $5,263,468  $2,466,338  $3,104,273  $67,670  $12,444,249  $7,772,967  $4,375,209  $9,998,429  
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Appendix F: Patents 
Patents in Worcester County 
Class Class Title 2006 2007 2008 2009 2010 Total 
424 
Drug, Bio-Affecting and 
Body Treating 
Compositions (includes 
Class 514) 
18 17 26 20 47 128 
435 
Chemistry: Molecular 
Biology and Microbiology 
13 11 12 13 19 68 
430 
Radiation Imagery 
Chemistry: Process, 
Composition, or Product 
Thereof 
10 11 9 4 10 44 
532 
Organic Compounds 
(includes Classes 532-570) 
6 10 5 9 10 40 
128 
Surgery (includes Class 
600) 
5 7 3 7 11 33 
210 
Liquid Purification or 
Separation 
3 7 3 4 12 29 
606 Surgery (instruments) 6 2 1 4 15 28 
604 
Surgery (Medicators and 
Receptors) 
2 5 1 3 7 18 
623 
Prosthesis (i.e., Artificial 
Body Members), Parts 
Thereof, or Aids and 
Accessories Therefor 
3 0 1 6 7 17 
520 
Synthetic Resins or 
Natural Rubbers (includes 
Classes 520-528) 
4 3 1 3 5 16 
382 Image Analysis 3 5 4 0 2 14 
530 
Chemistry: Natural Resins 
or Derivatives; Peptides 
or Proteins; Lignins or 
Reaction Products 
Thereof 
2 3 3 3 3 14 
436 
Chemistry: Analytical and 
Immunological Testing 
0 0 1 5 5 11 
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422 
Chemical Apparatus and 
Process Disinfecting, 
Deodorizing, Preserving, 
or Sterilizing 
0 0 1 3 4 8 
73 Measuring and Testing 2 1 2 1 1 7 
137 Fluid Handling 0 1 0 3 3 7 
222 
Dispensing (apparatus 
and process) 
0 1 3 1 2 7 
423 
Chemistry of Inorganic 
Compounds 
1 1 0 1 4 7 
429 
Chemistry: Electrical 
Current Producing 
Apparatus, Product, and 
Process 
2 2 1 1 1 7 
95 Gas Separation: Processes 0 3 1 1 1 6 
119 Animal Husbandry 1 1 1 1 1 5 
156 
Adhesive Bonding and 
Miscellaneous Chemical 
Manufacture 
2 0 2 1 0 5 
204 
Chemistry: Electrical and 
Wave Energy 
0 2 1 1 1 5 
241 
Solid Material 
Comminution or 
Disintegration 
1 1 1 2 0 5 
607 
Surgery: Light, Thermal, 
and Electrical Application 
1 1 2 1 0 5 
261 
Gas and Liquid Contact 
Apparatus 
1 0 2 0 0 3 
800 
Multicellular Living 
Organisms and 
Unmodified Parts Thereof 
and Related Processes 
0 0 0 2 1 3 
55 Gas Separation 1 0 0 1 0 2 
351 
Optics: Eye Examining, 
Vision Testing and 
Correcting 
0 0 2 0 0 2 
494 
Imperforate Bowl: 
Centrifugal Separators 
1 0 0 0 1 2 
585 
Chemistry of 
Hydrocarbon Compounds 
0 0 0 1 1 2 
602 
Surgery: Splint, Brace, or 
Bandage 
0 0 0 2 0 2 
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433 Dentistry 0 1 0 0 0 1 
601 Surgery: Kinesitherapy 0 0 1 0 0 1 
 
All Life Science Patents 88 96 90 104 174 552 
 
 
Appendix G: 2012 Premarket Notifications in Massachusetts 
KNUMBER APPLICANT CONTACT STREET1 STREET2 CITY STATE 
Z
I
P 
DEVICE 
NAME 
DATE 
RECEIVED 
DECISION 
DATE 
K122203 
BOSTON 
SCIENTIFIC 
CORP. 
LAURIE  
PANNELLA 
100 
BOSTON 
SCIENTIFIC 
WAY   MARLBOROUGH MA 
0
1
7
5
2 TRUETOME 25-Jul-12 17-Aug-12 
K122118 
CODMAN 
& 
SHURTLEFF
, INC. 
KATHY  
STRANGE 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
 
0
3
5
0 
HAKIM 
PROGRAMM
ABLE AND 
PRECISION 
VALVE 
SHUNT 
SYSTEM 17-Jul-12 03-Aug-12 
K122086 
MICROLINE 
SURGICAL, 
INC 
WILLIAM  
MCCALLU
M 
800 
CUMMING 
CENTER 
SUITE 
166T BEVERLY MA 
0
1
9
1
5 
THERMAL 
LIGATING 
SHEARS 16-Jul-12 23-Aug-12 
K121839 
LEMAITRE 
VASCULAR 
INC. 
ANDREW  
HODGKIN
SON 
63 SECOND 
AVENUE   BEDFORD MA 
0
1
8
0
3 
UNBALLOON 
NON-
OCCLUSIVE 
MODELING 
CATHETER 09-Jul-12 08-Aug-12 
K121974 
CONFORMI
S, INC. 
AMITA S 
SHAH 
11 NORTH 
AVENUE   BURLINGTON MA 
0
1
8
0
3 
CONFORMIS 
IUNI 
UNICONDYL
AR KNEE 
REPLACEME
NT SYSTEM 09-Jul-12 06-Sep-12 
K121990 
NAVILYST 
MEDICAL, 
INC. 
MARION 
W 
GORDON 
26 FOREST 
STREET   MARLBOROUGH MA 
0
1
7
5
2 
PICC 
CONVENIEN
CE KIT 06-Jul-12 03-Aug-12 
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K121954 
NAVILYST 
MEDICAL, 
INC. 
WANDA  
CARPINEL
LA 
26 FOREST 
STREET   MARLBOROUGH MA 
0
1
7
5
2 
NMI 
MICROCATH
ETER 03-Jul-12 17-Jul-12 
K121868 
HOLOGIC, 
INC. 
SARAH  
FAIRFIELD 
250 
CAMPUS 
DRIVE   MARLBOROUGH MA 
0
1
7
5
2 
MYOSURE 
LITE TISSUE 
REMOVAL 
DEVICE (1 
PACK), 
MYOSURE 
LITE TISSUE 
REMOVAL 
DEVICE (3 
PACK) 26-Jun-12 19-Jul-12 
K121789 
WUHU 
SNNA 
MEDICAL 
TREATMEN
T 
APPLIANCE 
TECHNOLO
GY CO., LTD 
CYNTHIA  
NOLTE 
49 PLAIN 
STREET   N. ATTLEBORO MA 
0
2
7
6
0 SHANGRING 19-Jun-12 03-Aug-12 
K121776 
CODMAN 
& 
SHURTLEFF
, INC. 
JOAN  
BARTLE 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
 
0
3
5
0 
AGILITY 
STEERABLE 
GUIDEWIRE 
NEUROSCOU
T STEERABLE 
GUDIEWIRE 18-Jun-12 14-Aug-12 
K121678 
GYRUS 
ACMI, INC. 
DOLAN  
MILLS 
136 
TURNPIKE 
RD.   
SOUTHBOROUG
H MA 
0
1
7
7
2 DTAD 07-Jun-12 30-Aug-12 
K121604 
OBP 
CORPORATI
ON 
JASON  
SWIFT 
360 
MERRIMAC
K STREET 
BUILDIN
G 9 LAWRENCE MA 
0
1
8
4
3 
ANOSPEC 
DISPOSABLE 
ANSOSCOPE 
WITH LIGHT 01-Jun-12 27-Jul-12 
K121367 
ZOLL 
MEDICAL 
CORPORATI
ON 
CHARLES 
W 
KOLIFRAT
H 
269 MILL 
ROAD   CHELMSFORD MA 
0
1
8
2
4 
ZOLL 
PROPAQ XM 
07-May-
12 21-Jun-12 
K121229 
SORIN 
GROUP 
ITALIA 
S.R.L. 
BARRY  
SALL 
195 WEST 
STREET   WALTHAM MA 
0
2
4
5
1 
INSPIRE 8 
DUAL 
HOLLOW 
FIBER 
OXYGENATO
R WITH 
WITH 
INTEGRATED 
HARDSHELL 24-Apr-12 23-Jul-12 
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VENOUS/CA
RDIOTOMY 
K121223 
PHILIPS 
ULTRASOU
ND, INC. 
PENNY  
GRECO 
3000 
MINUTEM
AN RD.   ANDOVER MA 
0
1
8
1
0 
QLAB WITH 
FHN AND 
VPQ PLUG-
IN 23-Apr-12 
15-May-
12 
K121184 
NEUROME
TRIX, INC. 
RAINER  
MAAS 
62 FOURTH 
AVE.   WALTHAM MA 
0
2
4
5
1 SENSUS 18-Apr-12 02-Aug-12 
K121186 
BOSTON 
SCIENTIFIC 
CORP. 
CORRIE  
GOODING 
100 
BOSTON 
SCIENTIFIC 
WAY   MARLBOROUGH MA 
0
1
7
5
2 
RADIAL JAW 
4 
PULMONAR
Y BIOPSY 
FORCEPS 18-Apr-12 
16-May-
12 
K121140 
DIAMOND 
DIAGNOSTI
CS, INC 
KATHY  
CRUZ 
333 Fiske 
St   Holliston MA 
0
1
7
4
6 
PROLYTE 
ELECTROLYT
E ANALYZER 16-Apr-12 22-Aug-12 
K121139 
COVIDIEN 
LLC 
JAMES  
MCMAHO
N 
15 CROSBY 
DR   BEDFORD MA 
0
1
7
3
0 
ACCUMESH 
DEPLOYMEN
T SYSTEM 16-Apr-12 
02-May-
12 
K121131 
STRAUMAN
N USA 
ELAINE  
ALAN 
60 
MINUTEM
AN ROAD   ANDOVER MA 
0
1
8
1
0 
BL, 04.1 MM 
RC, 
SLACTIVE 
8MM, TIZR 
AND 10MM, 
12, 14MM 13-Apr-12 06-Jun-12 
K121127 
CYNOSURE, 
INC. 
IRINA  
KULINETS 
5 CARLISLE 
ROAD   WESTFORD MA 
0
1
8
8
6 
SIDELAZE 
LASER BEAM 
DELIVERY 
ACCESSORY 
FOR 
CYNOSURE 
1440NM 
WAVELENGT
H LASERS 13-Apr-12 
13-May-
12 
K121089 
NAVILYST 
MEDICAL, 
INC. 
LORRAINE 
M 
HANLEY 
26 FOREST 
STREET   MARLBOROUGH MA 
0
1
7
5
2 NMI PICC III 10-Apr-12 23-Aug-12 
K121048 
BOSTON 
SCIENTIFIC 
CORP. 
JANIS F 
TARANTO 
100 
BOSTON 
SCIENTIFIC 
WAY   MARLBOROUGH MA 
0
1
7
5
2 
ULTRAFLEX 
TRACHEOBR
ONCHIAL 
STENT 
SYSTEM- 
STERILE 
UNCOVERED 06-Apr-12 03-Aug-12 
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K121060 
SPINEFRON
TIER, INC. 
FREDY H 
VARELA 
500 
CUMMING
S CENTER 
SUITE 
3500 BEVERLY MA 
0
1
9
1
5 
SPINE 
FRONTIER 
INDUS ACP 
SYSTEM 06-Apr-12 03-Jul-12 
K121040 
DIAMOND 
DIAGNOSTI
CS, INC. 
KATHY  
CRUZ 
333 FISKE 
ST.   HOLLISTON MA 
0
1
7
4
6 
SMARTLYTE 
ELECTROLYT
E ANALYZER 05-Apr-12 30-Aug-12 
K121039 
COPAN 
FLOCK 
TECHNOLO
GIES 
CYNTHIA  
SINCLAIR 
49 PLAIN 
STREET   
NORTH 
ATTLEBORO MA 
0
2
7
6
0 
COPAN 
MSWAB 
COLLECTION
, 
TRANSPORT 
AND 
PRESERVATI
ON SYSTEM 05-Apr-12 
25-May-
12 
K121020 
DEPUY 
SPINE, INC. 
KIRSTEN  
LEHMULL
ER 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7 
VIPER 
SYSTEM 04-Apr-12 
03-May-
12 
K120983 
BOSTON 
SCIENTIFIC 
CORPORATI
ON 
JANIS F 
TARANTO 
100 
BOSTON 
SCIENTIFIC 
WAY   MARLBOROUGH MA 
0
1
7
5
2 
ULTRAFLEX 
ESOPHAGEA
L NG STENT 
SYSTEM 02-Apr-12 
02-May-
12 
K120992 
STANMORE 
IMPLANTS 
WORLDWI
DE LTD 
NANCY C 
MACDON
ALD 
690 
CANTON 
STREET 
SUITE 
302 WESTWOOD MA 
0
2
0
9
0 
METS 
SMILES 
TOTAL KNEE 
REPLACEME
NT 02-Apr-12 05-Sep-12 
K120966 
MEDOS 
INTERNATI
ONAL SARL 
ROBIN  
DINARDO 
325 
PARAMOU
NT DRIVE   RAYNHAM MA 
0
2
7
6
7 
DEPUY 
PULSE 
LUMBAR 
CAGE 
SYSTEM 
30-Mar-
12 03-Jul-12 
K120944 COVIDIEN 
JENNIFER  
SULLIVAN 
15 
HAMPSHIR
E STREET   MANSFIELD MA 
0
2
0
4
8 
KENDALL 
SCD 700 
SEQUENTIAL 
COMPRESSI
ON 
CONTROLLE
R 
29-Mar-
12 
31-May-
12 
K120897 
SOFRADIM 
PRODUCTI
ON 
JAMES  
MCMAHO
N 
15 CROSBY 
DRIVE   BEDFORD MA 
0
1
7
3
0 
PROGRIP 
LAPARSCOPI
C SELF-
FIXATING 
MESH 
26-Mar-
12 29-Jun-12 
K120823 
FRESENIUS 
MEDICAL 
CARE 
NORTH 
AMERICA, 
DESIGN 
CENTE 
DENISE  
OPPERMA
NN 
920 
WINTER 
STREET   WALTHAM MA 
0
2
4
5
1
 
1
BVM 
HEMODIALY
SIS BLOOD 
TUBING SET 
WITH 
ATTACHED 
PRIMING 
21-Mar-
12 15-Jun-12 
120 
 
4
5
7 
SET AND 
TRANSDUCE
R 
PROTECTOR
S 
K120810 
FIBEROPTIC 
FABRICATI
ONS INC 
CAROL J 
MORELLO 
495 MAIN 
STREET   WILBRAHAM MA 
0
1
0
9
5 
FIBEROPTIC 
LASER 
DELIVERY 
SYSTEM 
16-Mar-
12 28-Jun-12 
K120808 
MEDTRONI
C INC. 
ANU  
GAUR 
35-37A 
CHERRY 
HILL DRIVE   DANVERS MA 
0
1
9
2
3
 
5
1
8
6 
EXPORT XT 
CATHETER, 
EXPORT AP 
CATHETER 
16-Mar-
12 07-Jun-12 
K120784 
PULPDENT 
CORPORATI
ON 
KENNETH 
J BERK 
80 Oakland 
St   WATERTOWN MA 
0
2
4
7
2 
TUFF-TEMP 
2.0 
15-Mar-
12 08-Jun-12 
K120686 
CODMAN 
& 
SHURTLEFF
, INC. 
KIM  
FONDA 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
 
0
3
5
0 
ORBIT 
GALAXY G2 
MICROCOIL 
DELIVERY 
SYSTEM 
06-Mar-
12 04-Apr-12 
K120674 COVIDIEN WING  NG 
15 
HAMPSHIR
E STREET   MANSFIELD MA 
0
2
0
4
8 
MAHURKAR 
ELITE ACUTE 
DUAL 
LUMEN 
CATHETER, 
ELITE ACUTE 
TRIPLE 
LUMEN 
CATHETER 
05-Mar-
12 04-Apr-12 
K120676 
MEVION 
MEDICAL 
SYSTEMS 
THOMAS 
H FARIS 
300 
FOSTER ST   LITTLETON MA 
0
1
4
6
0 
S-250 
PROTON 
BEAM 
RADIATION 
THERAPY 
SYSTEM 
05-Mar-
12 04-Jun-12 
K120622 
PALOMAR 
MEDICAL 
TECHNOLO
GIES, INC. 
SHARON  
TIMBERLA
KE 
15 
NETWORK 
DR   BURLINGTON MA 
0
1
8
0
3 
PALOMAR 
VECTUS 
LASER 
01-Mar-
12 
23-May-
12 
121 
 
K120593 
HOLOGIC, 
INC. 
SARAH  
FAIRFIELD 
250 
CAMPUS 
DRIVE   MARLBOROUGH MA 
0
1
7
5
2 
MYOSURE 
CONTROL 
UNIT 29-Feb-12 
23-Mar-
12 
K120611 
SONY 
ELECTRONI
CS, INC. 
CYNTHIA  
SINCLAIR 
49 PLAIN 
STREET   
NORTH 
ATTLEBORO MA 
0
2
7
6
0 
SONY PVM-
2551MD 
OLED 
MONITOR 29-Feb-12 28-Jun-12 
K120605 
COVIDIEN 
LLC 
JAMES  
MCMAHO
N 
15 CROSBY 
DR   BEDFORD MA 
0
1
7
3
0 
PERMACOL 
SURGICAL 
IMPLANT 28-Feb-12 
18-May-
12 
K120591 
DIAMOND 
DIAGNOSTI
CS, INC 
KATHY  
CRUZ 
333 Fiske 
St   Holliston MA 
0
1
7
4
6 
DIAMOND 
TOKYO 
BOEKI ISE 
MODULE 
CALIBRATOR 
1,2,1-2 28-Feb-12 17-Apr-12 
K120589 
DEPUY 
MITEK, A 
JOHNSON 
& 
JOHNSON 
COMPANY DEEP  PAL 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7 
MILAGRO 
INTERFEREN
CE SCREWS 28-Feb-12 24-Apr-12 
K120567 
GYRUS 
ACMI, INC. 
NEIL  
KELLY 
136 
TURNPIKE 
RD.   
SOUTHBOROUG
H MA 
0
1
7
7
2 
GYRUS AMCI 
PK BUTTON 
ELECTRODE 27-Feb-12 20-Jun-12 
K120586 
HAEMONE
TICS CORP. 
GREG  
CALDER 
400 Wood 
Rd   BRAINTREE MA 
0
2
1
8
4 
CELL SAVER 
ELITE 27-Feb-12 
22-May-
12 
K120525 
PHILIPS 
HEALTHCA
RE GROUP 
PENNY  
GRECO 
3000 
MINUTEM
AN ROAD   ANDOVER MA 
0
1
8
1
0
 
7
3
2
4 
QLAB 
QUANTIFICA
TION 
SOFTWARE 22-Feb-12 
09-Mar-
12 
K120497 
MEDICA 
CORP. 
PHOTIOS  
MAKRIS 
5 OAK 
PARK 
DRIVE   BEDFORD MA 
0
1
7
3
0 
EASYRA 
HBALC 
REGENT 
EASYCAL 
HBLC 
CALIBRATOR 
EASYQC 
HBALC 
MATERIAL 21-Feb-12 
14-May-
12 
122 
 
K120506 
SOFRADIM 
PRODUCTI
ON 
JAMES  
MCMAHO
N 
15 CROSBY 
DR   BEDFORD MA 
0
1
7
3
0 
PARIETEX 
COMPOSITE 
VENTRAL 
PATCH 21-Feb-12 13-Jun-12 
K120517 
MEDOS 
INTERNATI
ONAL SARL 
EUGENE  
BANG 
325 
PARAMOU
NT DR   RAYNHAM MA 
0
2
7
6
7 
DEPUY 
PULSE 
CERVICAL 
CAGE 
SYSTEM 21-Feb-12 26-Apr-12 
K120505 
FRESENIUS 
MEDICAL 
CARE 
NORTH 
AMERICA, 
DESIGN 
CENTE 
DENISE  
OPPERMA
NN 
920 
WINTER 
STREET   WALTHAM MA 
0
2
4
5
1
 
1
4
5
7 
FRESENIUS 
2008T 
HEMODIALY
SIS 
MACHINE 21-Feb-12 
06-Mar-
12 
K120474 
GYRUS 
ACMI, INC. 
GRAHAM  
BAILLE 
136 
TURNPIKE 
RD.   
SOUTHBOROUG
H MA 
0
1
7
7
2 
GYRUS ACMI 
TELESCOPE 
STORAGE-
STERILIZATI
ON TRAY 16-Feb-12 10-Jul-12 
K120449 
DEPUY 
MITEK 
YAYOI  
FUJIMAKI 
325 
PARAMOU
NT DRIVE   RAYNHAM MA 
0
2
7
6
7 
HEALIX 
ADVANCE 
PEEK 
ANCHOR 14-Feb-12 
11-May-
12 
K120437 
BIOLITEC 
SIA 
(LATVIA) 
HARRY  
HAYES 
1349 MAIN 
ROAD   GRANVILLE MA 
0
1
0
3
4 
TWISTER 
SIDE-FIRE 
FIBER OPTIC 
DELIVERY 
SYSTEM 13-Feb-12 26-Apr-12 
K120388 
HOLOGIC, 
INC. 
EILEEN M 
BOYLE 
35 CROSBY 
DR.   BEDFORD MA 
0
1
7
3
0 
INSIGHT - FD 
MINI C-ARM 
FLUOROSCO
PIC 
IMAGING 
SYSTEM 07-Feb-12 06-Apr-12 
K120185 
SORIN 
GROUP 
ITALIA 
S.R.L. 
BARRY  
SALL 
195 WEST 
STREET   WALTHAM MA 
0
2
4
5
1 
INSPIRE 6F 
HOLLOW 
FIBER 
OXYGENATO
R WITH 
INTEGRATED 
ARTERIAL 
FILTER AND 
HARDSHELL 
VENOUS/CA
RDIOTOMY 
RESERVIOR 06-Feb-12 
11-May-
12 
K120274 
CODMAN 
AND 
SHURTLEFF
, INC. 
KIM  
FONDA 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
DELTAMAXX 
18 
MICROCOIL 
SYSTEM 02-Feb-12 
02-Mar-
12 
123 
 
 
0
3
5
0 
K120321 
PHILIPS 
HEALTHCA
RE 
ROB  
BUTLER 
3000 
MINUTEM
AN RD   ANDOVER MA 
0
1
8
1
0 
CLEARVUE 
350/550 
DIAGNOSTIC 
ULTRASOUN
D SYSTEM 02-Feb-12 17-Feb-12 
K120316 
CONFORMI
S, INC. 
AMITA S 
SHAH 
1 North 
Ave Ste B   Burlington MA 
0
1
8
0
3 
ITOTAL 
CRUCIATE 
RETAINING 
(CR) KNEE 
REPLACEME
NT SYSTEM 01-Feb-12 19-Apr-12 
K120132 
PHILIPS 
MEDICAL 
SYSTEMS 
MARY  
KRUITWA
GEN 
3000 
MINUTEM
AN RD.   ANDOVER MA 
0
1
8
1
0
 
1
0
9
9 
SURESIGNS 
VS3 VITAL 
SIGNS 
MONITOR, 
SURESIGNS 
VS4 VITAL 
SIGNS 
MONITOR 27-Jan-12 14-Feb-12 
K120231 
BIOLITEC 
MEDICAL 
DEVICES, 
INC 
HARRY  
HAYES, 
PH.D 
1349 MAIN 
ROAD   GRANVILLE MA 
0
1
0
3
4 
EVOLVE HPD 
980/ 
1470NM 
MULTIWAVE
LENGTH 
DIODE 
LASER 
(EVOLVE 
DUAL) 25-Jan-12 24-Apr-12 
K120229 
CODMAN 
& 
SHURTLEFF
, INC. 
CATHERIN
E  
KILSHAW 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
 
0
3
5
0 
ENVOY 
DISTAL 
ACCESS 
GUIDING 
CATHETER 25-Jan-12 24-Feb-12 
K120213 
PULPDENT 
CORPORATI
ON 
KENNETH 
J BERK 
80 Oakland 
St   WATERTOWN MA 
0
2
4
7
2 
ETCH-RITE 
SUPREME 24-Jan-12 
30-Mar-
12 
K120117 
CODMAN 
& 
SHURTLEFF
, INC. 
MEGAN  
HERMAN 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7
 
0
3
CODMAN 
QUAD-LOCK 
STERILIZATI
ON 
CONTAINER 
SYSTEM 17-Jan-12 16-Apr-12 
124 
 
5
0 
K120095 
DEPUY 
MITEK, A 
JOHNSON 
& 
JOHNSON 
COMPANY 
SUSAN  
KAGAN 
325 
PARAMOU
NT DR.   RAYNHAM MA 
0
2
7
6
7 
SIDE EFFECT 
WITH HAND 
CONTROLS, 
HOOK 
ELECTRODE 
WITH HAND 
CONTROLS, 
2.3 WEDGE 
ELECTRODE 
WITH HAND 
CONTROLS, 
S90 WITH 
HAND 12-Jan-12 06-Apr-12 
K120086 
CARDIOSOL
UTIONS 
MICHELE  
LUCEY 
375 WEST 
ST.   
WEST 
BRIDGEWATER MA 
0
2
3
7
9 
CARIOSOLUT
IONS PERCU-
PRO 
STEERABLE 
INTRODCER 
65CM 
CARIOSOLUT
IONS PERCU-
PRO 
STEERABLE 
INTRODUCE
R 80CM 11-Jan-12 24-Apr-12 
K120080 
SHASER, 
INC. 
GLEN  
EMELOCK 
32 
HARRISON 
ST.   MELROSE MA 
0
2
1
7
6 
SHASER 
HRS2 HAIR 
REMOVAL 
SYSTEM 11-Jan-12 
25-May-
12 
K120078 
DEPUY 
MITEK INC., 
JOHNSON 
AND 
JOHNSON 
COMPANY 
YAYOI  
FUJIMAKI 
325 
PARAMOU
NT DRIVE   RAYNHAM MA 
0
2
7
6
7 
HEALIX 
ADVANCE 
BR ANCHOR 10-Jan-12 29-Feb-12 
K120055 
HAMILTON 
THORNE, 
INC. 
DIARMAID 
H 
DOUGLAS
-
HAMILTO
N 
100 
CUMMING
S CENTER-
SUITE 465E   Beverly MA 
0
1
9
1
5 
HANILTON 
THORNE 
INFRARED 
LASER 
OPTICAL 
SYSTEM-
ZILOS-TK  
HAMILTON 
THORNE 
INFRARED 
LASER 
OPTICAL 
SYSTEM-
LYKOS 09-Jan-12 24-Apr-12 
K120068 
CONFORMI
S, INC. 
AMITA  
SHAH 
1 North 
Ave Ste B   Burlington MA 
0
1
8
0
CONFORMIS 
ITOTAL CR 
KNEE 
REPLACEME 09-Jan-12 03-Feb-12 
125 
 
3 NT SYSTEM 
(KRS) 
K120003 
PULPDENT 
CORPORATI
ON 
KENNETH 
J BERK 
80 Oakland 
St   WATERTOWN MA 
0
2
4
7
2 NUCAL 03-Jan-12 05-Apr-12 
K120017 
FRESENIUS 
MEDICAL 
CARE, 
NORTH 
AMERICA 
DENISE  
OPPERMA
NN 
920 
WINTER 
STREET   WALTHAM MA 
0
2
4
5
1 
FRESENIUS 
2008 
HEMODIAYSI
S MACHINE 
WITH BIBAG 
SYSTEM 03-Jan-12 02-Feb-12 
K120004 
CHINA 
SHENYANG 
MED-LAND 
IMP/EXP 
CORP., LTD. 
ANN D 
MCGONIG
LE 
19 
SEDGEMEA
DOW RD   WAYLAND MA 
0
1
7
7
8 
(MULTIPLE) 
DIGITAL 
THERMOME
TER 03-Jan-12 23-Aug-12 
 
126 
 
 
WATERT
OWN MA 02472 TUFF-TEMP 2.0 15-Mar-12 08-Jun-12 SE DE EBG Summary DE
Tradition
al N N
RAYNHA
M MA
02767 
0350
ORBIT GALAXY G2 MICROCOIL DELIVERY 
SYSTEM 06-Mar-12 04-Apr-12 SE NE HCG Summary NE Special N N
MANSFIE
LD MA 02048
MAHURKAR ELITE ACUTE DUAL LUMEN 
CATHETER, ELITE ACUTE TRIPLE LUMEN 
CATHETER 05-Mar-12 04-Apr-12 SK GU MPB Summary GU Special N N
LITTLETO
N MA 01460
S-250 PROTON BEAM RADIATION THERAPY 
SYSTEM 05-Mar-12 04-Jun-12 SE RA LHN Summary RA
Tradition
al N N
BURLING
TON MA 01803 PALOMAR VECTUS LASER 01-Mar-12 23-May-12 SE SU GEX Summary SU
Tradition
al N N
MARLBO
ROUGH MA 01752 MYOSURE CONTROL UNIT 29-Feb-12 23-Mar-12 SE OB HIH Summary OB Special N N
NORTH 
ATTLEBO
RO MA 02760 SONY PVM-2551MD OLED MONITOR 29-Feb-12 28-Jun-12 SE SU GCJ Summary SU
Tradition
al N N
BEDFORD MA 01730 PERMACOL SURGICAL IMPLANT 28-Feb-12 18-May-12 SE SU FTM Summary SU
Tradition
al N N
Holliston MA 01746
DIAMOND TOKYO BOEKI ISE MODULE 
CALIBRATOR 1,2,1-2 28-Feb-12 17-Apr-12 SE CH JIT Summary CH
Tradition
al N N
RAYNHA
M MA 02767 MILAGRO INTERFERENCE SCREWS 28-Feb-12 24-Apr-12 SE OR MAI Summary OR
Tradition
al N N
SOUTHB
OROUGH MA 01772 GYRUS AMCI PK BUTTON ELECTRODE 27-Feb-12 20-Jun-12 SE GU FAS Summary GU
Tradition
al N N
BRAINTR
EE MA 02184 CELL SAVER ELITE 27-Feb-12 22-May-12 SE CV CAC Summary AN
Tradition
al N N
ANDOVE
R MA
01810 
7324 QLAB QUANTIFICATION SOFTWARE 22-Feb-12 09-Mar-12 SE RA LLZ Summary RA Special Y N
BEDFORD MA 01730
EASYRA HBALC REGENT EASYCAL HBLC 
CALIBRATOR EASYQC HBALC MATERIAL 21-Feb-12 14-May-12 CS CH LCP
Stateme
nt HE
Tradition
al N N
BEDFORD MA 01730 PARIETEX COMPOSITE VENTRAL PATCH 21-Feb-12 13-Jun-12 SE SU FTL Summary SU
Tradition
al N N
RAYNHA
M MA 02767 DEPUY PULSE CERVICAL CAGE SYSTEM 21-Feb-12 26-Apr-12 SE OR ODP Summary OR
Tradition
al N N
WALTHA
M MA
02451 
1457 FRESENIUS 2008T HEMODIALYSIS MACHINE 21-Feb-12 06-Mar-12 SE GU KDI Summary GU Special N N
SOUTHB
OROUGH MA 01772
GYRUS ACMI TELESCOPE STORAGE-
STERILIZATION TRAY 16-Feb-12 10-Jul-12 SE HO KCT Summary HO
Tradition
al N N
RAYNHA
M MA 02767 HEALIX ADVANCE PEEK ANCHOR 14-Feb-12 11-May-12 SE OR HWC Summary OR
Tradition
al N N
GRANVIL
LE MA 01034
TWISTER SIDE-FIRE FIBER OPTIC DELIVERY 
SYSTEM 13-Feb-12 26-Apr-12 SE SU GEX Summary SU
Tradition
al N N
BEDFORD MA 01730
INSIGHT - FD MINI C-ARM FLUOROSCOPIC 
IMAGING SYSTEM 07-Feb-12 06-Apr-12 SE RA OXO Summary RA Special N N
WALTHA
M MA 02451
INSPIRE 6F HOLLOW FIBER OXYGENATOR WITH 
INTEGRATED ARTERIAL FILTER AND HARDSHELL 
VENOUS/CARDIOTOMY RESERVIOR 06-Feb-12 11-May-12 SE CV DTZ Summary CV
Tradition
al N N
RAYNHA
M MA
02767 
0350 DELTAMAXX 18 MICROCOIL SYSTEM 02-Feb-12 02-Mar-12 SE NE HCG Summary NE Special N N
ANDOVE
R MA 01810
CLEARVUE 350/550 DIAGNOSTIC ULTRASOUND 
SYSTEM 02-Feb-12 17-Feb-12 SE RA IYN Summary RA
Tradition
al Y N
Burlingto
n MA 01803
ITOTAL CRUCIATE RETAINING (CR) KNEE 
REPLACEMENT SYSTEM 01-Feb-12 19-Apr-12 SE OR JWH Summary OR
Tradition
al N N
ANDOVE
R MA
01810 
1099
SURESIGNS VS3 VITAL SIGNS MONITOR, 
SURESIGNS VS4 VITAL SIGNS MONITOR 27-Jan-12 14-Feb-12 SE CV DXN Summary CV Special N N
GRANVIL
LE MA 01034
EVOLVE HPD 980/ 1470NM 
MULTIWAVELENGTH DIODE LASER (EVOLVE 
DUAL) 25-Jan-12 24-Apr-12 SE SU GEX Summary SU
Tradition
al N N
RAYNHA
M MA
02767 
0350 ENVOY DISTAL ACCESS GUIDING CATHETER 25-Jan-12 24-Feb-12 SE NE DQY Summary CV Special N N
WATERT
OWN MA 02472 ETCH-RITE SUPREME 24-Jan-12 30-Mar-12 SE DE KLE Summary DE
Tradition
al N N
RAYNHA
M MA
02767 
0350
CODMAN QUAD-LOCK STERILIZATION 
CONTAINER SYSTEM 17-Jan-12 16-Apr-12
RAYNHA
M MA 02767
SIDE EFFECT WITH HAND CONTROLS, HOOK 
ELECTRODE WITH HAND CONTROLS, 2.3 
WEDGE ELECTRODE WITH HAND CONTROLS, 
S90 WITH HAND 12-Jan-12 06-Apr-12
WEST 
BRIDGEW
ATER MA 02379
CARIOSOLUTIONS PERCU-PRO STEERABLE 
INTRODCER 65CM CARIOSOLUTIONS PERCU-
PRO STEERABLE INTRODUCER 80CM 11-Jan-12 24-Apr-12
MELROSE MA 02176 SHASER HRS2 HAIR REMOVAL SYSTEM 11-Jan-12 25-May-12
RAYNHA
M MA 02767 HEALIX ADVANCE BR ANCHOR 10-Jan-12 29-Feb-12
Beverly MA 01915
HANILTON THORNE INFRARED LASER OPTICAL 
SYSTEM-ZILOS-TK  HAMILTON THORNE 
INFRARED LASER OPTICAL SYSTEM-LYKOS 09-Jan-12 24-Apr-12
Burlingto
n MA 01803
CONFORMIS ITOTAL CR KNEE REPLACEMENT 
SYSTEM (KRS) 09-Jan-12 03-Feb-12
WATERT
OWN MA 02472 NUCAL 03-Jan-12 05-Apr-12
WALTHA
M MA 02451
FRESENIUS 2008 HEMODIAYSIS MACHINE WITH 
BIBAG SYSTEM 03-Jan-12 02-Feb-12
WAYLAN
D MA 01778 (MULTIPLE) DIGITAL THERMOMETER 03-Jan-12 23-Aug-12
127 
 
Appendix H: 2011 NIH/NSF Small Business Innovation Research Grants/STTR 
Title 
Contract 
Number 
A
g
e
n
c
y Branch Program 
Y
e
a
r 
P
h
a
s
e 
Award 
Amount SBC Street 
Stree
t 2 City 
SBIR Phase I: 
Development of a 
Long Life 
Microchannel Plate 
Photomultiplier 
Tube for High Flux 
Applications 
through the 
Innovative 
Application of 
Nanofilms 1046903 
N
S
F NSF SBIR 
2
0
1
1 1 149991 
Arradian
ce, Inc. 
142 
North 
Road 
Suite 
F-
150 Sudbury 
IgA Protease as 
Therapy to Reverse 
IgA Nephropathy 
4R44DK08
3147-02 
H
H
S HHS SBIR 
2
0
1
1 2 871770 
IGAN 
BIOSCIE
NCES, 
INC. 
198 TREMONT 
ST Boston 
SBIR Phase I: Cost-
Effective 
Anastomotic 
System Featuring 
Compliant 
Anastomoses 1046481 
N
S
F NSF SBIR 
2
0
1
1 1 149979 
Sterling 
biomedi
cal 2 DURHAM DR Lynnfield 
SBIR Phase II: A 
Novel 
Antimicrobial 
Polymer for 
Medical Devices 1058279 
N
S
F NSF SBIR 
2
0
1
1 2 418443 
Sterling 
biomedi
cal 2 DURHAM DR Lynnfield 
SBIR Phase II: 
Novel Antioxidants 
to Improve 
Thermo-Oxidative 
Stability of 
Biolubricants and 
Biodiesel 1138520 
N
S
F NSF SBIR 
2
0
1
1 2 500000 Polnox 
225 
Stedma
n Street 
Unit 
23 Lowell 
SBIR Phase I: Thin-
Film Spectrally-
Tunable Optical 
Filter with Wide 
Bandwidth for 
Visible and Near 
Infrared Spectrum 1046556 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Raydex 
Technol
ogy, Inc. 
655 Concord 
Ave, Unit 704 Cambridge 
SBIR Phase I: 
Development of a 
Commercial 
Culture of 
Dehalococcoides 
for anaerobic 
treatment of PCBs 1113457 
N
S
F NSF SBIR 
2
0
1
1 1 150000 BCI 
39 Clarendon 
Street Watertown 
SBIR Phase I: Novel 
volumetric 1047120 
N
S NSF SBIR 
2
0 1 149615 
Metama
gnetics 36 Station St Sharon 
128 
 
efficient design 
and packaging of a 
broadband 
integrated 
circulator-antenna 
(BICA) 
F 1
1 
Inc. 
SBIR Phase I: Ultra-
low profile 
wideband 
metamaterial 
antennas based 
upon advanced 
textured ferrite 
materials 1113687 
N
S
F NSF SBIR 
2
0
1
1 1 145881 
Metama
gnetics 
Inc. 36 Station St Sharon 
SBIR Phase II: 
System for 
Location-Based 
Mobile Consumer 
Analytics 1127482 
N
S
F NSF STTR 
2
0
1
1 2 498395 Cadio 
38 Ossipee Rd, 
Suite 2 Somerville 
Attomole-Level 
High-Throughput 
Genomics 
4R44HG0
05279-02 
H
H
S HHS SBIR 
2
0
1
1 2 1502971 
HELICOS 
BIOSCIE
NCE 
CORPOR
ATION 
ONE KENDALL 
SQUARE Cambridge 
Improving self 
delivering 
properties of RNAi 
compounds 
through medicinal 
chemistr 
1R43GM0
96548-01 
H
H
S HHS SBIR 
2
0
1
1 1 273824 
RXI 
PHARM
ACEUTIC
ALS 
CORPOR
ATION 60 PRESCOTT ST Worcester 
Novel RNAi 
therapy for ALS 
and other 
Neurodegenerativ
e Disorders 
1R43NS07
4671-01 
H
H
S HHS SBIR 
2
0
1
1 1 304559 
RXI 
PHARM
ACEUTIC
ALS 
CORPOR
ATION 60 PRESCOTT ST Worcester 
SBIR Phase I: Next 
Generation 
Electrical 
Impedance 
Myography for 
Neuromuscular 
Disease 
Assessment 1046826 
N
S
F NSF SBIR 
2
0
1
1 1 149956 
CONVER
GENCE 
MEDICA
L 
DEVICES
, INC. 
400 
TradeCenter, 
Suite 5900 Woburn 
A device for rapid, 
painless, bedside 
muscle evaluation 
of children 
1R43NS07
3188-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 289901 
CONVER
GENCE 
MEDICA
L 
DEVICES
, INC. 
400 
TradeCenter, 
Suite 5900 Woburn 
The Hearthside 
Book Club: 
Pioneering 
Dementia-Level-
Appropriate 
Reading Materials 
1R43AG03
9907-01 
H
H
S HHS SBIR 
2
0
1
1 1 149397 
HEARTH
STONE 
ALZHEI
MER 
CARE, 
LTD 
130 
New 
Boston 
Street 
Suite 
103 Woburn 
Minimally Invasive 
Pediatric VAD for 
4R44HL09
9192-02 
H
H HHS SBIR 
2
0 2 1122294 
ABIOME
D, INC. 
22 CHERRY HILL 
DRIVE Danvers 
129 
 
Treatment of 
Acute Heart Failure 
S 1
1 
SBIR Phase II: High 
Performance 
Supercapacitors 
Based on Nano-
engineered 
Electrodes 1058570 
N
S
F NSF SBIR 
2
0
1
1 2 487872 
Agiltron 
Corpora
tion 15 Cabot Road Woburn 
Infant Breath 
1R43HD0
65380-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 149939 
Agiltron 
Corpora
tion 15 Cabot Road Woburn 
A Portable High 
Resolution 
Detector for Rapid 
Field Arsenic Test 
in Drinking Wate 
2R44EH00
0385-02 
H
H
S HHS SBIR 
2
0
1
1 2 499140 
Agiltron 
Corpora
tion 15 Cabot Road Woburn 
RandD-OTHER R 
and D-B RES 
N43ES110
008 
H
H
S HHS SBIR 
2
0
1
1 1 147753 
Agiltron 
Corpora
tion 15 Cabot Road Woburn 
Information 
Technology 
Enabled Treatment 
of Adolescent 
Depression 
2R44MH0
85350-02 
H
H
S HHS SBIR 
2
0
1
1 2 949734 
VERITAS 
HEALTH 
SOLUTI
ONS, 
LLC 
800 
West 
Cummin
gs Park 
Suite 
2950 Woburn 
Optical Surgical 
Probe for 
Assessing Human 
Oral Mucosa Graft 
Vascularization 
1R43DE02
1935-01 
H
H
S HHS SBIR 
2
0
1
1 1 196853 
Radiatio
n 
Monitor
ing 
Devices, 
Inc. 44 Hunt Street Watertown 
Device for 
Measuring 
Capillary Blood 
Flow and the 
Onset of Shock 
1R43HL10
6851-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 220639 
Radiatio
n 
Monitor
ing 
Devices, 
Inc. 44 Hunt Street Watertown 
High Performance, 
Low Cost PET 
Scintillators 
1R44EB01
2443-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 189406 
Radiatio
n 
Monitor
ing 
Devices, 
Inc. 44 Hunt Street Watertown 
Instrument to 
Identify Hazardous 
Children's Products 
that Could Cause 
Lead Poison 
2R44ES01
5439-02 
H
H
S HHS SBIR 
2
0
1
1 2 951056 
Radiatio
n 
Monitor
ing 
Devices, 
Inc. 44 Hunt Street Watertown 
Simultaneous PET-
MR Small Animal 
Imaging 
4R44NS06
6521-02 
H
H
S HHS SBIR 
2
0
1
1 2 1187392 
Radiatio
n 
Monitor
ing 
Devices, 
Inc. 44 Hunt Street Watertown 
Multibeam Healing 
for Laser 
9R44RR03
1472-03 
H
H HHS SBIR 
2
0 2 1592997 
Radiatio
n 44 Hunt Street Watertown 
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Micromachining in 
Manufacturing 
S 1
1 
Monitor
ing 
Devices, 
Inc. 
Global Proteomic 
Screening by 
MALDI 
Spectrometric 
Imaging of Protein-
Bead Arrays 
1R43CA16
1965-01 
H
H
S HHS SBIR 
2
0
1
1 1 299730 
AMBER
GEN, 
INC 
313 PLEASANT 
ST Watertown 
Alzheimer's 
Disease 
Therapeutic 
4R44AG03
4760-02 
H
H
S HHS SBIR 
2
0
1
1 2 2409606 
APHIOS 
CORPOR
ATION 3 E GILL ST Woburn 
TAS:: 75 0896::TAS 
SBIR PHASE I TOPIC 
NCCAM 002 
N43CO11
0117 
H
H
S HHS SBIR 
2
0
1
1 1 94448 
APHIOS 
CORPOR
ATION 3 E GILL ST Woburn 
SBIR PHASE 1 
TOPIC 43 
N43HB11
0034 
H
H
S HHS SBIR 
2
0
1
1 1 149440 
APHIOS 
CORPOR
ATION 3 E GILL ST Woburn 
SBIR Phase II: 
Force-Controlled 
Robotic Arm 
Capable of Sub-
Millimeter 
Precision 1058474 
N
S
F NSF SBIR 
2
0
1
1 2 481971 
Barrett 
Technol
ogy Inc 
625 MOUNT 
AUBURN ST Cambridge 
Integrated 
molecular 
diagnostic system 
for the point-of-
care 
1R41AI09
2913-01 
H
H
S HHS STTR 
2
0
1
1 1 482810 
BIOHELI
X 
CORPOR
ATION 
500 Cummings 
Center Beverly 
Monolithic Media 
and Technology for 
Bioprocessing 
1R43GM0
99199-01 
H
H
S HHS SBIR 
2
0
1
1 1 146027 
BIOLINK 
PARTNE
RS 
109 SCHOOL 
STREET Watertown 
Developing small 
molecule 
therapeutics for 
lupus 
1R41AR06
0620-01 
H
H
S HHS STTR 
2
0
1
1 1 583195 
BIOMED
ICAL 
RESEAR
CH 
MODELS
, INC. 
67 MILLBROOK, 
ST, STE 422 Worcester 
Rapid Testing of 
Drug-Resistant 
BCR-
ABL(+)Leukemia 
Cells 
1R43CA15
3614-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 199691 
BioSens
e 
Technol
ogies 
Inc. 4 ARROW DR Woburn 
A Bioactive 
Prosthetic Vascular 
Graft 
2R42HL08
7466-
02A1 
H
H
S HHS STTR 
2
0
1
1 2 748950 
BIOSURF
ACES 
200 Homer 
Avenue, Unit 1P Ashland 
Development of 
Specific Gene 
Silencing Methods 
and Reagents 
1R43GM0
96635-01 
H
H
S HHS SBIR 
2
0
1
1 1 312194 
BOSTON 
BIOMED
ICAL, 
INC. 
333 
PROVIDENCE 
HWY Norwood 
New 
Communication 
9R44DC01
2275-
H
H HHS SBIR 
2
0 2 1023545 
CHAMEL
EON 14 PARKMAN ST Natick 
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Technology for 
Suddenly 
Speechless 
Hospitalized 
Patients 
02A1 S 1
1 
ADAPTI
VEWARE
, LLC 
VASCULAR SENSOR 
FOR WOMEN'S 
REPRODUCTIVE 
HEALTH RESEARCH 
1R43HD0
65520-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 147185 
CORPOR
A 
SYSTEM
S, INC. 
14 SUMMER 
STREET Malden 
SBIR Phase I: 
Titanium 
Automotive 
Powertrain 
Componenets For 
Increased Fuel 
Efficiency And 
Reduced Emissions 1045207 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
DYNAM
ET 
TECHNO
LOGY, 
INC. Eight A Street Burlington 
Cell-based Model 
for Electrical 
Stimulation Safety 
Studies 
1R43NS07
3195-01 
H
H
S HHS SBIR 
2
0
1
1 1 280846 
EIC 
Laborat
ories, 
Inc. 
EIC 
LABORA
TORIES, 
INC. 
111 
DOW
NEY 
ST Norwood 
On-Site 
Multiplexed GMO 
Detector to 
Facilitate 
Traceability 
1R43FD00
3958-01 
H
H
S HHS SBIR 
2
0
1
1 1 149997 
EIC 
Laborat
ories, 
Inc. 
EIC 
LABORA
TORIES, 
INC. 
111 
DOW
NEY 
ST Norwood 
A sensor-based 
remote monitoring 
system to prevent 
falls in older adults 
1R43AG03
9214-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 339409 
ENVIRO
NMENT 
AND 
HEALTH 
GROUP, 
INC. 
1280 
MASSACHUSETT
S AVE, #505 Cambridge 
Self-Directed 
Online Training 
Program for 
Multicultural 
Dementia 
Caregivers 
1R43AG04
1571-01 
H
H
S HHS SBIR 
2
0
1
1 1 292485 
ENVIRO
NMENT 
AND 
HEALTH 
GROUP, 
INC. 
1280 
MASSACHUSETT
S AVE, #505 Cambridge 
SBIR Phase I: Novel 
Emergency 
Communication 
System for Mines 1046812 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
FERRO 
SOLUTI
ONS, 
INC. 
5 Constitution 
Way Woburn 
SBIR Phase I: 
Magneto-electric-
MEMs-enabled 
wireless power for 
medical implants 1113641 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
FERRO 
SOLUTI
ONS, 
INC. 
5 Constitution 
Way Woburn 
Prevention of 
Tumor Recurrence 
Following Surgical 
Resection (Phase 
II) 
2R44CA13
5967-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 1415731 
FIFTH 
BASE, 
LLC 
200 Upland 
Road Newton 
Rapid sensitive 
low-cost test for 
resistant microbes 
causing hospital 
infections 
2R44AI08
0016-
03A1 
H
H
S HHS SBIR 
2
0
1
1 2 2906840 
FIRST 
LIGHT 
BIOSCIE
NCES, 
INC. 1 OAK PARK DR Bedford 
Oral Antibody 1R43DK08 H HHS SBIR 2 1 145306 AVAXIA 26 PEMBERTON Wayland 
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Therapy for Celiac 
Disease 
0526-
01A1 
H
S 
0
1
1 
BIOLOGI
CS, INC. 
RD 
Electrochemical 
Home Monitoring 
System for Lithium 
Blood Level 
2R44MH0
90582-02 
H
H
S HHS SBIR 
2
0
1
1 2 1022417 
Giner, 
Inc. 
89 Rumford 
Avenue Newton 
Advanced Gas 
Sensor 
2R44OH0
09016-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 848562 
Giner, 
Inc. 
89 Rumford 
Avenue Newton 
Novel Glycosylated 
Delta Opioid 
Receptor Agonists 
for Chronic 
Inflammatory Pain 
2R44DA02
6653-02 
H
H
S HHS SBIR 
2
0
1
1 2 992331 
BIOUSIA
N 
BIOSYST
EMS, 
INC.  
(BBI) 51 FOLLEN RD Lexington 
Development of a 
Fiberless 
Transflectance 
Noninvasive 
Glucose Monitor 
2R44DK08
3797-02 
H
H
S HHS SBIR 
2
0
1
1 2 994342 
GROVE 
INSTRU
MENTS, 
INC. 
100 
Grove 
Street 
Suite 
315 Worcester 
Silicone Coatings 
for Biostable 
Chronic Neural 
Prostheses 
2R44NS06
0377-
02A2 
H
H
S HHS SBIR 
2
0
1
1 2 2078683 
GVD 
CORP. 45 Spinelli Place Cambridge 
Motivational 
Interviewing: An 
Experiential Online 
Training Tool 
1R43MH0
92951-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 202983 
CENTER 
FOR 
SOCIAL 
INNOVA
TION, 
LLC 
200 Reservoir 
Street Needham 
Online Tool To 
Recognize and 
Respond to Elder 
Homelessness 
1R43AG04
1537-01 
H
H
S HHS SBIR 
2
0
1
1 1 147360 
CENTER 
FOR 
SOCIAL 
INNOVA
TION, 
LLC 
200 Reservoir 
Street Needham 
Confirmatory 
Immunoblot Test 
for Chagas' Disease 
2R44AI08
0021-03 
H
H
S HHS SBIR 
2
0
1
1 2 2410129 
IMMUN
ETICS, 
INC. 
27 DRYDOCK 
AVE. Boston 
A Clinical Decision 
Support Tool for 
Electronic Health 
Records 
1R43DA03
1489-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 322562 
INFLEXXI
ON, INC. 
320 NEEDHAM 
STREET, SUITE 
100 Newton 
Web-based Self-
Management of 
Chronic Pain in 
Parkinsons Disease 
1R43NS07
1731-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 177251 
INFLEXXI
ON, INC. 
320 NEEDHAM 
STREET, SUITE 
100 Newton 
Pain Assessment 
Interview and 
Clinical Advisory 
System 
2R44DA02
6359-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 1339877 
INFLEXXI
ON, INC. 
320 NEEDHAM 
STREET, SUITE 
100 Newton 
Staying Off 
Substances: A 
Tailored Early 
Recovery Program 
2R44DA02
6645-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 1584781 
INFLEXXI
ON, INC. 
320 NEEDHAM 
STREET, SUITE 
100 Newton 
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for Teens 
MyStudentBody-
Community 
College: A Health 
Website for 
Students 
2R44DA02
7190-02 
H
H
S HHS SBIR 
2
0
1
1 2 1370736 
INFLEXXI
ON, INC. 
320 NEEDHAM 
STREET, SUITE 
100 Newton 
Hydrogel Particle-
Based microRNA 
Profiling for 
Discovery and 
Cancer Diagnostics 
2R44CA14
1980-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 2000001 
ELUCIGE
L 
TECHNO
LOGIES 
1 KENDALL SQ 
BLG 1400W FL 3 Cambridge 
SBIR Phase I: 
Vibration-Based 
Cleaning for Ash 
Removal from 
Diesel Particulate 
Filters 1046952 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Filter 
Sensing 
Technol
ogies, 
Inc. Po Box 425197 Cambridge 
SBIR Phase I: Novel 
proteolysis-based 
tools for metabolic 
engineering of 
amino acid 
producing strains 1113506 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Ginkgo 
BioWork
s 7 Tide St Unit 2B Boston 
Interactive Sensor 
Technology to 
Measure 
Adherence to 
Prescribed 
Therapeutic Foot 
1R43DK09
3236-01 
H
H
S HHS SBIR 
2
0
1
1 1 395082 
Biosensi
cs, LLC 
101 
MONMOUTH ST, 
APT 504 Brookline 
Virus-Targeted 
Therapy for 
Malignancies 
1R43CA15
3474-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 288895 
PHOENI
CIA 
BIOSCIE
NCES, 
INC. 45 Beaver Rd Weston 
in vivo Studies of 
Clinical Stage 
Globin Modulators 
1R41HL11
0727-01 
H
H
S HHS STTR 
2
0
1
1 1 304344 
PHOENI
CIA 
BIOSCIE
NCES, 
INC. 45 Beaver Rd Weston 
Novel Diagnostic 
Sequencing System 
for HIV Resistance 
Testing 
2R44AI07
4232-
03A1 
H
H
S HHS SBIR 
2
0
1
1 2 2952955 
INTELLI
GENT 
BIO-
SYSTEM
S, INC. 34 Bear Hill Rd. Waltham 
SBIR Phase I: 
Classroom 
VideoAnalyst: 
Automated Video 
Content Analysis 
for Classroom 
Evaluations 1047232 
N
S
F NSF SBIR 
2
0
1
1 1 149883 
INTUVISI
ON 
10 
Tower 
Office 
Park 
ste 
200 Woburn 
Automated 
Molecular 
Diagnostics for 
Rapid Detection of 
Dengue Viremia 
Using Whole 
4R44AI08
5892-02 
H
H
S HHS SBIR 
2
0
1
1 2 1707133 
IQUUM, 
INC. 
700 Nickerson 
Rd Marlborough 
SBIR Phase II: 1058417 N NSF SBIR 2 2 499868 LUMAR 15 Ward Street Somerville 
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Nanometer-Level 
Fidelity in Maskless 
Lithography 
S
F 
0
1
1 
RAY LLC 
Validation of an In 
Vitro Human 
Airway Model 
2R44ES01
4312-02 
H
H
S HHS SBIR 
2
0
1
1 2 835982 
MATTEK 
CORPOR
ATION 200 HOMER AVE Ashland 
Validation of 
Human Vaginal 
Tissue Assay for 
Endocrine 
Disruptors 
2R44ES01
5641-02 
H
H
S HHS SBIR 
2
0
1
1 2 993515 
MATTEK 
CORPOR
ATION 200 HOMER AVE Ashland 
Human Corneal 
Model for Ocular 
Irritation Assay 
9R44ES02
0074-02 
H
H
S HHS SBIR 
2
0
1
1 2 924517 
MATTEK 
CORPOR
ATION 200 HOMER AVE Ashland 
Identification of 
Serologic 
Biomarkers in 
Sarcoidosis 
1R43AI09
2886-01 
H
H
S HHS SBIR 
2
0
1
1 1 301893 
MEDICA
L 
DISCOV
ERY 
PARTNE
RS, LLC 
715 ALBANY ST., 
ROOM L803 Boston 
A NOVEL BIS-
INDOLE 
COMPOUND 
AGAINST 
CATHETER 
COLONIZATION 
1R41AI09
6702-01 
H
H
S HHS STTR 
2
0
1
1 1 599998 
MICROB
IOTIX, 
INC 
ONE 
INNOVATION DR Worcester 
Type III Secretion 
Inhibitors for Anti-
Infective Therapy 
2R44AI06
8185-
03A1 
H
H
S HHS SBIR 
2
0
1
1 2 3000000 
MICROB
IOTIX, 
INC 
ONE 
INNOVATION DR Worcester 
Quinoline-based 
Inhibitors of 
BoNT/A LC 
1R43AI09
2964-01 
H
H
S HHS SBIR 
2
0
1
1 1 599718 
MICROB
IOTIX, 
INC 
ONE 
INNOVATION DR Worcester 
SBIR Phase I: A 
Nanosensor-based 
device for rapid 
microbial 
detection in water 
samples 1046990 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Nanobio
sym, 
Inc. 
200 Boston Ave, 
Suite 4700 Medford 
A Rapid Point-of-
care Diagnostic for 
Neisseria 
gonorrhoeae STDs 
1R43AI09
6768-01 
H
H
S HHS SBIR 
2
0
1
1 1 600000 
Network 
Biosyste
ms, Inc. 
830 Winter 
Street Waltham 
SBIR Phase I: 
Synthetic 
respiration for 
improved bio-fuels 
production. 1046634 
N
S
F NSF SBIR 
2
0
1
1 1 148960 
NEW 
ENGLAN
D 
BIOLABS
, INC. 240 County Road Ipswich 
Isolation of 
functional IgGs in 
the cytoplasm of a 
novel E. coli 
expression host 
1R41AI09
2969-
01A1 
H
H
S HHS STTR 
2
0
1
1 1 213422 
NEW 
ENGLAN
D 
BIOLABS
, INC. 240 County Road Ipswich 
NOVEL ENZYME 
REAGENTS FOR 
4R44GM0
95209-02 
H
H HHS SBIR 
2
0 2 903660 
NEW 
ENGLAN 240 County Road Ipswich 
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EPIGENETICS 
STUDIES. 
S 1
1 
D 
BIOLABS
, INC. 
Improving 
Pediatric 
Developmental 
Screening and 
Communications: 
A CME 
1R43HD0
63173-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 138891 
NEW 
ENGLAN
D 
RESEAR
CH 
INSTITU
TES, 
INC. 9 GALEN ST Watertown 
Benzodiazepine 
Analogs as Novel 
Treatments for 
Catatonia 
1R43MH0
95315-01 
H
H
S HHS SBIR 
2
0
1
1 1 686852 
ORGANI
X, INC. 240 SALEM ST Woburn 
Device for 
Automating 
Zebrafish 
Processing 
2R44GM0
90598-02 
H
H
S HHS SBIR 
2
0
1
1 2 833379 
PHYLON
IX 
PHARM
ACEUTIC
ALS, 
INC. 
100 INMAN ST, 
STE 300 Cambridge 
Advanced Laser 
Source for High-
speed Adaptive 
Optics OCT 
1R43EY02
1396-01 
H
H
S HHS SBIR 
2
0
1
1 1 215122 
Physical 
Sciences 
Inc. 
20 New England 
Business Center Andover 
Compact Hydrogen 
Peroxide Sensor 
for Sterilization 
Cycle Monitoring 
1R44EB01
3517-01 
H
H
S HHS SBIR 
2
0
1
1 1 196723 
Physical 
Sciences 
Inc. 
20 New England 
Business Center Andover 
SBIR Phase II: 
Novel Polymeric 
Membrane for 
Hydrocarbon 
Separation 1048608 
N
S
F NSF SBIR 
2
0
1
1 2 409578 
Porogen 
Corpora
tion 6C Gill Street Woburn 
Emergency 
Operations Plans 
for Individuals with 
Disabilities 
1R41HD0
69070-
01A1 
H
H
S HHS STTR 
2
0
1
1 1 260855 
PRAXIS, 
INC. 13 WEST STREET Belmont 
Developmental 
Disabilities 
Dentistry Online 
1R42DE02
0979-
01A1 
H
H
S HHS STTR 
2
0
1
1 1 1192970 
PRAXIS, 
INC. 13 WEST STREET Belmont 
Risk Management 
in Developmental 
Disabilites 
4R42HD0
63179-02 
H
H
S HHS STTR 
2
0
1
1 2 1304624 
PRAXIS, 
INC. 13 WEST STREET Belmont 
Methods and 
Instrumentation 
for Hydrostatic 
Pressure-Enhanced 
Tissue Fixation 
1R43GM0
90582-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 160978 
PRESSU
RE 
BIOSCIE
NCE, 
INC. 14 Norfolk Ave South easton 
SBIR Phase I: 
Engineered Ligands 
for Enhanced 
Stability of 
Colloidal Quantum 
Dots in Lighting 
and Display 1047180 
N
S
F NSF SBIR 
2
0
1
1 1 149823 
QD 
VISION, 
INC. 
29 Hartwell 
Avenue Lexington 
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Applications 
Fully Compensated 
Dynamic Shim 
System for In Vivo 
MRI and MRS 
9R42RR03
1457-02 
H
H
S HHS STTR 
2
0
1
1 2 748196 
RESONA
NCE 
RESEAR
CH, INC. 5 FORTUNE DR Billerica 
TAS::75 0849::TAS 
N43CO11
0062 
H
H
S HHS SBIR 
2
0
1
1 1 199391 
RESONA
NCE 
RESEAR
CH, INC. 5 FORTUNE DR Billerica 
SBIR Phase II: Chip-
Scale 
Micromechanical 
Gyroscope for 
Angular Roation 
Detection, Stability 
and Control 1058078 
N
S
F NSF SBIR 
2
0
1
1 2 499625 
Sand 9, 
Inc. 
One 
Kendall 
Square 
Suite 
B230
5 Cambridge 
SOFTWARE FOR 
AUDITORY 
PROSTHESIS 
RESEARCH 
2R44DC01
0524-02 
H
H
S HHS SBIR 
2
0
1
1 2 1149472 
SENSIM
ETRICS 
CORP. 
14 SUMMER 
STREET Malden 
Plasma 
synthesized doped 
boron nanopowder 
for magnesium 
diboride 
superconductors 
2R44EB00
7139-02 
H
H
S HHS SBIR 
2
0
1
1 2 1030516 
Specialt
y 
Material
s, Inc. 
1449 
MIDDLESEX 
STREET Lowell 
ACES: A Product to 
Suppress or 
Enhance Critical 
Components in 
Acoustic Signals 
1R43DC01
1475-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 298678 
SPEECH 
TECHNO
LOGY/A
PPLIED 
RESEAR
CH 
CORP. 
  
Bedford 
Nano-Crystalline 
Ceramic Coatings 
for the Reduction 
of Sliding 
Resistance of Orth 
1R43DE02
2218-01 
H
H
S HHS SBIR 
2
0
1
1 1 114173 
Spire 
Corpora
tion 
One Patriots 
Park Bedford 
High Resolution 
Neuro-MRI 
9R44MH0
97272-02 
H
H
S HHS SBIR 
2
0
1
1 2 829759 
STERN 
MAGNE
TICS, 
LLC. 5 Fortune Drive Billerica 
SBIR Phase II: A 
Multithreaded 
Storage Engine 
using Highly-
Concurrent Fractal 
Trees 1058565 
N
S
F NSF SBIR 
2
0
1
1 2 500000 
Tokutek, 
Inc. 
1 Militia Drive, 
Suite 11 Lexington 
A point-of-care 
device for 
generating nitric 
oxide for 
inhalation 
1R43AI09
1160-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 152430 
WHALE
N 
BIOMED
ICAL, 
INC 11 MILLER ST Somerville 
Artificial Lung 
Based on a Novel 
Microfluidic 
Technology 
2R44HL09
1593-
02A1 
H
H
S HHS SBIR 
2
0
1
1 2 1519727 
Infoscite
x 
Corpora
tion 
303 Bear Hill 
Road Waltham 
Microfabricated 2R44NS05 H HHS SBIR 2 2 3003413 Infoscite 303 Bear Hill Waltham 
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Implantable 
Flowmeter for CSF 
Shunts Phase II 
6628-
02A1 
H
S 
0
1
1 
x 
Corpora
tion 
Road 
Wearable Device 
for Continuous 
Hemodialysis 
2R42DK07
2646-
02A1 
H
H
S HHS STTR 
2
0
1
1 2 1949759 
Infoscite
x 
Corpora
tion 
303 Bear Hill 
Road Waltham 
Novel 
serotonergic, pro-
cognitive 
antipsychotic 
therapies 
1R43MH0
92962-01 
H
H
S HHS SBIR 
2
0
1
1 1 699792 
Galenea 
Corpora
tion 
300 Technology 
Square Cambridge 
In vitro tools for 
preclinical analysis 
of cognitive 
therapies for 
schizophrenia 
1R43MH0
93029-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 628877 
Galenea 
Corpora
tion 
300 Technology 
Square Cambridge 
SBIR Phase I: A 
low-cost real-time 
bio-
electrochemical 
nitrate sensor for 
surface water 
monitoring 1046608 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Cambria
n 
Innovati
on, Inc. 
27 
Drydock 
Ave. 
2nd 
Floor Boston 
SBIR Phase I: High 
Efficiency Thin Film 
Photovoltaics 1045862 
N
S
F NSF SBIR 
2
0
1
1 1 146045 
Realtim
e Dx, 
Inc. 
106 North 
Hancock Street Lexington 
SBIR Phase I: 
Compliant 
Nonlinear Quasi-
Passive Orthotic 
Joint 1046005 
N
S
F NSF SBIR 
2
0
1
1 1 147000 
Adicep 
Technol
ogies 
26 Sweeny Ridge 
Road Bedford 
SBIR Phase I: 
Intraoperative 
detection and 
ablation of 
microscopic 
residual cancer in 
the tumor bed 1046761 
N
S
F NSF SBIR 
2
0
1
1 1 147505 
Lumicell 
Diagnos
tics, Inc 
1000 WINTER ST 
STE3800 Waltham 
Engineered 
imaging 
nanoparticle for 
realtime detection 
of cancer in the 
tumor bed 
1U43CA16
5024-01 
H
H
S HHS SBIR 
2
0
1
1 1 212752 
Lumicell 
Diagnos
tics, Inc 
1000 WINTER ST 
STE3800 Waltham 
TAS::75 0849::TAS 
SBIR TOPIC 307 
PHASE I NOVEL 
IMAGING AGENTS 
TO EXPAND THE 
CLINICAL TOOLKIT 
FOR CANCER 
DIAGNOSIS, 
STAGING, AND 
TREATMENT 
N43CO11
0122 
H
H
S HHS SBIR 
2
0
1
1 1 248461 
Lumicell 
Diagnos
tics, Inc 
1000 WINTER ST 
STE3800 Waltham 
SBIR Phase I: 
Cloud-Enabled 1047053 
N
S NSF SBIR 
2
0 1 150000 
Affectiv
a 
411 
Waverle
Build
ing 3, Waltham 
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Analysis Of Facial 
Affect 
F 1
1 
y Oaks 
Rd. 
Suite 
329 
SBIR Phase I: 
Computer-Aided 
Mosaic Design and 
Construction 1047077 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Artaic 
LLC 
21 Drydock 
Avenue Boston 
SBIR Phase I: High-
Throughput Agile 
Robotic 
Manufacturing 
System for Tile 
Mosaics 1113606 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Artaic 
LLC 
21 Drydock 
Avenue Boston 
SBIR Phase I: 
Environmental 
Biofilm 
Decontamination 
and Enhanced 
Energy Efficiency 
with Engineered 
Phage 1113071 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Novoph
age 
783 Cambridge 
Street Cambridge 
SBIR Phase I: 
Epitaxially Grown 
GaSb Thin Films on 
GaAs Substrates 
For Near-Field 
Conversion of Heat 
to Electricity 1113125 
N
S
F NSF SBIR 
2
0
1
1 1 149848 MTPV 
8 Saint 
Mary's 
Street 
Roo
m 
609 Boston 
SBIR Phase I: 
Spray-Formed Soft 
Magnetic Material 
for Efficient 
Hybrid-Field 
Electric Machines 1113202 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
Persim
mon 
Technol
ogies 
300 Bridge 
Street 
South 
hamilton 
SBIR Phase I: 
Improved Cold 
Thermal Energy 
Storage for 
Refrigeration 
Applications 1113206 
N
S
F NSF SBIR 
2
0
1
1 1 147539 
Prometh
ean 222 Third St Cambridge 
SBIR Phase I: 
Realizing 
Broadband 
Frequency Sound 
Absorption in 
Micro-Slit Panels 1113541 
N
S
F NSF SBIR 
2
0
1
1 1 150000 
America
n 
Acoustic
al Prod 
311 
Hoppingbrook 
Road Holliston 
Prevention of 
Retinopathy of 
Prematurity with a 
Novel Bifunctional 
Redox Reagent 
1R43EY02
1379-01 
H
H
S HHS SBIR 
2
0
1
1 1 220613 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Bifunctional 
Modulation of 
Redox Imbalance 
for Treatment of 
Septic Shock 
1R43GM0
96475-01 
H
H
S HHS SBIR 
2
0
1
1 1 243702 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Novel Means to 
Establish Free 
Radical Balance in 
1R43HL10
6810-
01A1 
H
H
S HHS SBIR 
2
0
1 1 231328 
RADIKAL 
THERAP
EUTICS, 8 SOLVIVA RD West tisbury 
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the Neonatal 
Premature Lung 
1 INC. 
Vasodilating 
Nitroxide for 
Therapy of Limb 
Ischemia-Perfusion 
Injury 
1R43HL10
8370-01 
H
H
S HHS SBIR 
2
0
1
1 1 225163 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Bifunctional Redox 
Agent for the 
Treatment of 
PPHN 
1R43HL11
0374-01 
H
H
S HHS SBIR 
2
0
1
1 1 237906 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Tr1-Specific 
Tolerance: a Novel 
Treatment of 
Multiple Sclerosis 
1R43NS07
6002-01 
H
H
S HHS SBIR 
2
0
1
1 1 625465 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Repolarization of 
Activated Th1 
Cells: a Novel 
Means to Treat IBD 
1R43AI09
2832-01 
H
H
S HHS SBIR 
2
0
1
1 1 263034 
RADIKAL 
THERAP
EUTICS, 
INC. 8 SOLVIVA RD West tisbury 
Crystalline 
Endolysin 
Treatment for 
Tuberculosis in 
TB/HIV co-infected 
patients 
1R43AI09
5120-01 
H
H
S HHS SBIR 
2
0
1
1 1 541150 
PROCRY
STA 
BIOLOGI
X, INC. 
12 MICHIGAN 
DR Natick 
Dendritic Cell-
Targeted HIV 
Vaccine Product 
1R43AI09
5159-01 
H
H
S HHS SBIR 
2
0
1
1 1 297572 
CELLDEX 
THERAP
EUTICS, 
INC. 119 4th Avenue Needham 
Development of 
Tissue Scaffold of 
High Strength and 
Porosity 
1R43AR06
0591-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 138591 
BIO2 
TECHNO
LOGIES, 
INC. 12R CABOT RD Woburn 
Amelioration of 
Claustrophobia 
and Disruptive 
Patient Motion in 
MR Imaging 
1R43AT00
6296-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 640032 
HYPNAL
GESICS, 
LLC 157 IVY ST Brookline 
MMP Inhibitor For 
Orofacial Pain 
1R43DE02
2207-01 
H
H
S HHS SBIR 
2
0
1
1 1 250000 
AQUILU
S 
PHARM
ACEUTIC
ALS, 
INC. 
225 MYSTIC 
VALLEY PKWY Winchester 
Development of a 
discovery platform 
based on 
microfluidics and 
fluorescent cell f 
1R43DK09
2122-01 
H
H
S HHS SBIR 
2
0
1
1 1 695816 
NIVART
A, INC. 
139 
WOODPECKER 
RD Stoughton 
High Resolution 
Scanning 
Magnetometry 
1R43EB01
3958-01 
H
H
S HHS SBIR 
2
0
1
1 1 150043 
MOMEN
T 
TECHNO
LOGIES, 
LLC 120 Second Ave Boston 
Robotic System for 
Minimally Invasive 
Neurosurgical 
Endoscopic 
1R43EB01
4063-01 
H
H
S HHS SBIR 
2
0
1
1 1 99730 
STERLIN
G POINT 
RESEAR
CH, LLC 53 Oxford Street Winchester 
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Procedures 
Develop and Test 
an Online 
Biohazard 
Simulator to Train 
Skilled Support 
Personnel 
1R43ES02
0140-01 
H
H
S HHS SBIR 
2
0
1
1 1 98719 
GRYPHO
N 
SCIENTI
FIC, LLC 973 Hale Street Beverly 
Vision-QOL-CAT: A 
Functional Health 
CAT for those with 
Visual Disorders 
1R43EY02
1390-01 
H
H
S HHS SBIR 
2
0
1
1 1 98632 
JOHN 
WARE 
RESEAR
CH 
GROUP, 
INC. 
1 INNOVATION 
DR, STE 400 Worcester 
Long-Acting 
Mucus-Penetrating 
Steroid Particles 
for Treatment of 
Eye Inflammation 
1R43EY02
1705-01 
H
H
S HHS SBIR 
2
0
1
1 1 255595 
KALA 
PHARM
ACEUTIC
ALS, 
INC. 
135 Beaver 
Street Waltham 
Mucus-Penetrating 
Antibiotics for 
Lung Infections 
Associated with 
Cystic Fibrosis 
1R43HL10
6899-01 
H
H
S HHS SBIR 
2
0
1
1 1 180415 
KALA 
PHARM
ACEUTIC
ALS, 
INC. 
135 Beaver 
Street Waltham 
Development of an 
Instrument to 
Determine Protein 
Stability at any 
Desired Temper 
1R43GM0
96751-01 
H
H
S HHS SBIR 
2
0
1
1 1 134793 
AVIA 
BIOSYST
EMS, 
LLC 
775 
EAST 
FALMO
UTH 
HIGHW
AY 
SUIT
E 193 
East 
falmouth 
Development and 
Commercial 
Optimization of 
Circular DNA 
Conversion for 
Opti-pore 
1R43HG0
06212-01 
H
H
S HHS SBIR 
2
0
1
1 1 181725 
NOBLEG
EN 
BIOSCIE
NCES, 
INC. 58 ELSINORE ST Concord 
Steerable Oxygen 
Sensing Catheter 
for Cardiac 
Resynchronization 
Therapy (CRT) Pro 
1R43HL10
2983-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 188628 
OXUS 
MEDICA
L, INC. 19 RADMORE ST Worcester 
12-lead MRI-
Compatible ECG 
for physiological 
monitoring and 
scanner 
synchronizati 
1R43HL11
0427-01 
H
H
S HHS SBIR 
2
0
1
1 1 191624 
E-
TROLZ, 
INC 
1600 OSGOOD 
ST, STE 2-17 
North 
andover 
Intramural drug 
infusion balloon 
for preventing 
vascular restenosis 
1R43HL11
0530-01 
H
H
S HHS SBIR 
2
0
1
1 1 194164 
MEDI-
SOLVE 
COATIN
GS, LLC 14 TECH CIRCLE Natick 
Development of 
HeartLander as an 
epicardial injection 
delivery system 
1R43HL11
4022-01 
H
H
S HHS SBIR 
2
0
1
1 1 98519 
HEARTL
ANDER 
SURGIC
AL, INC. 
90 WILDWOOD 
DR Westwood 
Forced Exercise: A 
New Therapy for 
the Treatment of 
Parkinson's 
1R43NS06
7744-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 196238 
EXERCY
CLE  
COMPA
NY 
31 HAYWARD 
ST, STE B1 Franklin 
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Disease 
Continuous 
Countercurrent 
Tangential 
Chromatography 
1R43RR03
1935-
01A1 
H
H
S HHS SBIR 
2
0
1
1 1 183000 
CHROM
ATAN 
CORPOR
ATION 85 NEEDHAM ST Dedham 
High Throughput 
Manufacturing for 
Three-Dimensional 
Microfluidic 
Devices 
1R44EB01
2415-01 
H
H
S HHS SBIR 
2
0
1
1 1 67200 
FEMTOF
AB, INC. 
812 Memorial 
Dr. #1908 Cambridge 
A FAP-Activated 
Proteasome 
Inhibitor for Killing 
Solid Tumors 
1R41CA15
6930-
01A1 
H
H
S HHS STTR 
2
0
1
1 1 245638 
ARISAPH 
PHARM
ACEUTIC
ALS, 
INC. 
100 HIGH 
STREET Boston 
High-throughput 
portable software 
for fragment-
based drug design 
1R41GM0
97907-01 
H
H
S HHS STTR 
2
0
1
1 1 98055 
ACPHAR
IS, INC. 160 N MILL ST Holliston 
Noninvasive 
neonatal glucose 
monitor 
1R41HD0
69207-01 
H
H
S HHS STTR 
2
0
1
1 1 462835 
FLUORO
METRIX 
CORPOR
ATION 
24 TIMBER EDGE 
RD Stow 
TAS::75 0893::TAS 
RAPID LARGE 
SCALE 
PRODUCTION OF 
PROTEIN 
THERAPEUTICS 
N43DA11
0015 
H
H
S HHS SBIR 
2
0
1
1 1 150000 
ANTAGE
N 
PHARM
ACEUTIC
ALS, 
INC. 
650 ALBANY ST 
UNIT 112 Boston 
MA Total 
      
$83,008,312 
    Worcester Total 
      
$6,642,896 
    Biomedical 
Research Models 
and Microbiotix 
Inc. Total 
      
$4,782,911 
    Percentage of 
Worcester County 
Funds to 
Biomedical 
Research Models 
and Microbiotix 
Inc. Total 
      
72% 
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Appendix I: Business Formation 
 
  
NAICS 
61131 
Colleges 
and 
universitie
s (1.9%)
NAICS 
622 
Hospitals 
(4.5%)
NAICS 
541380 
Testing 
laboratori
es (30%)
NAICS 
334516 
Analytical 
laboratory 
instrumen
t mfg. 
(30%)
NAICS 
541712 
Other 
physical 
and 
biological 
research 
(22%)
NAICS 
541711 
Research 
and 
developm
ent in 
biotechnol
ogy
NAICS 
339115 
Ophthalmi
c goods 
manufact
uring
NAICS 
339113 
Surgical 
appliance 
and 
supplies 
manufact
uring
NAICS 
339112 
Surgical 
and 
medical 
instrumen
t 
manufact
uring
NAICS 
334517 
Irradiation 
apparatus 
manufact
uring
NAICS 
334510 
Electrome
dical 
apparatus 
manufact
uring
NAICS 
3254 
Pharmace
utical and 
medicine 
manufact
uring
TOTAL # 
ESTABLI
SHMENT
S
Year Annual Annual Annual Annual Annual Annual Annual Annual Annual Annual Annual Annual
2001 1 1 7 2 5 9 25
2002 1 1 8 2 6 5 9 32
2003 1 1 7 2 6 5 11 34
2004 1 1 8 2 4 4 6 1 6 9 43
2005 1 1 8 2 3 4 6 1 7 9 42
2006 1 1 8 2 3 4 5 1 7 8 39
2007 1 1 8 2 5 41 3 5 5 1 6 10 86
2008 1 1 7 2 6 40 3 5 5 1 6 11 87
2009 1 1 7 2 6 40 5 5 5 1 6 12 90
2010 1 1 6 2 6 40 5 5 6 1 7 11 91
2011 1 1 5 2 6 44 3 5 6 1 8 10 92
NAICS 
541712 
Other 
physical 
and 
biological 
research 
(22%)
NAICS 
541711 
Research 
and 
developm
ent in 
biotechnol
ogy
NAICS 
334516 
Analytical 
laboratory 
instrumen
t mfg. 
(30%)
NAICS 
622 
Hospitals 
(4.5%)
NAICS 
61131 
Colleges 
and 
universitie
s (1.9%)
NAICS 
3254 
Pharmace
utical and 
medicine 
manufact
uring
NAICS 
339115 
Ophthalmi
c goods 
manufact
uring
NAICS 
339113 
Surgical 
appliance 
and 
supplies 
manufact
uring
NAICS 
339112 
Surgical 
and 
medical 
instrumen
t 
manufact
uring
NAICS 
334510 
Electrome
dical 
apparatus 
manufact
uring
NAICS 
334517 
Irradiation 
apparatus 
manufact
uring
NAICS 
541380 
Testing 
laboratori
es (30%)
2007 102 580 25 10 3 95 13 63 85 42 17 8
2008 120 631 24 10 3 91 14 65 87 39 16 7
2009 132 649 23 9 3 87 17 61 83 42 16 7
2010 147 673 23 9 4 82 17 59 85 41 14 6
2011 165 686 24 9 4 78 14 59 82 45 15 5
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Appendix J: Biomanufacturing 
Number of biomanufacturing Companies located in Worcester County: 
 
1. Company Name  Address  Town/City, State, Zip 
Code  
Phone Number  
2. ABBOTT 
Bioresearch 
Center, Inc.  
100 Research Drive  Worcester, MA 01606  508-849-2500  
3. Abco Welding & 
Industrial 
Supply, Inc.  
31 Sword St  Auburn, MA 01501  508-791-9293  
4. ACMI 
Corporation  
136 Turnpike Road  Southborough, MA 
01772  
508-804-2600  
5. Advanced Cell 
Technology Inc  
One Innovation Drive  Worcester, MA 01605  508-756-1212  
6. Aearo Co.  90 Mechanic Street  Southbridge, MA 01550  508-764-5500  
7. Albright 
Technologies Inc  
25 Litchfield St  Leominster, MA 01453  978-466-5870  
8. Alpha Analytical 
Labs  
8 Walkup Drive  Westborough, MA 01581  508-898-9220  
9. Alpha-Beta 
Technology Inc 
(ABTI)  
One Innovation Drive  Worcester, MA 01605  508-798-6900  
10. Analox 
Instruments Usa 
Inc  
104 Sunset Ln  Lunenburg, MA 01462  978-582-9368  
11. Antigen Express 
Inc  
100 Barber Avenue  Worcester, MA 01606  508-852-8783  
12. AO SOLA  14 Mechanic Street  Southbridge, MA, 01550  508-764-5000  
13. Araios Inc.  One Innovation Drive  Worcester, MA 01605  617-413-3020  
14. Arrhythmia 
Research 
Technology Inc.  
25 Sawyer Passway  Fitchburg, MA 01420  978-345-5000  
15. Athena 
Diagnostics, Inc  
377 Plantation Street  Worcester, MA 01605  508-756-2886  
16. Ats Laboratories Inc  
17. Attogen Inc.  100 Barber Ave  Worcester, MA 01606  
18. Auralgesic 
Company, Inc.  
16 Johnson Way  Rutland, MA 01543  508-886-6749  
19. Avecia 
Biotechnology, 
Inc.  
125 Fortune Ave  Milford, MA 01757  508-532-2500  
20. Averica 
Discovery 
Service Inc.  
One Innovation Drive, 
Biotech III  
Worcester, MA 01605  508-757-4600  
21. Averion 
International 
Corp  
225 Turnpike Road  Southborough, MA 
01772  
508-597-6000  
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22. Bioactives LLC  1 Dix Street  Worcester, MA 01609  617-489-0424  
23. BioDynamics, 
Inc.  
29 Prospect Street  West Boylston, MA 
01583  
508-835-6258  
24. Biohybrid 
Technologies  
910 Boston Turnpike 
Road  
Shrewsbury, MA 01545  508-842-4460  
25. Biomeasure, 
Incorporated  
27 Maple Street  Milford, MA 01757  508-478-0144  
26. Biomedical 
Polymers Inc  
42 Linus Allian Ave  Gardner, MA 01440  978-632-2555  
27. Biomedical 
Research 
Models, Inc  
10 New Bond Street  Worcester, MA 01606  508-852-0606  
28. BioPal, Inc.  80 Webster Street  Worcester, MA 01603  508-770-1190  
29. Biopartners Inc  10 Andy Rd  Worcester, MA 01602  508-755-4645  
30. BioReliance 
Biotech Inc.  
381 Plantation Street  Worcester, MA 01605  508-791-8000  
31. Biosource, Inc.  1200 Millbury Street 
Suite 7F  
Worcester, MA 01607  508-363-2367  
32. BioValve 
Technologies 
Inc.  
One Innovation Drive  Worcester, MA 01606  508-421-9500  
33. BioVest 
International, 
Inc.  
377 Plantation St, 
Biotech 4  
Worcester, MA 01605  508-793-0001  
34. Blue Sky 
Biotech, Inc.  
60 Prescott Street  Worcester, MA 01605  508-831-1295  
35. Boston Medical 
Products, Inc.  
117 Flanders Road  Westborough, MA 01581  508-898-9300  
36. Brendan 
Bioscience, LLC  
3A Business Way  Hopedale, MA 01747  508-473-8899  
37. Brochu Bio-Lab 
Services  
400 Thompson Road  Webster, MA 01570  508-943-9750  
38. BURLE Electro-
Optics, Inc.  
PO Box 1159, Sturbridge 
Bus. Park  
Sturbridge, MA 01566  508-347-4000  
39. Cellthera Inc.  431 High Street  Southbridge, MA 01550  508-765-0276  
40. Central Coating 
Co, Inc.  
165 Shrewsbury St  West Boylston, MA 
01583  
508-835-6225  
41. CereMedix, Inc.  One Innovation Drive  Worcester, MA 01605  508-459-5924  
42. Charles River  57 Union St  Worcester, MA 01608  508-890-0100  
43. Coley 
Pharmaceutical 
Group, Inc.  
93 Worcester St.  Wellesley, MA 02481  781-431-9000  
44. Consistent Cardiogram 
Corp  
25 Winthrop 
Street  
Worcester, MA 01604  
45. Cool Laser 
Optics  
57 E Main Street  Westborough, MA 01581  508-870-0066  
46. Crescent Innovations Inc  
47. Cryogenic 
Institute of New 
England  
90 Ellsworth St  Worcester, MA 01610  508-459-7447  
48. Cyberkinetics 100 Foxborough Blvd.  Foxborough, MA 02035  508-549-9981  
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Neurotechnolog
y  
49. Databased Inc  
50. Dosco Sheet 
Metal & mfg  
6 Grafton St  Millbury, MA 01527  508-865-9998  
51. Doss Plastics, 
Inc.  
94 Ashland Ave.  Southbridge, MA 01550  508-764-3211  
52. Eac  
53. East Acres 
Farms Inc.  
236 Blackmer Rd.  Southbridge, MA 01550  508-765-0535  
54. Eastwest 
Pharmaceutical 
International  
33 Hemingway St  Shrewsbury, MA 01545  508-791-8544  
55. ECI Biotech, Inc  85 Prescott Street  Worcester, MA 01605  508-752-2209  
56. Eden Research plc  
57. Emuge 
Corporation  
1800 Century Dr  West Boylston, MA 
01583  
508-595-3619  
58. Entegrion Inc.  
59. EpigenDX  15 Harris Ln  Ashland, MA 01721  508-881-6810  
60. Filtrona 
Extrusion Inc  
170 Bartlett St  Northborough, MA 
01532  
508-393-2553  
61. Fisher Scientific  8 Forge Pkwy  Franklin, MA 02038  508-553-5000  
62. Funnel 
Insruments LLC  
79 Hecla St  Uxbridge, MA 01569  508-278-0800  
63. Gene-IT  25 Winthrop Street  Worcester, MA 01604  508-754-7300  
64. Genetex Optics 
Inc  
183 West Main  Dudly, MA 01571  508-943-3860  
65. Genzyme 
Genetics  
3400 Computer Drive  Westborough, MA 01581  508-898-9001  
66. GLSynthesis, Inc  One Innovation Drive  Worcester, MA 01605  508-845-9484  
67. GlucaDel Consulting  
68. GlycoSolutions, 
Corp.  
25 Winthrop Street  Worcester, MA 01604  508-756-6418  
69. Gyrus Acmi  136 Turnpike Road  Southborough, MA 
01772  
508-8042600  
70. Hematech  377 Plantation St.  Worcester, MA 01605  508-792-0682  
71. Hightech 
Precision 
Moulders LLC  
30 Patriots Circle  Leominster, MA 01453  978-534-5000  
72. Hypnion Inc  381 Plantation Street  Worcester, MA 01605  508-438-2800  
73. Hypromatrix, 
Inc.  
100 Barber Ave  Worcester, MA 01606  508-856-7900  
74. Imaging 
Diagnostics, Inc.  
98 Pratts Junction Rd  Sterling, MA 01564  978-422-8601  
75. Imaging 
Diagnostics, Inc.  
99 Pratts Junction Rd  Sterling, MA 01565  978-422-8602  
76. Indigene 
Pharmaceuticals
, Inc.  
115 Flanders Rd.  Westborough, MA 01581  508-389-1701  
77. Infonetics Corp.  2 Flint Meadow Ln.  Shrewsbury, MA 01345  508-845-9824  
78. Informatics & Computing Resources Center  
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79. Infussafe  13 Massachusetts Ave  Harvard, MA 01451  978-805-3183  
80. Innovend  30 Patriots Cir  Leominster, MA 01453  978-534-5000  
81. Insight 
Neuroimaging 
Systems, LLC  
111 Canterbury St  Worcester, MA 01610  508-799-6464  
82. Integrated 
Pharmaceuticals 
Inc  
310 Authority Dr  Fitchburg, MA 01420  978-696-0020  
83. JR Medical 
Technology  
123 Briar Wood Ave  Southbridge, MA 01550  508-764-2121  
84. Kinefac Corp  156 Goddard Memorial 
Drive  
Worcester, MA 01603  508-754-6891  
85. Laser 
Therapeutics Inc  
101 Waterside Dr  Centerville, MA 02632  508-790-9300  
86. Latham 
Laboratories Inc  
Worcester Biotechnology 
Park  
Worcester, MA 01605  
87. Lex Company  178 Lincoln Street  Worcester, MA 01605  
88. LINOS 
Photonics, Inc.  
459 Fortune Blvd.  Milford, MA 01757  508-478-6200  
89. Liporx 
Pharmaceutical
s Inc  
One Innovation Drive  Worcester, MA 01605  
90. Luxtec 
Corporation  
326 Clark St.  Worcester, MA 01606  508-856-9454  
91. Mar-lee 
Companies  
190 Authority Dr  Fitchburg, MA 01420  978-343-9600  
92. Mar-lee 
Companies, Inc  
180 Authority Dr  Fitchburg, MA 01420  978-348-1291  
93. Mass 
Biotechnology 
Research Park  
One Innovation Drive  Worcester, MA 01605  508-755-2230  
94. Mass Histology 
Service  
31 Huron Ave  Worcester, MA 01605  508-853-9363  
95. Massachusetts 
Biomedical 
Initiatives  
60 Prescott Street  Worcester, MA 01605  508-797-4200  
96. Mass Micro 
Laboratories, 
Inc.  
25 Winthrop Street  Worcester, MA 01604  508-752-0858  
97. Medcon Biolab 
Technologies  
50 Brigham Hill Rd  Grafton, MA 01519  508-839-4203  
98. Medical 
Equipment 
Specialists Inc  
14 Lake Ave  Worcester, MA 01604  508-757-3390  
99. Microbiotix Inc  One Innovation Drive  Worcester, MA 01605  508-757-2800  
100. Micron Products 
Inc  
25 Sawyer Passway  Fitchburg, MA 01420  978-345-5000  
101. Miniature Tool 
& Die, Inc.  
15 Trolley Crossing Rd  Charlton, MA 01507  508-248-0111  
102. Mossman 
Associates Inc  
9 Village Cir  Milford, MA 01757  508-488-6169  
103. Mtm 134 Flanders Rd Ste 325  Westborough, MA 01581  508-366-8334  
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Laboratories Inc  
104. Netoptix Corp  PO Box 550, Sturbridge 
Buisness Park  
Sturbridge, MA 01566  508-347-9191  
105. New England 
Peptide Inc  
65 Zub Lane  Gardner, MA 01440  888-343-5974  
106. New World 
Laboratories  
25 Winthrop Street  Worcester, MA 01604  
107. News Technical 
Gases  
31 Sword Street  Auburn, MA 01501  508-791-9293  
108. NOVAGENESIS  One Innovation Drive, 
Biotech III  
Worcester, MA 01605  508-797-6682  
109. NP Medical, Inc.  101 Union Street  Clinton, MA 01510  978-365-2500  
110. NuGenesis 
Technologies 
Corporation  
1900 West Park Drive  Westborough, MA 01581  508-616-9876  
111. Oliver M Dean 
Inc  
125 Brooks St  Worcester, MA 01606  508-856-9100  
112. Omega 
PharmServices, 
Inc.  
113 Cedar St. Suite S-6  Milford, MA 01757  508-482-9330  
113. OPCO 
Laboratory Inc  
704 River Street  Fitchburg, MA 01420  978-345-2522  
114. OPTIM, Inc.  64 Technology Park Road  Sturbridge, MA 01566  800-225-7486  
115. Optimum 
Technologies, 
Inc.  
68 West Street  Southbridge, MA 01550  508-765-8100  
116. Pgm Plastics Inc  774 Crawford St  Fitchburg, MA 01420  978-342-6767  
117. Pharm Development Consulting  
118. Physical 
Research  
451 Worcester Road; 
Route 20  
Charlton, MA 01507  508-865-9103  
119. Phytera Inc  377 Plantation Street  Worcester, MA 01605  508 792-6800  
120. Plant 
Pharmaceutical
s Inc  
One Innovation Drive  Worcester, MA 01605  
121. PolyCarbon 
Industries, Inc.  
435 Lancaster Street  Leominster, MA 01453  978-772-2111  
122. PolyOrg, Inc.  10 Powers Street  Leominster, MA 01453  978-466-7978  
123. Precision Optics 
Corporation  
22 E Broadway  Gardner, MA 01440  978-630-1800  
124. ProFoldin  
125. Pyrosequencing 
Inc  
2200 West Park Drive, 
Suite 320  
Westborough, MA 01581  508-389-9911  
126. Q-One 
Biotechnologies, 
Ltd.  
381 Plantation Street  Worcester, MA 01604  508-791-8000  
127. Radius Product 
Development  
200 Union St  Clinton, MA 01510  978-368-3200  
128. REM Inc  
129. RenalPlant 
Corporation  
5 Leonard Drive  Southborough, MA 
01722  
508-624-0150  
130. RES-TECH 22 Marshall Street  Clinton, MA 01510  978-368-0146  
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Corporation  
131. Rocheleau Tool 
& Die Co Inc  
117 Industrial Rd  Fitchburg, MA 01420  978-345-1723  
132. RXi 
Pharmaceuticals 
Corporation  
1 Innovation Drive  Worcester, MA 01605  508-767-3861  
133. Saint-Gobain 
Abrasives Inc.  
1 New Bond St.  Worcester, MA 01606  508-795-5000  
134. Schott Fiber 
Optics, Inc  
122 Charlton Street  Southbridge, MA 01550  800-343-6120  
135. Seatech 
Bioproducts 
Corp  
159 Memorial Drive; Unit 
C  
Shrewsbury, MA 01545  508-842-9292  
136. Select 
Engineering Inc  
260 Lunenburg St  Fitchburg, MA 01420  978-345-4400  
137. SelectX 
Pharmaceuticals
, Inc.  
One Innovation Drive, 
Biotech III  
Worcester, MA 01605  508-798-0216  
138. SeraCare 
Diagnostics  
25 Birch Street  Milford, MA 01757  508-478-5510  
139. Shire Biologics 
Inc  
30 Bearfoot Road  Northborough, MA 
01532  
508-351-9944  
140. SquiCor Labs 
Inc.  
80 Optical Drive  Southbridge, MA 01550  360-450-4140  
141. Steelcraft  115 W. Main Street  Millbury, MA 01463  508-865-4445  
142. Steris-Isomedix 
Services  
435 Whitney Street  Northborough, MA 
01532  
508-393-9323  
143. Stethographics 
Inc  
21 Wayside Rd  Westborough, MA 01581  508-320-2841  
144. Targeted Cell 
Therapies  
60 Prescott Street  Worcester, MA 01605  508-517-8400  
145. Techman 
International 
Corp  
16B Sturbridge Road  Charlton, MA 01507  508-248-2900  
146. Technical 
Innovation 
Center, Inc.  
100 Barber Avenue  Worcester, MA 01606  508-799-6700  
147. T M Electronics  45 Main Street  Boylston, MA 01505  508-856-0500  
148. TranXenoGen, 
Inc.  
800 Boston Turnpike  Shrewsbury, MA 01545  508-936-4200  
149. Valeritas, LLC  800 Boston Turnpike 
(Route 9)  
Shrewsbury, MA 01545  508-845-1177  
150. Valmed, Inc.  221 Spring Street  Shrewsbury, MA 01545  508-845-3438  
151. Vascular 
Sciences  
44 Edward Drive  North Grafton, MA 
01536  
508-887-9486  
152. Verax 
Biomedical 
Incorporated  
377 Plantation St, 
Biotech 4  
Worcester, MA 01605  508-755-7029  
153. Viking Systems  134 Flanders Rd  Westborough, MA 01581  508-366-8882  
154. Vista Medical 
Technologies  
134 Flanders Road  Westborough, MA 01581  508-366-3668  
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155. VivaScan Corp.  560 Prospect St  West Boylston, MA 
01583  
508-852-1600  
156. Water 
Corporation  
34 Maple Street  Milford, MA 01757  508-478-2000  
157. Welgen, Inc.  25 Winthrop Street  Worcester, MA 01604  888-493-5436  
158. WesaGen Inc  
159. Zoaan 
Diagnostics, Inc.  
159 Memorial Drive; Unit 
C  
Shrewsbury, MA 01545  508-842-9020  
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Appendix K: Federal funding for academic, non-profit, commercial and health 
NIH Funding for Companies and Institution in Worcester County 
Companies/ 
Institutions 2007 2008 2009 2010 2011 2012 
Total for each 
company/insti
tution 
ADVANCED 
CELL 
TECHNOLOGY 
 
$199,532 
    
199532 
ASSUMPTION 
COLLEGE 
    
$187,709 
 
187709 
BIOMEDICAL 
RESEARCH 
MODELS, INC. 
$287,296 $767,501 $891,829 
$1,202,18
0 
$1,498,494 $754,629 
$5,401,929 
BIOPAL, INC 
$795,036 $749,792 
 
$487,625 $358,316 $629,423 
$3,020,192 
CLARK 
UNIVERSITY 
(WORCESTER, 
MA) 
$1,007,56
7 
$631,164 $690,953 $698,147 $755,791 $627,299 
$4,410,921 
COLLEGE OF 
THE HOLY 
CROSS 
$304,261 $359,114 
  
$341,672 
 
$1,005,047 
ECI BIOTECH 
$358,311 $787,863 $511,472 
  
$298,291 
$1,955,937 
GLSYNTHESIS, 
INC. 
$3,126,53
0 
$2,335,24
5 
$2,167,087 
$1,699,71
0 
$935,484 
$1,715,5
14 
$11,979,570 
GROVE 
INSTRUMENT
S, LLC 
$100,000 $953,153 $1,189,186 
$1,106,74
9 
$631,627 $450,297 
$4,431,012 
INSIGHT 
NEUROIMAGI
NG SYSTEMS, 
INC. 
$99,510 
     
$99,510 
JEFFREY D. 
MANCEVICE, 
INC. 
$8,870 
     
$8,870 
JOHN WARE 
RESEARCH 
GROUP, INC. 
   
$1,381,85
2 
$869,521 
 
$2,251,373 
MICROBIOTIX
, INC 
$4,792,92
0 
$6,063,20
9 
$6,493,444 
$5,469,57
8 
$4,054,356 
$8,080,9
24 
$34,954,431 
OXUS 
MEDICAL, 
INC. 
 
   
$188,628 
 
$188,628 
RXI 
PHARMACEU  
  
$298,544 $876,927 $292,272 
$1,467,743 
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TICALS 
CORPORATIO
N 
SIGNABLOK, 
INC. 
     
$443,567 
$443,567 
UNIV OF 
MASSACHUS
ETTS MED 
SCH 
WORCESTER 
$118,856,
210 
$122,800,39
1 
135,430,351 
$153,380,89
3 
$153,534,616 
$134,169
,972 
$818,172,433 
VERAX 
BIOMEDICAL, 
INC. 
$713,042 
     
$713,042 
WORCESTER 
POLYTECHNIC 
INSTITUTE 
$672,885 $463,678 $1,551,124 
$1,581,26
5 
$621,287 $335,971 
$5,226,210 
WORCESTER 
STATE 
COLLEGE 
   
$206,302 
  
$206,302 
Total 131122438 
$136,110,64
2 148925446 167512845 164854428 147798159 896323958 
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Appendix L: Capital and Human Resources 
 
  
NSF Survey of Science and Engineering Research Facilities - Worcester County
Total Net Assignable Square Feet 
2003 University of Massachusetts Worcester Biological Sciences 297449
2003 University of Massachusetts Worcester Computer Sciences 0
2003 University of Massachusetts Worcester Engineering (FY 2003,2005) 0
2003 University of Massachusetts Worcester Mathematical Sciences 0
2003 University of Massachusetts Worcester Medical Sciences 279839
2003 University of Massachusetts Worcester Physical Sciences 0
2003 University of Massachusetts Worcester Other Science and Engineering Fields 0
2003 Worcester Polytechnic Institute Biological Sciences 11534
2003 Worcester Polytechnic Institute Computer Sciences 5631
2003 Worcester Polytechnic Institute Engineering (FY 2003,2005) 68211
2003 Worcester Polytechnic Institute Mathematical Sciences 2224
2003 Worcester Polytechnic Institute Medical Sciences 0
2003 Worcester Polytechnic Institute Physical Sciences 18105
2003 Worcester Polytechnic Institute Other Science and Engineering Fields 0
2005 Clark University Biological Sciences 30000
2005 Clark University Computer Sciences 10000
2005 Clark University Earth, Atmospheric, and Ocean Sciences 0
2005 Clark University Engineering (FY 2003,2005) 0
2005 Clark University Mathematical Sciences 10000
2005 Clark University Medical Sciences 0
2005 Clark University Physical Sciences 30000
2005 Clark University Other Science and Engineering Fields 0
2005 University of Massachusetts Worcester Biological Sciences 222301
2005 University of Massachusetts Worcester Computer Sciences 0
2005 University of Massachusetts Worcester Engineering (FY 2003,2005) 0
2005 University of Massachusetts Worcester Mathematical Sciences 0
2005 University of Massachusetts Worcester Medical Sciences 145516
2005 University of Massachusetts Worcester Physical Sciences 0
2005 University of Massachusetts Worcester Other Science and Engineering Fields 0
2005 Worcester Polytechnic Institute Biological Sciences 13422
2005 Worcester Polytechnic Institute Computer Sciences 399
2005 Worcester Polytechnic Institute Engineering (FY 2003,2005) 46514
2005 Worcester Polytechnic Institute Mathematical Sciences 0
2005 Worcester Polytechnic Institute Medical Sciences 0
2005 Worcester Polytechnic Institute Physical Sciences 16332
2005 Worcester Polytechnic Institute Other Science and Engineering Fields 0
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Market Snapshot of Lab Space in Boston, Cambridge, and the Suburbs (including Worcester) – 
Q3 2012 Statistics 
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Appendix M: Workforce Education Level 
 
  
2000 Educational Attainment of Employed in 
Central Massachusetts
Less than 
High School High School
Some 
College
Associate's 
Degree
Total Less 
than 
Bachelor's 
Degree
Total Less than 
Bachelor's 
Degree
Bachelor's 
Degree
Master's 
Degree or 
more
Bachelor'
s Degree 
or more
Bachelor's 
Degree or 
more
Architecture & Engineering 89                      708               1,195            749                     2,741               2,741                 2,367           1,226         3,593      3,593          
Life, Physical, & Social Sciences 36                      278               198               89                       601                   601                     933              1,420         2,353      2,353          
Computer & Mathematical 57                      277               1,128            443                     1,905               1,905                 2,733           1,197         3,930      3,930          
Healthcare Practitioners & Technical Services 158                   1,033           2,906            3,126                 7,223               7,223                 4,896           4,680         9,576      9,576          
Healthcare Support 955                   2,507           2,148            851                     6,461               6,461                 487              226            713          713             
Personal Care & Service 1,226                2,597           1,827            638                     6,288               6,288                 756              314            1,070      1,070          
Production 7,255                12,722         4,849            1,200                 26,026             26,026               1,202           283            1,485      1,485          
2008-2010 Educational Attainment of Employed 
in Central Massachusetts
Less than 
High School High School
Some 
College
Associate's 
Degree
Total Less 
than 
Bachelor's 
Degree
Total Less than 
Bachelor's 
Degree
Bachelor's 
Degree
Master's 
Degree or 
more
Bachelor'
s Degree 
or more
Bachelor's 
Degree or 
more
Architecture & Engineering 37                      595               739               638                     2,009               2,009                 2,885           981            3,866      3,866          
Life, Physical, & Social Sciences 21                      109               184               108                     422                   422                     1,131           2,307         3,438      3,438          
Computer & Mathematical -                    365               975               607                     1,947               1,947                 3,477           1,848         5,325      5,325          
Healthcare Practitioners & Technical Services 16                      1,276           2,461            4,128                 7,881               7,881                 6,505           5,928         12,433    12,433       
Healthcare Support 1,018                2,977           4,006            1,310                 9,311               9,311                 988              227            1,215      1,215          
Personal Care & Service 1,255                3,490           2,971            953                     8,669               8,669                 1,625           335            1,960      1,960          
Production 4,131                9,795           3,999            1,033                 18,958             18,958               1,112           336            1,448      1,448          
Workforce Education Levels in Central 
Massachusetts
Less than 
Bachelor's 
Degree
Bachelor's 
Degree or 
more
Less than 
Bachelor's 
Degree
Bachelor's 
Degree or 
more
Less than 
Bachelor's 
Degree
Bachelor's 
Degree or 
more
Architecture & Engineering 2,741                3,593           2,009            3,866                 -732 273                     
Life, Physical, & Social Sciences 601                   2,353           422               3,438                 -179 1,085                 
Computer & Mathematical 1,905                3,930           1,947            5,325                 42 1,395                 
Healthcare Practitioners & Technical Services 7,223                9,576           7,881            12,433               658 2,857                 
Healthcare Support 6,461                713               9,311            1,215                 2850 502                     
Personal Care & Service 6,288                1,070           8,669            1,960                 2381 890                     
Production 26,026             1,485           18,958         1,448                 -7068 -37
Total Degrees in Workforce 51,245             22,720         49,197         29,685               -2048 6,965                 
2008-2010 Educational Attainment of Employed 
in Central Massachusetts
Total Less 
than 
Bachelor's 
Degree
Bachelor's 
Degree or 
more
Architecture & Engineering 2,009                3,866           
Life, Physical, & Social Sciences 422                   3,438           
Computer & Mathematical 1,947                5,325           
Healthcare Practitioners & Technical Services 7,881                12,433         
Healthcare Support 9,311                1,215           
Personal Care & Service 8,669                1,960           
Production 18,958             1,448           
Total Degrees in Workforce 49,197             29,685         
2000 2008-2010 Net Change
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Appendix N: STEM Degrees Awarded 
 
 
Worcester County Colleges Massachusetts Colleges
Degree: Doctorate Degree: Doctorate
Year 2006 2007 2008 2009 2010 Year 2006 2007 2008 2009 2010
Degrees Granted 58 61 60 74 92 Degrees Granted 1238 1403 1372 1387 1374
Degree: Masters Degree: Masters
Year 2006 2007 2008 2009 2010 Year 2006 2007 2008 2009 2010
Degrees Granted 253 304 298 335 353 Degrees Granted 3119 3213 3373 3450 3620
Degree: Bachelors Degree: Bachelors
Year 2006 2007 2008 2009 2010 Year 2006 2007 2008 2009 2010
Degrees Granted 947 896 1015 970 1013 Degrees Granted 7228 7164 7662 7701 8118
